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ABSTRACT 
Ritobrata Goswami 
 
 
TRANSCRIPTION FACTORS IN THE DEVELOPMENT OF Th9 CELLS 
 
Cytokines are extracellular proteins that mediate communication between cells. T helper 
cell subsets secrete specific cytokines that promote the development of inflammation. 
Naïve CD4+ T cells activated and primed in the presence of TGF-β and IL-4 
predominantly secrete IL-9, a cytokine that acts as a growth factor for T cells and mast 
cells, and promotes allergic inflammation. The transcription factors downstream of TGF-
β- and IL-4-induced signaling, and that are required for expression of IL-9, have not been 
previously examined. IL-4 signaling induces the expression of IRF4, a transcription 
factor required for the development of Th9 cells. IL-4 and the downstream-activated 
factor STAT6 also interfere with the expression of the transcription factors T-bet and 
Foxp3 that inhibit IL-9 production from Th9 cells. The TGF-β pathway induces the 
expression of PU.1, another transcription factor required for Th9 development. In the 
absence of PU.1 there is increased association of a subset of histone deacetylases to the 
Il9 promoter. In developing Th9 cells, PU.1 can bind to the Il9 promoter and recruit 
specific histone acetyltransferases, including Gcn5 to the Il9 gene. Gcn5 functionally 
contributes to Il9 expression as IL-9 production is diminished when Gcn5 expression is 
reduced, although other cytokines expressed by Th9 cells are not affected. While Gcn5 is 
not required for PU.1 or IRF4 binding to Il9, it is important for controlling histone 
 vi 
acetylation at the Il9 gene promoter. Together these data define the STAT6-dependent 
transcription factor network in Th9 cells and the mechanism of PU.1-dependent IL-9 
induction in Th9 cells and might indicate that targeting IL-9 regulation is a viable 
approach for treating inflammatory disease. 
 
 
 
 
 
                                                                                 Mark H. Kaplan, Ph.D.-Chair 
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INTRODUCTION 
Innate and adaptive immunity 
Humans are exposed to pathogens every day. However, the human body is protected 
from the potential damaging effects by a plethora of effector cells and molecules which 
make up the immune system. The innate and adaptive immune systems, the two arms of 
the immune system provide immunity. The innate immune system acts as the first line of 
defense helping in faster clearance of pathogens. The adaptive immune system is critical 
for providing long-lasting immunity against subsequent infections. Together, both innate 
and adaptive immune systems act as sentinels against encountered pathogens by 
mounting immune responses. 
 
The innate immune system is non-specific; all the pathogens are attacked equally. 
Physical and chemical barriers are employed by the innate immune system as defense 
mechanisms. The skin is a very important barrier as it cannot be penetrated by most 
organisms unless its physical integrity is lost. The gastrointestinal and respiratory tracts, 
lined with sticky mucus, act as a trap for many microorganisms. The stomach releases 
hydrochloric acid and protein-digesting enzymes, which can destroy many pathogens. 
Saliva, sweat, and tears contain lysozyme, an enzyme capable of lysing the cell wall of 
Gram-positive bacteria. Microorganisms can be removed from lungs by ciliary action and 
sloughing off skin expels pathogens as well. However, pathogens can breach the barriers 
and form infection which is fought by the innate immune system. The effector functions 
required to mount host response to the invading pathogens include opsonization, 
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activation of complement system of blood proteins, and initiation of controlled pro-
inflammatory immune responses.  
 
Specialized cell types including granulocytes (mast cells, neutrophils, basophils, and 
eosinophils), phagocytes (dendritic cells, macrophages, neutrophils) and natural killer 
(NK) cells mediate innate immune effector functions. The granulocytes and the 
macrophages release cytokines upon activation. Macrophages also secrete proteins 
known as chemokines that attract phagocytes such as neutrophils and monocytes bearing 
specific chemokine receptors. Upon activation macrophages and eosinophils can release 
reactive oxygen species, cytokines including IL-13, and TNF-α and enzymes such as 
elastase (Hogan et al., 2008; Rothenberg and Hogan, 2006).  
 
NK cells contain small granules in their cytoplasm, which contain proteins such as 
perforins and proteases such as granzymes. When released near a target cell, perforin 
forms pores in the target cell membrane. NK cells are activated by macrophage-derived 
cytokines and play critical roles in antibody-dependent cell-mediated cytotoxicity. NK 
cells also play role in tumor cell detection and tumor immunosurveillance activates NK 
cells (Zamai et al., 2007).  
 
NKT cells, a subset T of cells that express NK1.1, the marker for NK cells, as well as αβ 
T cell receptor. These cells are divided into two classes: the classical NKT and the non-
classical NKT cells (Godfrey et al., 2004). The T cell receptor repertoire on NKT cells is 
limited; NKT cells recognize lipids and glycolipids presented by CD1d molecules instead 
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of peptide-MHC complexes. Activated NKT cells can secrete various cytokines including 
IL-4, IFN-γ, IL-17 and GM-CSF (Kronenberg, 2005; Rachitskaya et al., 2008). 
 
γδ T cells are another limited subset of T cells, which express γ chain and δ chain on the 
surface of T cells, and can function in both innate and adaptive immunity. The restricted 
T cell receptor of γδ T cells can be used as pattern recognition receptors (PRRs) to mount 
defense against microbes. However, γδ T cells have been linked to adaptive immunity as 
well (Holtmeier and Kabelitz, 2005). 
 
Phagocytes are the critical innate immune cells which protect our body by phagocytosing 
harmful foreign particles. These cells fight infections and also clear dead cell debris from 
our body. Professional phagocytes such as macrophages, mast cells, dendritic cells, and 
neutrophils have receptors on their surfaces to detect pathogens such as bacteria. The 
receptors on phagocytes include Toll-like receptors, scavenger receptors and opsonin 
receptors. Phagocyte-mediated pathogen killing can occur intracellularly or 
extracellularly (Dale et al., 2008). Intracellular killing is both oxygen-dependent (by 
superoxide production, use of the enzyme myeloperoxidase) and oxygen-independent 
(lysozymes, proteases). The complement system which is activated by antibody-
dependent and independent mechanisms, enhances engulfment of microbes by 
phagocytes. Phagocytes also act as antigen presenting cells (APCs). Professional APCs 
include macrophages and dendritic cells. After engulfment by phagocytes, proteins from 
pathogens are broken down into small peptides which are then bound to major 
histocompatibility complex (MHC) molecules. MHC-peptide complex moves to the cell 
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surface to activate the lymphocytes and begin adaptive immune response. Eosinophils 
have also been found to act as APCs.  
 
The innate immune system is capable of recognizing certain conserved structures found 
in a large body of pathogens. The system with its hundreds of receptors or PRRs can 
identify structures of invading microorganisms known as pathogen-associated molecular 
patterns (PAMPs). PRRs share structural characteristics such as calcium-dependent 
leucine domains and leucine rich domains. These receptors are conserved and cannot 
recognize self thereby posing no danger to the host. PAMPs include peptidoglycans, 
bacterial polysaccharide, bacterial DNA, double stranded RNA. Once PRRs recognize 
PAMPs and get activated, innate immune cells are capable of secreting various cytokines 
and chemokines and process and present antigen to adaptive immune cells (Thompson et 
al., 2011). 
 
The features of adaptive immune system are the specificity, memory, adaptability, and 
discrimination between self and non-self antigens. The B and T lymphocytes are the 
major cell types involved in the adaptive immune response. According to clonal selection 
theory, prior to contact with antigen, B and T cells exist with all antigenic specificities. 
The highly diverse receptors on B and T cells are capable of identifying a large number 
of diverse antigens. T cell receptor is composed of αβ or γδ chains while B cell receptor 
is membrane-bound form of the antibody. Upon encountering its cognate antigen and 
receiving signals from T cells, B cells differentiate into plasma cells which make 
antibodies in response to foreign proteins including bacteria and viruses. During germinal 
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center reaction B cells hypermutate the variable regions of the immunoglobulin gene and 
undergo class switching (Teng and Papavasiliou, 2007). Some activated B cells become 
memory B cells, and are important for fighting subsequent infections. 
 
T cells are divided into two types based on the presence of the surface glycoproteins CD4 
and CD8. CD8+ T cells, also known as cytotoxic T lymphocytes are important for 
destroying intracellular pathogens. CD8+ T cells play important role in 
immunosurveillance and kill infected cells exhibiting viral proteins in the surface of class 
I MHC molecules. CD4+ T cells are referred to as T helper cells which are critical for 
both antibody-mediated and cell-mediated immunity. Macrophages and dendritic cells act 
as APCs in cell-mediated immunity while B cells present antigens to CD4+ T cells 
during antibody-mediated immunity. CD4+ T cells are critical for providing immunity as 
infections such as HIV and AIDS are associated with depletion of CD4+ T cells. T helper 
cells direct other immune cells to execute effector functions. 
 
JAK-STAT pathway 
Naïve CD4+ T cells proliferate and polarize towards different effector CD4+ T cells 
including pro-inflammatory Th1, Th2, Th17 and immunoregulatory Treg cells based on 
their interaction with cognate antigen and also on the cytokine milieu. Cytokine-mediated 
T helper cell differentiation depends upon the activation of the Janus family tyrosine 
kinases (JAKs)/Signal Transducer and Activator of Transcription (STAT) pathway. 
STAT molecules control CD4+ T cell stability and plasticity. The Janus kinase family 
consists of 4 members, JAK1, JAK2, JAK3, and, TYK2; while the STAT family of 
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transcription factors includes, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and 
STAT6. Cytokine stimulation by JAKs through type I and II cytokine receptors results in 
the activation of STAT proteins. After cytokine binding, receptor chains associate and 
elicit JAK auto-phosphorylation or trans-phosphorylation and activation. Subsequently, 
JAKs phosphorylate specific tyrosine residues on the receptor cytokine tail which serve 
as STATs docking sites. In turn, phosphorylated tyrosine residues allow STAT molecules 
to form homo or heterodimers through the interaction of SH2 domain. The dimerization 
facilitates STAT protein translocation and binding to gene-specific promoter elements 
(O'Shea and Murray, 2008; Shuai and Liu, 2003). Each T helper cell lineage is dependent 
on distinct STAT molecules for its differentiation and effector functions, and activation is 
dependent on the cytokine environment in which the cell develops. 
 
Transcriptional regulation of Th1 cells 
Th1 cells are characterized by the production of IFN-γ and lymphotoxin-α. Naïve CD4+ 
T cells when cultured in the presence of IL-12 and blocking IL-4 antibodies polarize into 
Th1 cells (Hsieh et al., 1993; Manetti et al., 1993). IFN-γ can activate and enhance 
microbicidal activity of macrophages (Suzuki et al., 1988). Th1 cells are critical for 
immunity against intracellular bacteria, fungi, protozoa (Fieschi et al., 2004; Fieschi et 
al., 2003; Hsieh et al., 1993). 
 
Role of STAT molecules in Th1 cell differentiation 
Th1 cells, which secrete high levels of IFN-γ, require IL-12 and IFN-γ for their 
differentiation. IL-12 signals through activated JAK2 and Tyk2, and activates STAT4, 
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the key transcription factor for Th1 commitment (Zhu and Paul, 2010). STAT4-deficient 
CD4+ T cells fail to produce IFN-γ after IL-12 or Listeria monocytogenesis stimulation 
and STAT4-deficient mice die of uncontrolled worm burden in response to Toxoplasma 
gondii (Cai et al., 2000; Kaplan et al., 1996b; Thierfelder et al., 1996). IL-12 synergizes 
with IL-18 for driving Th1 differentiation which is STAT4-dependent (Barbulescu et al., 
1998; Ouyang et al., 1999; Yang et al., 1999). IFN-γ signals through STAT1 and STAT1-
deficient mice have impaired Th1 differentiation (Afkarian et al., 2002). JAK3 and 
STAT5 activation is required for optimal IFN-γ secretion. JAK3-deficient T cells fail to 
produce IFN-γ and IL-2 activated STAT5 is required for optimal IFN-γ secretion (Shi et 
al., 2008b). 
 
Lineage-specific transcription factors and other factors required for Th1 differentiation 
Downstream of specific STAT family members, other transcription factors are required 
for Th1 cell development. T-bet (Tbx21), a T-box family transcription factor has been 
shown to be the master regulator of Th1 cell differentiation. Tbx21 expression is 
inducible upon TCR stimulation. T-bet is preferentially expressed in Th1 cells, compared 
to Th2 cells. Ectopic expression of T-bet in Th2 cells can induce IFN-γ secretion (Mullen 
et al., 2002; Szabo et al., 2000). In vitro, T-bet-deficient Th1 cells have diminished IFN-γ 
production and in vivo T-bet-deficient mice elicit impaired Th1 response after antigen 
immunization (Szabo et al., 2002). Even though IFN-γ/STAT1 is a key pathway of T-bet 
induction, STAT4 also controls Tbx21 expression and collaborates with T-bet to induce 
IL-12Rβ2 and IL-18Rα expression (Afkarian et al., 2002; Lighvani et al., 2001; Thieu et 
al., 2008; Usui et al., 2003; Usui et al., 2006). STAT1-deficient T cells have attenuated T-
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bet levels after T. gondii infection; however, IFN-γ secretion remains unchanged 
(Lieberman et al., 2004). The synergistic effects of IL-12 and IL-18 in driving Th1 
differentiation are in part via T-bet induction (Zhu and Paul, 2010). H2.0-like homeobox-
1 or Hlx, is a Th1-specific transcription factor, induced by T-bet. Hlx, a homeobox gene 
interacts with T-bet to induce heritable Th1 gene expression (Mullen et al., 2002). 
Transgenic mice constitutively expressing Hlx in CD4+ T cells generated increased 
numbers of Th1 cells in response to keyhole limpet hemocyanin immunization (Zheng et 
al., 2004). Runx3, a Runt-related transcription factor is selectively upregulated in Th1 
cells. In Th1 cells, Runx3 interacts with T-bet and enhances IFN-γ production while 
reducing Il4 expression via binding of Runx3/T-bet complex to the Ifng promoter and Il4 
silencer, respectively (Djuretic et al., 2007; Yagi et al., 2010). Ectopic Runx3 expression 
in CD4+ T cells or Runx3-expressing transgenic mice have increased Th1 responses 
(Kohu et al., 2009). Runx3-mediated Ifng expression is suppressed by GATA3 (Yagi et 
al., 2010). The Ets family transcription factor, ERM which is specifically expressed in 
Th1 cells is an IL-12-inducible and STAT4-dependent gene. However, ectopic ERM 
expression in STAT4-deficient Th1 cells fails to rescue IFN-γ production suggesting it 
may have functions in Th1 cells that are not yet defined (Ouyang et al., 1999). The helix-
loop-helix transcription repressor Twist1 is expressed in Th1 cells but not in Th2 or Th17 
cells (Niesner et al., 2008). Twist1 is induced by IL-12/Stat4 signaling but not IFN-
γ/Stat1 signaling (Niesner et al., 2008). Ectopic expression of Twist1 diminishes the 
production of Th1 cytokines in vitro correlated with a decrease in Th1-mediated 
inflammation model in vivo (Niesner et al., 2008). Twist1 reduces the expression of T-
bet, Runx3 and IL-12Rβ2 and regulates Ifng gene expression by forming complex with 
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Runx3 (Pham et al., 2012).  Ectopically expressed Runx3, but not T-bet or IL-12Rβ2 can 
compensate for the Twist1 effect on IFN-γ production (Pham et al., 2012).  The Ca2+ 
dependent transcription factors, nuclear factor activator of T cells (NFATs) are also 
important for the polarization of effector CD4+ T cells. STAT1 along with TCR-induced 
transcription factors AP-1, NF-κB bind to the Tbx21 promoter thereby facilitating its 
transcription in Th1 cells (Afkarian et al., 2002). Therefore expression and interaction of 
several Th1-associated transcription factors are required for optimal Th1 responses 
(Figure 1). 
 
Figure 1: Transcription factor network of Th1 cells 
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Epigenetic regulation of Th1 cells 
Chromatin structure modification plays an important role in polarizing subset-specific 
gene expression. Studies to elucidate the mechanism of Th1-specific IL12Rβ2 expression 
was addressed in human Th1 cells.  Two DNase I hypersensitive sites (HS) are present in 
the 5′-upstream region of the IL12RB2 gene. HS1 contains IFN-γ activated sequence 
(GAS) element, consensus STAT protein binding sequences. HS2 is the core promoter of 
the IL12RB2 gene (Letimier et al., 2007). In mice, interferon regulatory factor1 (IRF1) 
can directly activate the β1 chain of IL-12R by binding to an IFN-stimulated response 
element (ISRE) in the promoter of IL12Rβ1 gene (Kano et al., 2008). STAT4 binding 
promotes hyperacetylation of Il18r1 thereby preventing the recruitment of DNA 
methyltransferases and repression of Il18r1 locus (Yu et al., 2007). A scanning of the 
Tbx21 locus for STAT1 and STAT4 binding yielded an enhancer element 13Kb upstream 
of transcription start site containing 2 binding sites (Yang et al., 2007b). The Ifng gene 
contains specific DNase I hypersensitive sites in the 1
st
 and 3
rd
 introns (Agarwal and Rao, 
1998). Histones 3 and 4 undergo hyperacetylation at the Ifng promoter (Avni et al., 2002; 
Fields et al., 2002). In Th1 cells, H4 acetylation and H3K4 methylation, both positive 
chromatin marks, span a 50kb region of the Ifng gene (Hamalainen-Laanaya et al., 2007; 
Schoenborn and Wilson, 2007; Zhou et al., 2004). Conserved non-coding sequences 
(CNSs) are evolutionary conserved and are associated with transcription factor binding 
sites as well as cis-acting elements. There are two CNSs, one 6kb upstream and another 
18kb downstream of the transcription start site of the Ifng gene (Bream et al., 2004; Lee 
et al., 2004; Shnyreva et al., 2004). The CNS-6 site, contains a DNase I hypersensitivity 
in naïve T cells and the transcription factors T-bet, STAT5, and NFAT1 can bind to this 
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site (Bream et al., 2004; Lee et al., 2004; Shi et al., 2008b). Furthermore, enhancer 
elements of the Ifng gene were identified at CNS-54, CNS-34, and CNS-22 sites (Hatton 
et al., 2006). Th1-specific H4 acetylation and T-bet binding occur at CNS-34, and CNS-
22 sites. In addition to histone acetylation, the Ifng locus also undergoes DNA 
methylation (Schoenborn et al., 2007). Multiple CNS of the Ifng locus can bind STAT4, 
T-bet or both (Chang and Aune, 2005; Hatton et al., 2006). In Th2 cells, the Ifng locus is 
characterized by high level of di-and tri-methylation of H3K27, repressive chromatin 
modifications while DNA is demethylated at CpG residues at CNS-54, intron, and 
CNS+18-20 regions during Th1 development (Chang and Aune, 2007; Schoenborn et al., 
2007). The significance of the presence of H3K9Me2, another repressive chromatin mark 
at the Ifng locus in Th1 cells is not well understood (Chang and Aune, 2007). Therefore 
histone modifications which remodel the chromatin at the Ifng locus during Th1 
differentiation define the Th1 cell responses (Figure 2). 
 
Figure 2: Epigenetic regulation in Th1 cells 
 
Transcriptional regulation of Th2 cells 
Naïve T cells activated by antigen in the presence of IL-4 differentiate into Th2 cells. 
These cells produce IL-4, IL-5, and IL-13. Th2 cells are critical for providing immunity 
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against extracellular parasites (Zhu and Paul, 2008). Production of these cytokines also 
enable B cell help towards antibody production, a function which has also been attributed 
to T follicular helper cells (Crotty, 2011). IL-4 acts as B-cell switch factor and as a 
positive feedback loop in Th2 differentiation (Kopf et al., 1993; Le Gros et al., 1990; 
Swain et al., 1990). IL-5 is the key eosinophil development and recruitment cytokine, 
while IL-13 is responsible for reducing worm burden and inducing airway inflammation 
and hypersensitivity (Coffman et al., 1989; Urban et al., 1998; Wynn, 2003).  
 
STAT molecules in Th2 differentiation 
IL-4 signaling is transmitted through STAT6, and STAT6 is required for Th2 
development in vitro (Kaplan et al., 1996a; Shimoda et al., 1996). Mice injected with 
neutralizing IL-4 antibodies or Stat6-/- mice have defective worm clearance after 
nematode infection, while CD4+ T cells from mice expressing constitutively active 
STAT6 (STAT6VT) have a bias towards Th2 cell lineage (Bruns et al., 2003; Else et al., 
1994; Sehra et al., 2008; Takeda et al., 1996). However, the development of some Th2-
cytokine secreting cells can occur in vivo in the absence of Stat6 (Jankovic et al., 2000; 
van Panhuys et al., 2008). IL-4R/STAT6 signaling is shown to be required for generating 
memory IL-4 responses and stabilization of Th2 phenotype (Finkelman et al., 2000; 
Jankovic et al., 2000). STAT6 is also required for the expression of Th2 transcription 
factors Gfi-1 and Gata3 (Lee and Rao, 2004; Zhu et al., 2002). In addition to the IL-
4/STAT6 pathway, IL-2-mediated STAT5 activation induces the production of IL-4, IL-
5, and IL-13 by Th2 cells (Zhu et al., 2003). STAT5 is required in priming for IL-4 
production which is enhanced by IL-2 in vivo possibly by regulating IL-4Rα (Cote-Sierra 
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et al., 2004; Liao et al., 2008). Th2 cell development is impaired in Stat5A-/- mice in 
spite of normal STAT6 phosphorylation by IL-4 (Kagami et al., 2001). Ectopic 
expression of either Stat5A or Stat5B restores Th2 differentiation in Stat5A-/- mice 
(Kagami et al., 2001). Constitutively active Stat5A expression can induce restricted Th2 
cytokine production and allergy airway inflammation in the absence of STAT6 (Takatori 
et al., 2005; Zhu et al., 2003). STAT3 which is required for the differentiation and 
effector function of Th17 and Tfh cells is activated in Th2 cells (Nurieva et al., 2008; 
Stritesky et al., 2011; Yang et al., 2007a). STAT3 deficiency leads to attenuated Th2 
cytokine production and decreased Th2-specific transcription factor expression (Stritesky 
et al., 2011). STAT3-deficient T cells show significantly lower allergic inflammation and 
cooperates with STAT6 to promote Th2 cells development (Stritesky et al., 2011). 
 
Additional transcription factors required for Th2 differentiation 
Along with multiple STAT molecules that signal during Th2 cell differentiation, other 
transcription factors are required for Th2 development. IL-4-activated STAT6 induces 
GATA3, the master regulator of Th2 cells (Zheng and Flavell, 1997). GATA3 is 
specifically expressed in Th2 cells and directly regulates the expression of Th2 cytokines 
(Agarwal et al., 2000; Kishikawa et al., 2001; Siegel et al., 1995; Yamashita et al., 2002; 
Zhang et al., 1997; Zhang et al., 1998a). GATA3 is able to autoactivate its own 
transcription and can induce Th2 differentiation in Th1-polarizing conditions (Ouyang et 
al., 2000). In vivo, a dominant negative form of GATA3 results in diminished allergic 
inflammation, while T-cell specific deletion of GATA3 has impaired initiation and 
maintenance of Th2 responses (Pai et al., 2004; Zhang et al., 1999; Zhu et al., 2004). In 
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addition to GATA3, the transcription factor c-Maf is required for IL-4 expression. c-Maf 
is expressed in Th2 cells and is a potent transactivator of IL-4 (Ho et al., 1996; Ho et al., 
1998). c-Maf transgenic mice have enhanced Th2 responses in vivo (Ho et al., 1998). 
Mice deficient in c-Maf display diminished IL-4 but unaltered IL-13 production from 
Th2 cells and c-Maf fails to transactivate Il5 or Il10 promoters (Kim et al., 1999). IRF4, a 
member of the interferon regulatory factor family is also associated with Th2 
differentiation. IRF4-deficient T cells have impaired Th2 differentiation (Lohoff et al., 
2002; Rengarajan et al., 2002). Synergistic effects of IRF4 and NFATc2 to augment 
transcriptional activation of IL-4 are dependent upon physical interaction between IRF4 
and NFATc2 (Rengarajan et al., 2002). Irf4 expression can be traced to a subpopulation 
of Th2 cells which express high levels of IL-10 (Ahyi et al., 2009). IRF4 over expression 
enhances IL-4 and IL-10 production without any changes in IL-5 and IL-13 expression 
(Ahyi et al., 2009). IRF4 can bind directly to the Il10 gene and can transactivate Il10 
control elements in reporter assay (Ahyi et al., 2009). IL-4/STAT6 signaling activates the 
transcription factor Growth factor independence 1 (Gfi-1), which favors the growth of 
GATA3
hi
 cells (Zhu et al., 2002). CD4+ T cell specific deletion of Gfi-1 attenuates Th2 
proliferation in vitro and impairs Th2 responses in vivo (Zhu et al., 2006b). Gfi-1 plays 
important role in regulating IL-5 and IFN-γ in Th2 cells by controlling GATA3 protein 
stability via repression of ubiquitin/proteasome-dependent GATA3 degradation 
(Shinnakasu et al., 2008). The transcription factor JunB, which is selectively expressed in 
Th2 cells, can activate and bind to the Il4 promoter synergistically with c-Maf (Li et al., 
1999). JunB-deficient Th2 cells have reduced IL-4, IL-5 but not IL-13 production in vitro 
and impaired allergic airway inflammation in vivo (Hartenstein et al., 2002). Dec2, a 
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basic helix-loop-helix family transcription factor is specifically expressed in Th2 cells 
and its expression is regulated by STAT6 (Liu et al., 2009). Dec2 binds and activates the 
expression of Gata3 and Junb (Yang et al., 2009). Dec2 transgenic mice demonstrate 
strong Th2 responses, while knockdown of Dec2 expression or Dec2-deficient mice have 
impaired Th2 differentiation both in vitro and in vivo (Liu et al., 2009; Yang et al., 2009). 
Mechanistically Dec2 induces IL-2Rα expression and synergistically controls IL-2 
signaling with IL-4 to promote Th2 differentiation (Liu et al., 2009). Batf, a member of 
basic leucine zipper transcription factor family, has been shown to be important for Th17 
differentiation; however, Batf is also required for the development of functional Th2 cells 
(Betz et al., 2010). A hematopoietic transcription factor Ikaros, is also a regulator of Th2 
cells. Ikaros-deficient Th2 cells have impaired IL-4, IL-5, and IL-13 but enhanced IFN-γ 
production (Quirion et al., 2009). In naïve T cells, Ikaros is able to associate with Th2 
locus regulatory regions while Ikaros-deficient T cells display diminished Gata3 and c-
Maf with increased Tbx21 and Stat1 expression (Quirion et al., 2009). In Th2-polarizing 
conditions, Ikaros is required to suppress Ifng expression (Thomas et al., 2010). The ETS 
family transcription factor, PU.1 controls the heterogeneity of Th2 cells (Chang et al., 
2005). PU.1 is expressed in the CCL22
hi
IL-4
lo
 population of Th2 cells (Chang et al., 
2005). Enforced expression of PU.1 reduces Th2 cytokine production while RNAi-
mediated reduced PU.1 expression results in augmented Th2 cytokine production (Chang 
et al., 2009; Chang et al., 2005). Mechanistically PU.1 interferes with the binding of 
GATA3 in IL-4
lo
 cells without altering GATA3 protein levels (Chang et al., 2009; Chang 
et al., 2005). NFATs regulate the transcription of several cytokines and their receptors, 
and are also important for Th2 differentiation. IL-4-activated STAT6 together with AP-1, 
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NF-κB, and NFAT drive Il4 transcription (Chuvpilo et al., 1993; Macian et al., 2000). 
NFATc2 binds to the Il4, Il5, and Il13 promoters and many enhancer elements within the 
Il4 locus (Ansel et al., 2006). IRF4 synergizes with NFATc2 and c-Maf to enhance Il4 
promoter activity (Rengarajan et al., 2002). IRF4 and NFATc2 also synergize to augment 
Th2-specific enhancer activity of CNS-9, a distal cis-regulatory element upstream of Il10 
gene loci (Lee et al., 2009). Thus the expression of these transcription factors is required 
for optimal Th2 differentiation (Figure 3).  
 
Figure 3: Transcriptional regulation of Th2 cells 
 17 
Chromatin modifications of Th2 cells 
The Il4, Il5, and Il13 loci are closely linked on mouse chromosome 11, and on human 
chromosome 5. The locus control region (LCR) of Il4-Il13 lies in 25kb region of Rad50 
at the 5’end of Il13 (Fields et al., 2004). The expression of Il5, which lies on the other 
side of Rad50, may not be controlled by this LCR. During Th2 differentiation chromatin 
modifications occur at the Il4-Il13 loci. Several distinct clusters of DNase I 
hypersensitive sites have been identified in the Il4 locus (Agarwal et al., 2000; Agarwal 
and Rao, 1998; Fields et al., 2004; Lee and Rao, 2004; Takemoto et al., 1998). Naïve T 
cells and Th1 cells display identical patterns of HSS across the Il4 locus; however, 
additional HSSs are present in Th2 cells including Il4 HSI, II, III, and V and Il13 HSI, II, 
and III, HSS2 and HSS3 and RHS1, 4 and 7 within the Il5 and Rad50 genes (Agarwal et 
al., 2000; Fields et al., 2004; Takemoto et al., 1998). Deletion of RHS7 reduces the 
production of IL-4 and IL-13 in Th2 cells (Lee et al., 2005). Il4 HSII, HSIII, Il13 HSI, 
and a conserved GATA response element function as enhancers in Th2 cells (Monticelli 
et al., 2005; Yamashita et al., 2002). HS IV which is accessible in both Th1 and Th2 cells 
is a potential target for IL-4 silencing in Th1 cells (Ansel et al., 2004). During the early 
stages of Th2 differentiation GATA3 binds to the regulatory regions within the Il4 locus 
to create a transcriptionally permissive chromatin structure. However, during the later 
stages of Th2 differentiation GATA3 is important for Il5, and Il13 but not Il4 expression. 
In Th2 cells GATA3 binding to HSS3 within the Il4 locus allows recruitment of histone 
acetyltransferases CBP and p300 which mediate histone acetylation (Baguet and Bix, 
2004; Yamashita et al., 2002). GATA3 also binds to RHS7/Rad50 of Th2 locus control 
region (Spilianakis and Flavell, 2004). GATA3 is also recruited to the Ifng promoter in 
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Th2 cells to silence its expression (Chang and Aune, 2007). Modifications of histone tails 
also contribute to gene expression. Acetylation of H3K9 and H3K14 residues are present 
at Il4 promoter but not at the HSIV region in Th2 cells (Ansel et al., 2006; Avni et al., 
2002). H3K4Me3 is found at the Ifng gene promoter in Th2 cells, but not Th1 cells (Wei 
et al., 2009). Histone methyltransferases MLL and EZH2 are required for permissive 
H3K4Me3 modification in Th2 cells and repressive H3K27Me3 modification in Th1 
cells, respectively (Koyanagi et al., 2005; Yamashita et al., 2006). GATA3 regulates 
modifications of mono-and di-methylation of H3K4 and H3K27Me3 at the enhancer 
regions of the Il4 and Ifng genes in Th2 cells (Wei et al., 2011). The key histone 
modifications which regulate Th2 cytokine gene expression is depicted below (Figure 4). 
 
Figure 4: Chromatin modifications of Th2 cells 
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Cross regulation between Th1 and Th2 cells 
T helper cell differentiation requires positive signal from cytokines and cross-inhibition 
of other effector phenotypes. Cross talk between IFN-γ-producing Th1 cells and IL-4-
producing Th2 cells has been documented. TGF-β can suppress both Th1 and Th2 
responses (Gorelik et al., 2000). IL12Rβ2 induction by T-bet, which is dependent on 
IFN-γ/STAT1 signaling, is inhibited by IL-4 (Szabo et al., 1997). Ectopic expression of 
T-bet represses Gata3 expression (Usui et al., 2006). Conversely, GATA3 and IL-4 are 
upregulated in the absence of T-bet even in a strong Th1 environment (Yagi et al., 2010). 
T-bet suppresses GATA3 function by binding to it (Hwang et al., 2005). Runx3 co-
operates with T-bet to promote IFN-γ production while silencing the Il4 gene in Th1 cells 
by directly binding to the Il4 locus (Djuretic et al., 2007; Naoe et al., 2007; Yagi et al., 
2010). Runx3 inhibits GATA3 function by interacting with GATA3 protein (Kohu et al., 
2009). In Th2 cells, GATA3 blocks the expression of STAT4, and Th2 cells from 
GATA3
fl/fl
CD4-Cre mice exhibit increased levels of STAT4 compared to wild-type Th2 
cells (Usui et al., 2006). GATA3-deficiency results in IL-12 and IFN-γ-independent IFN-
γ production, likely by the increased activity of Runx3 (Yagi et al., 2010; Zhu et al., 
2004). Runx3 induces Eomes expression and ectopic Runx3 expression in Th2 cells 
induces T-bet-independent Ifng expression (Kohu et al., 2009; Yagi et al., 2010). 
However, GATA3 and T-bet double-deficient Th1 cells do not express Eomes (Yagi et 
al., 2010). IL-4 can possibly induce Eomes expression in GATA3-limiting conditions. 
Ectopic expression of constitutively active of STAT5 in Th1 cells can induce Th2 
polarization without altering Gata3 expression. But, Tbx21 expression is repressed in 
these cells implying that the relative amount of GATA3/T-bet regulated by STAT5 
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signaling affects Th1 and Th2 differentiation (Zhu et al., 2003). The transcription factor 
Gfi-1 suppresses Th1 differentiation, while Ikaros limits Th1 responses by inhibiting 
Tbx21 expression (Quirion et al., 2009; Zhu et al., 2006b). 
 
Transcriptional regulation of Th17 cells 
Th17 cells, which have been described in the last decade, are pro-inflammatory cells 
which secrete IL-17A, IL-17F, IL-21, and IL-22. Th17 cells provide immunity to several 
extracellular pathogens including defense against infections from Candida, Citrobacter 
and Klebsiella (Happel et al., 2005; Huang et al., 2004; Mangan et al., 2006). TGF-β, IL-
6, and IL-21 are required for the differentiation of Th17 cells (Bettelli et al., 2006; Korn 
et al., 2007; Mangan et al., 2006; Nurieva et al., 2007; Veldhoen et al., 2006a; Zhou et 
al., 2007). However; an alternative mode of pathogenic Th17 cells differentiation without 
TGF-β signaling has been recently documented (Ghoreschi et al., 2010). IL-23 is required 
for Th17 cell maintenance but not development (McGeachy et al., 2007; Stritesky et al., 
2008). The cytokine IL-1β augments IL-23 responsiveness and promotes Th17 
differentiation (Cho et al., 2006; Cua et al., 2003; Veldhoen et al., 2006b).  
 
STAT family members in the development of Th17 cells 
The cytokines IL-6, IL-21, and IL-23, essential for Th17 differentiation, activate STAT3 
(Nurieva et al., 2007; Yang et al., 2007a; Zhou et al., 2007). Subsequently the importance 
of STAT3 in Th17 cell development was shown in several studies (Mathur et al., 2007; 
Yang et al., 2007a). STAT3-deficient T cells have impaired IL-17A, IL-17F, IL-22, and 
IL-23R expression (Yang et al., 2007a). STAT3 deficiency leads to attenuated expression 
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of RORγt and RORα, the Th17 cell lineage-specific transcription factors (Yang et al., 
2007a; Yang et al., 2008b). IL-6 activated STAT3 represses the expression of Foxp3, the 
transcription factor which is required for Treg differentiation. Foxp3 down regulation is 
associated with decreased Treg differentiation and increased Th17 differentiation 
(O'Malley et al., 2009; Yang et al., 2007a; Yao et al., 2007). Patients with Job’s 
syndrome have STAT3 mutations and impaired Th17 differentiation (Ma et al., 2008; 
Milner et al., 2008). In Th17 cells IL-23 signals through both STAT3 and STAT4. IL-17 
production from Th17 cells stimulated with IL-23 and IL-18 require STAT4 (Mathur et 
al., 2007). 
 
Role of additional transcription factors in Th17 development 
Two retinoic acid-related orphan receptor family members, RORγt (an isoform of RORγ) 
and RORα have been shown to regulate Th17 cell differentiation (Ivanov et al., 2006; 
Yang et al., 2008b). RORγt, required for lymphoid organogenesis and thymocyte survival 
is specifically expressed in cells of immune system (Eberl and Littman, 2003; Sun et al., 
2000). Over expression of RORγt promotes Th17 differentiation while RORγt-deficient T 
cells have impaired Th17 differentiation (Ivanov et al., 2006; Nurieva et al., 2007; Zhou 
et al., 2007).  RORγt and STAT3 act in concert to induce Il17 expression (Zhou et al., 
2007). RORα, similar to RORγt can be induced by TGF-β, and IL-6 in a STAT3-
dependent fashion (Yang et al., 2008b). RORα-deficiency leads to selective decrease in 
Il17 and Il23r expression, while double deficiency of RORα and RORγt results in total 
inhibition of IL-17 production and EAE development (Yang et al., 2008b). IRF4, an 
inducer of GATA3 in Th2 cells is also required for Th17 development. Mice deficient in 
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IRF4 show defective Th17 differentiation in response to TGF-β and IL-6 (Brustle et al., 
2007). Even though RORγt expression is diminished in Irf4-/- Th17 cells, ectopic 
expression of RORγt in IRF4-deficient T cells can partially restore Th17 differentiation. 
IRF4-deficient T cells display impaired IL-21-mediated autocrine response, although the 
precise mechanisms are not well understood (Chung et al., 2009; Huber et al., 2008). 
IRF4 may be responsible for early Th17 differentiation (Chung et al., 2009). IRF4 can 
interact with NFATp and possibly modulates NFATp-dependent IL-2 production that 
inhibits IL-17 production (Chen et al., 2007). Studies also demonstrate aryl hydrocarbon 
receptor (AHR), a type I nuclear receptor to be critical in Th17 cell differentiation 
(Quintana et al., 2008; Veldhoen et al., 2008a). Th17 cells have the highest expression of 
Ahr compared to other Th cells (Veldhoen et al., 2008a). AHR-deficient Th17 cells 
display activated levels of STAT1 and STAT5, negative regulators of Th17 development 
(Kimura et al., 2008). Th17 cells from AHR-deficient mice do not express IL-22 
(Veldhoen et al., 2008a). Administration of the AHR ligand FICZ augments IL-17 
production from Th17 cells in vitro and Th17-specific genes expression during EAE in 
vivo (Quintana et al., 2008; Veldhoen et al., 2008a). Batf, which is expressed in both Th2 
and Th17 cells, is required for Th17 development (Betz et al., 2010; Schraml et al., 
2009). Batf-deficient CD4+ and CD8+ T cells fail to produce IL-17 with increased Treg 
differentiation in vivo, and these mice are protected from EAE (Schraml et al., 2009). In 
Th17 cells, Batf forms heterodimer with JunB and binds to the Il17, Il21, and Il22 
promoters (Schraml et al., 2009). Batf synergizes with RORγt to induce Il17 expression, 
but the precise role of Batf in Th17 cells is not fully understood (Schraml et al., 2009). 
The transcription factor Bcl6 which plays critical role in inhibiting Th2 cell 
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differentiation and promoting Tfh differentiation is also required for Th17 development 
(Johnston et al., 2009; Kusam et al., 2003; Mondal et al., 2010; Nurieva et al., 2009; Yu 
et al., 2009). Bcl6 expression is up regulated under Th17 conditions and Bcl6-deficient 
mice display impaired Th17 differentiation (Mondal et al., 2010). Ectopic expression of 
Bcl6 in CD4+ T cells suppresses Il4 but enhances Il17 expression (Mondal et al., 2010). 
Bcl6-deficient T cells develop normal Th17 responses in vivo, possibly because Bcl6-
deficient macrophages display augmented expression of IL-6, IL-23, and TGF-β. Thus 
Bcl6 may be required for optimal Th17 differentiation but it plays a compensatory role in 
Th17 development in the macrophage lineage (Mondal et al., 2010). c-Maf, Th2-related 
transcription factor is expressed in Th17 cells. TGF-β synergizes with IL-6 and IL-27 for 
Maf expression and c-Maf regulation of IL-10 production in Th17 cells (Xu et al., 2009). 
c-Maf regulated IL-10 production in Th17 cells is not STAT6/GATA3 dependent (Xu et 
al., 2009). c-Maf is also able to bind and activate the Il21 promoter (Hiramatsu et al., 
2010). c-Maf is critical for memory Th17 responses. IL-23R, important for Th17 
responses is a potential target of c-Maf, and over expression of c-Maf does not enhance 
early stages of Th17 differentiation but expands the memory population (Sato et al., 
2011). NF-κB family member IκBζ synergizes with RORγt and RORα to regulate Th17 
differentiation (Okamoto et al., 2010). Another NF-κB family member, c-Rel also plays 
key role in Th17 differentiation (Chen et al., 2010). Therefore, in addition to RORγt and 
RORα which co-ordinate the diverse cytokine-induced signals, additional transcription 
factors are required to control Th17 cell differentiation (Figure 5). 
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Figure 5: Transcriptional regulation of Th17 cells 
 
Epigenetic regulation of Th17 cells 
The Il17a gene in mice is linked to the Il17f gene on chromosome 1. Even though the 
expression of Il17a and Il17f is linked there can be specific expression of one or the other 
gene (Liang et al., 2007). During Th17 differentiation, both the Il17a and Il17f promoters 
undergo histone H3 acetylation and H3K4Me3 methylation suggesting enhanced 
accessibility of the locus (Akimzhanov et al., 2007). Eight CNS regions have been 
identified in the locus and four of them residing in the intergenic region, undergo specific 
histone acetylation (Akimzhanov et al., 2007). STAT3 can bind to this intergenic region 
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and permissive histone marks are STAT3-dependent (Durant et al., 2010). There are 
STAT3-dependent p300 binding sites at the Il17 locus (O'Shea et al., 2011). CNS2, a cis 
element in the Il17-Il17f locus can physically interact with the Il17 and Il17f promoters 
(Wang et al., 2012). CNS2-deficient T cells demonstrate attenuated IL-17 and IL-17F 
production which can be attributed to impaired chromatin architecture in the Il17-Il17f 
locus because of defective recruitment of histone modifying enzymes p300 and JMJD3 
(Wang et al., 2012). How RORγt contributes to chromatin modifications in Th17 cells is 
not understood. As we appreciate the flexibility of Th cells, it is not surprising that the 
histone methylation pattern of transcription factor genes required for lineage decisions 
display bivalent modifications of genes, even when they are not expressed (Wei et al., 
2009). In vitro generated Th17 cells have been shown to be unstable while memory Th17 
cells exhibit a more stable phenotype associated with specific chromatin modifications 
(Bending et al., 2009; Lexberg et al., 2008; Mukasa et al., 2010; Shi et al., 2008a). Thus, 
the presence of multiple CNS regions in the Il17 locus is required for its epigenetic 
regulation (Figure 6). 
 
Figure 6: Epigenetic regulation of Th17 cells 
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Transcriptional regulation of T regulatory (Treg) cells 
Regulatory T cells are a distinct T cell subset which control pro-inflammatory responses 
of effector Th cells and promote self-tolerance (Sakaguchi et al., 1995). Tregs suppress T 
cell activation by weak stimuli and protect elimination of commensal bacteria by the 
immune system (Baecher-Allan et al., 2002; Dembic, 2008). Naturally occurring Treg 
(nTregs) cells are derived from thymus and have suppressive functions. Naïve CD4+ T 
cells exposed to TGF-β gives rise to inducible Tregs (iTregs) in the periphery, and these 
cells have similar properties of nTregs (DiPaolo et al., 2007). Retinoic acid can augment 
Treg differentiation (Benson et al., 2007; Coombes et al., 2007; Mucida et al., 2007; Sun 
et al., 2007). Naïve T cells differentiated to iTregs produce the suppressive cytokine 
TGF-β (Li et al., 2006b). The markers used to identify Tregs include CD25, cytotoxic T 
lymphocyte-associated antigen 4 (CTLA4), glucocorticoid-induced tumor necrosis factor 
receptor family-related gene (GITR), and CD127 (Liu et al., 2006; McHugh et al., 2002; 
McNeill et al., 2007; Read et al., 2000; Sakaguchi et al., 1995; Seddiki et al., 2006; 
Takahashi et al., 2000). However, these markers are not Treg-specific and controversy 
exists on whether Helios, an Ikaros family transcription factor can be used to differentiate 
nTregs from iTregs (Lan et al., 2012; Thornton et al., 2010). 
 
Role of STAT proteins in Treg cell development 
IL-2/IL-2R plays an important role Treg development as IL-2Rβ-deficient mice lose 
functional Tregs (Malek and Bayer, 2004). IL-2 signaling is suggested to be required for 
Treg activation, function and survival but not for homeostasis even though debate persists 
on the actual role of IL-2/IL-2R signaling (Burchill et al., 2007; D'Cruz and Klein, 2005; 
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Davidson et al., 2007; Fontenot et al., 2005; Furtado et al., 2002; Setoguchi et al., 2005). 
However, IL-2-activated STAT5 is required for the development of Treg cells (Burchill 
et al., 2007; Davidson et al., 2007). STAT5-deficient T cells blocks Treg development 
while reconstitution of IL2rb-/- mice with activated STAT5 reinstates Treg development 
(Burchill et al., 2007). STAT5 binds directly to the Foxp3 gene, the master transcription 
factor of Treg cells (Burchill et al., 2007). Thus STAT5 may directly induce Foxp3 
expression (Burchill et al., 2007; Yao et al., 2007). STAT3, required for Th17 
development has been shown to be important for the maintenance of nTreg phenotype 
and in vivo Treg differentiation (Pallandre et al., 2007). Other STAT proteins including 
STAT4 and STAT6 repress Treg development (Chapoval et al., 2010; O'Malley et al., 
2009; Takaki et al., 2008; Xu et al., 2011). 
 
Role of additional transcription factors in Treg cell differentiation 
The transcription factor Foxp3 has been identified as a reliable marker for Treg cells in 
both human and mice (Bennett et al., 2001; Chatila et al., 2000; Fontenot et al., 2003; 
Hori et al., 2003; Khattri et al., 2003; Wildin et al., 2001). These studies revealed that 
Foxp3 is able to convert CD4+CD25- T cells into suppressive CD4+CD25+ T cells. 
Foxp3 has both transcriptional activator and repressor functions (Marson et al., 2007; 
Zheng et al., 2007). Even though Foxp3 expression is CD4+ T cell-specific, some CD8+ 
T cells express Foxp3 (Fontenot et al., 2003). Mutations in Foxp3 result in two severe 
autoimmune syndromes in human, namely IPEX and XLAAD (Bennett et al., 2001; 
Chatila et al., 2000; Wildin et al., 2001). T cell-specific Foxp3 deletion results in 
lymphoproliferative autoimmune disease as observed in Foxp3-deficient mice. Mice 
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lacking CTLA-4, TGF-β, and TGF-βR on T cells display similar phenotypes as observed 
in Foxp3-deficient mice. Although Foxp3 is critical for the development of Tregs, its role 
as lineage-specific transcription factor of Tregs has been challenged recently (Gavin et 
al., 2007; Lin et al., 2007). Foxp3 may be important to enhance and stabilize already 
established features of Treg cells mediated by IL-2 signaling (Gavin et al., 2007). 
Additionally, Foxp3 augments the expression of Fgl2, CD39, CD73, GRAIL or CTLA4, 
which are usually up regulated by conventional T cells following TCR activation (Gavin 
et al., 2007). The suppressive nature of mature Tregs in the periphery may require 
persistent expression of Foxp3 (Williams and Rudensky, 2007).  
 
The NFAT signaling cascade is required for Treg differentiation. In the absence of AP-1, 
signaling through calcium-calcineurin activates NFAT, which in turn upregulates Cbl-b 
expression, thereby inducing Foxp3 expression in a positive feedback loop by down 
regulating TCR signals (Heissmeyer et al., 2004; Sundrud and Rao, 2007; Wohlfert et al., 
2006). Apart from activating the Foxp3 promoter, NFAT and Smad3 induce Foxp3 
expression through its 120-bp enhancer of the Foxp3 intron between +2079 and +2198 
nucleotides (Tone et al., 2008; Wu et al., 2006). NFAT and Foxp3 co-operate with each 
other and bind to the Il2, Cd25, and Ctla4 promoters to induce their expression (Hu et al., 
2007; Wu et al., 2006). TCR induced NF-κB responsive element is located in the Foxp3 
promoter and upon TCR activation c-Rel, a NF-κB family member binds to the Foxp3 
enhancer region (Long et al., 2009). A Runt-related family member transcription factor, 
Runx1 is also required for Treg differentiation. Runx1 and Foxp3 can interact physically 
and functionally (Ono et al., 2007). In Treg cells Runx1 co-operates with Foxp3/NFAT 
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complex to activate Cd25, Ctla4, and Gitr expression (Hu et al., 2007). Th2 master 
regulator GATA3 has been shown to be important for the function of Treg cells (Wang et 
al., 2011; Wohlfert et al., 2011). GATA3 is expressed in Foxp3+ Tregs from barrier sites 
and Treg-specific GATA3 deletion leads to spontaneous inflammation in mice and the 
Tregs do not accumulate in the inflamed tissues (Wang et al., 2011; Wohlfert et al., 
2011). GATA3 binds to the cis-acting elements of Foxp3 thereby controlling its 
expression (Wang et al., 2011). Thus, multiple transcription factors cooperate with Foxp3 
to regulate the transcription of immunoregulatory Treg cells (Figure 7). 
 
Figure 7: Transcriptional regulation of Treg cells 
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Epigenetic regulation of Treg cells 
Expression of Foxp3 is stabilized by chromatin modifications during Treg development. 
A 30.8 kb genomic fragment containing Foxp3 gene can rescue the lymphoproliferative 
disorder of scurfy mice (Brunkow et al., 2001). An intronic enhancer between non-coding 
exons 2b and 1 of the Foxp3 gene is highly conserved and is responsible for regulation of 
Foxp3 expression. The CNS3 in the first intron of Foxp3 has functional ATF and CREB 
binding sites (Kim and Leonard, 2007). There is selective demethylation of CpG islands 
within the Foxp3 promoter in CD4+CD25+ Treg cells (Floess et al., 2007). CD4+CD25+ 
Treg cells have increased histone H3 acetylation compared to CD4+CD25- conventional 
T cells within the Foxp3 locus (Floess et al., 2007). In humans, FOXP3 demethylation 
acts as a stable mark of natural Treg expression (Baron et al., 2007). In the Treg-specific 
demethylated region (TSDR), DNA demethylation is apparent in in vivo generated 
Foxp3+ Treg cells (Polansky et al., 2008). TSDR methylation results in reduced 
transcriptional activity of Foxp3, while inhibition of DNA methylation leads to induction 
and stabilization of Foxp3 during priming and restimulation (Polansky et al., 2008). An 
upstream enhancer region of the Foxp3 gene with CpG residues recruits various DNMTs 
and other transcriptional repressors in naïve CD4+ T cells and iTregs but not in nTregs 
(Lal et al., 2009). Histone H3 acetylation of the upstream Foxp3 enhancer is observed in 
nTregs but not iTregs suggesting differences between nTreg and iTreg enhancer structure 
(Lal et al., 2009). The various epigenetic modifications that regulate the expression of 
Foxp3 are summarized below (Figure 8). 
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Figure 8: Chromatin modification of Treg cells 
 
Cross regulation of Th17, Tregs, Th1 and Th2 cells 
Ectopic RORγt expression inhibits STAT4 activation and T-bet induction when Th17 
cells are treated with IL-12 (Mukasa et al., 2010). IFN-γ and IL-27 inhibit Th17 
differentiation, the later by a STAT1-dependent mechanism (Batten et al., 2006; 
Harrington et al., 2005; Stumhofer et al., 2006). Deletion of T-bet in both CD4 and CD8+ 
T cells induces IL-17 production (Harrington et al., 2005; Intlekofer et al., 2008; 
Lazarevic et al., 2011; Mathur et al., 2006; Park et al., 2005; Yang et al., 2008a). IL-4-
induced Gfi-1, which promotes Th2 differentiation, blocks polarization of Th17 and 
iTregs (Zhu et al., 2009). Thus it is evident that Th1 and Th2 cell signaling pathway 
inhibit Th17 responses. However, whether Th17 signals restrict Th1 and Th2 responses 
need to be determined. TGF-β is the key cytokine for the differentiation of Th17 and 
Tregs, in the presence of IL-6 and IL-2, respectively. Mice without TGF-β do not develop 
Th17 and Treg cells and suffer from Th1-mediated autoimmune responses (Li et al., 
2006a; Veldhoen et al., 2006b). IL-6-activated STAT3 suppresses Foxp3 expression in 
developing Treg cells (Korn et al., 2007; Xu et al., 2007; Yang et al., 2008a; Yang et al., 
2007a; Zhou et al., 2008). Foxp3-mediated RORγt-induced IL-17 suppression may occur 
in a cell-intrinsic fashion. While naïve cells transduced with RORγt induces IL-17, co-
transduction of RORγt and Foxp3 reduces the induction of IL-17 (Zhou et al., 2008). The 
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RORγt-Foxp3 balance can be tipped to a Treg phenotype in the presence of retinoic acid 
and IL-2 which reduce RORγt expression and enhance TGF-β-induced Foxp3 expression 
(Coombes et al., 2007; Laurence et al., 2007; Mucida et al., 2007; Sun et al., 2007). The 
deficiency in IRF4, the transcription factor required for Th17 differentiation leads to 
increased Foxp3 expression and diminished RORγt expression. Treg-specific deletion of 
IRF4, also a target of Foxp3 leads to impaired abrogation of Th2 cell responses (Zheng et 
al., 2009). Foxp3 and Runx1 interaction in Tregs is required for IFN-γ inhibition and up 
regulation of Treg-specific markers (Ono et al., 2007). Pro-inflammatory cytokines block 
TGF-β-induced Foxp3 expression in a STAT3-dependent fashion. Therefore, mounting 
evidence from recent studies suggest that helper T cell subsets are not probably 
terminally differentiated and thus Th17 and Treg cells both regulated by TGF-β can 
cross-regulate with Th1 and Th2 cells.  
 
Transcriptional regulation of T follicular helper (Tfh) cells  
Tfh cells are CD4+ T cells are required to provide B cell help leading to antibody 
production, somatic hypermutation and class switching for long-lasting humoral 
immunity. Tfh cells were identified in human tonsils with CD4+ T cells expressing high 
levels of CXCR5 (Breitfeld et al., 2000; Kim et al., 2001; Schaerli et al., 2000). The 
cytokines IL-6 and IL-21 promote for Tfh cell differentiation (Chtanova et al., 2004; 
Eddahri et al., 2009; Nurieva et al., 2008; Suto et al., 2008). IL-6 has been demonstrated 
to induce IL-21 production (Eddahri et al., 2009; Nurieva et al., 2008; Suto et al., 2008). 
IL-21 signaling is required for increased CXCR5 expression on Tfh cells (Vogelzang et 
al., 2008). One study suggests that even though the absence of one of these cytokines 
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does not affect Tfh cell numbers, combined deficiency of both IL-6 and IL-21 leads to 
significantly reduced Tfh cell numbers (Eto et al., 2011). Tfh cells are characterized by 
the expression and production of CXCR5, inducible co-stimulator (ICOS), programmed 
death-1 (PD-1), and IL-21 (Breitfeld et al., 2000; Good-Jacobson et al., 2010; Hutloff et 
al., 2004; Schaerli et al., 2000). Mice with disrupted ICOS-ICOS ligand interaction or 
patients with ICOS mutations have decreased Tfh cell numbers (Akiba et al., 2005; 
Bauquet et al., 2009; Bossaller et al., 2006). Studies suggest that ICOS signaling via 
PI3K is important to increase expression of Tfh-specific genes such as c-Maf, and IL-21 
(Bauquet et al., 2009; Gigoux et al., 2009; Rolf et al., 2010), however whether ICOS is 
required to maintain Tfh differentiation is not completely understood.  Studies in mice 
deficient in PD-1 or its ligand PD-L1 indicate that PD-1/PD-L1 interactions may control 
long-lived plasma cells either positively or negatively (Good-Jacobson et al., 2010; 
Hamel et al., 2010; Hams et al., 2011). 
 
STAT family members in the development of Tfh cells 
Both IL-6 and IL-21 signal through STAT3 and STAT3-deficient CD4+ T cells 
demonstrate impaired differentiation of Tfh cells (Nurieva et al., 2008). T cell specific 
STAT3-deficient mice have defective germinal center B cell formation (Nurieva et al., 
2008). However, one report suggests normal CXCR5+ CD4+ T cells in Stat3
CD4-/-
 mice 
(Eddahri et al., 2009). IL-12 and IL-12 induced STAT4 induces genes that contribute to 
both Tfh and Th1 cell phenotypes during early Th1 differentiation (Nakayamada et al., 
2011).STAT5 negatively regulates Tfh cell differentiation and function (Johnston et al., 
2012; Nurieva et al., 2012). STAT5 inhibits the expression of CXCR5, c-Maf, and IL-21 
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in Tfh cells but positively regulates the expression of Blimp-1 (Nurieva et al., 2012). In 
the absence of STAT5 CD4+ T cells have increased germinal center B cell numbers and 
Tfh cell development (Johnston et al., 2012; Nurieva et al., 2012). 
 
Additional transcription factors required for Tfh cell development 
Bcl6, a transcriptional repressor, is the master regulator of Tfh cells (Johnston et al., 
2009; Nurieva et al., 2009; Yu et al., 2009). Tfh cells express high level of Bcl6 and Bcl6 
over expression leads to in vivo Tfh cell differentiation (Johnston et al., 2009).Bcl6 
regulates germinal center B cell differentiation by suppressing key signaling pathways 
(Basso et al., 2010; Crotty, 2011). A cluster of micro-RNAs that negatively regulate 
CXCR5, a key Tfh molecule, is suppressed by Bcl6 (Yu et al., 2009). Transcription 
factors associated with other T helper subsets are suppressed by Bcl6 (Nurieva et al., 
2009). Bcl6 suppresses the expression of Blimp-1, associated with non-Tfh cells to 
restrict non-Tfh differentiation (Crotty et al., 2010). 
 
The transcription factor Batf, required for Th2 and Th17 differentiation is also important 
for Tfh cell development (Betz et al., 2010). Batf-deficient mice have reduced number of 
Tfh cells and defects in germinal center development (Betz et al., 2010). Tfh cells 
produce IL-21, which is regulated by c-Maf (Bauquet et al., 2009). c-Maf-deficient mice 
have defective Tfh differentiation in vivo which may result from impaired induction or 
maintenance of IL-21 in the absence of c-Maf (Bauquet et al., 2009). IL-6 activates Maf 
expression and c-Maf directly binds to the Il21 promoter (Hiramatsu et al., 2010; Pot et 
al., 2009). Therefore c-Maf plays an important role in the regulation of IL-21, a cytokine 
 35 
produced by Tfh cells. The role of IRF4 in Tfh cell development is not well understood. 
IRF4-deficient mice show defect in Tfh cells but it is not clear whether this effect is due 
to defect in CD4+ T cell activation (Kwon et al., 2009). IRF4 induces Blimp-1 in CD4+ 
T cells (Kwon et al., 2009) while IRF4 and Bcl6 repress each other in germinal center B 
cells (Saito et al., 2007) making it difficult to elucidate the role of IRF4 in Tfh cell 
development. Therefore multiple transcription factors contribute to the development of 
Tfh cells. 
 
Epigenetic regulation of Tfh cells 
Studies have indicated plasticity between Tfh cells and other effector T cells (O'Shea and 
Paul, 2010). It is possible that Tfh cells may differentiate into Th1 cells while Treg and 
Th2 cells can become Tfh cells (O'Shea and Paul, 2010). In ex vivo Tfh cells and Tfh-like 
cells, the Bcl6 locus bears H3K4Me3 marks (Lu et al., 2011). Th1, Th2, and Th17 cells 
also display positive H3K4Me3 marks at the Bcl6 locus suggesting that these effector T 
cells have the ability to become Tfh cells (Lu et al., 2011). Both positive H3K4Me3 and 
negative H3K27Me3 marks are observed in Prdm1 gene which encodes the 
transcriptional repressor Blimp-1 in all effector T cells suggesting possible plasticity 
between Tfh and other effector T cells (Lu et al., 2011). Further studies need to be 
performed to understand the epigenetic regulation between Tfh and non-Tfh cells. 
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Transcriptional regulation of Th9 cells 
The newest member of CD4+ T cell family is the Th9 cell. Culturing Th2 cells with 
TGF-β or treating naïve CD4+ T cells with TGF-β and IL-4 gives rise to predominantly 
IL-9-secreting Th9 cells (Dardalhon et al., 2008; Veldhoen et al., 2008b). Th9 cells make 
very low amounts of Th2 cytokines IL-4, IL-5, and IL-13. The levels of IL-10 produced 
by Th9 cells vary among a number of reports (Chang et al., 2010; Dardalhon et al., 2008; 
Veldhoen et al., 2008b). Th9 cells promote allergic airway inflammation (Chang et al., 
2010; Staudt et al., 2010). Th9 cells play a protective role in worm expulsion as 
transgenic mice expressing a dominant negative form of TGF-βR fail to mount protective 
immune responses leading to increased worm burden (Veldhoen et al., 2008b). Adoptive 
transfer of Th9-polarized cells can promote the development of EAE and EAU, though 
the inflammation that develops is distinct from Th1- or Th17-mediated immunity (Jager 
et al., 2009; Tan et al., 2010). Contrary to these studies, IL-9 from Th9 cells could 
promote regulatory function (Elyaman et al., 2009). IL-9 can synergize with TGF-β to 
differentiate naïve CD4+ T cells into Th17 cells (Elyaman et al., 2009). 
 
Transcription factors in Th9 cell development 
Differentiation of Th9 cells requires both TGF-β and IL-4 signals. IL-4 signaling 
activated STAT6 is required in the development of Th9 cells similar to its requirement in 
Th2 cells (Dardalhon et al., 2008). The role of the other STAT molecules has not been 
examined. Although one report has demonstrated that downstream molecules of the TGF-
β signaling pathway, Smad2 and Smad3 are probably not required for Il9 expression, 
another study has documented the requirement of Notch receptors and Smad3 signaling 
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in the induction of Th9 cells (Elyaman et al., 2012; Takimoto et al., 2010). Notch 
signaling mediated by Jagged2 ligand but not Delta-like 1 promotes Th9 differentiation 
by activating the Il9 gene (Elyaman et al., 2012). 
The transcription factor, PU.1, promotes the development of IL-9-secreting T cells. PU.1-
deficient T cells exhibit attenuated IL-9 production, while ectopic expression of PU.1 in 
Th2 and Th9 cells can further induce IL-9 production (Chang et al., 2010). PU.1 is able to 
act directly on Il9 gene as it can bind to the Il9 promoter in Th9 cells (Chang et al., 2010). 
PU.1 is also required for IL-9 production in human T cells as inhibiting PU.1 expression 
in human T cells is associated with diminished IL-9 production (Chang et al., 2010). The 
transcription factor IRF4, required for the development of Th2 and Th17 cells is also 
essential for Th9 cell development (Staudt et al., 2010). IRF4-deficient CD4+ T cells 
display impaired Th9 cell differentiation (Staudt et al., 2010). IRF4 is able to 
transactivate Il9 gene by binding directly to its promoter (Staudt et al., 2010). Multiple 
transcription factor binding sites are identified at the Il9 promoter including PU.1, IRF4, 
AP-1, and NF-κB (Perumal and Kaplan, 2011). TCR-activated transcription factors 
NFAT1 and NF-κB (p65) synergize to induce IL-9 in Th9 cells (Jash et al., 2012). Both 
NFAT1 and p65 can bind to the Il9 promoter and NFAT1-deficient mice exhibit impaired 
IL-9 production resulting from inaccessible chromatin at the Il9 promoter (Jash et al., 
2012). Multiple transcription factors including AP-1, NF-κB, and c-Jun play important 
roles in the activation of human IL-9 in T cells (Zhu et al., 1996). In mast cells GATA1 
promotes IL-9 production and Il9 promoter activation which is p38MAPK-dependent 
(Stassen et al., 2007).  
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Epigenetic regulation of Th9 cells 
Il9 gene undergoes chromatin modification in Th9 cells. Three CNS regions have been 
identified in the Il9 gene (Perumal and Kaplan, 2011). The CNS1 and CNS0 regions have 
been shown to harbor binding sites of several transcription factors (Chang et al., 2010). 
The CNS2 region identified between human and mouse sequences is not conserved 
among other species (Perumal and Kaplan, 2011). Total acetylation of histone H3 and H4 
and acetylation of histone H3K9 and H3K18, all permissive chromatin marks are highest 
in Th9 cells at CNS1 and CNS2 of the Il9 gene when compared to other T helper subsets 
(Chang et al., 2010). Th9 cells have the lowest histone trimethylated H3K27, a repressive 
chromatin mark compared to the other Th subsets (Chang et al., 2010). In contrast, even 
though Tregs have acetylation marks similar to Th9 cells, the Il9 locus in Tregs has more 
trimethylated H3K27 compared to Th9 cells (Chang et al., 2010). This suggests that 
active Il9 expression is associated with a combination of high H3 acetylation and low 
H3K27 methylation. In the absence of PU.1, total H3 acetylation is reduced; however, 
total H4 acetylation remains unchanged (Chang et al., 2010). PU.1-deficiency does not 
alter H3 acetylation of Il9 in either Th2 or Th17 cells thereby implying Th9-specific 
histone modification (Chang et al., 2010). Whether IRF4 regulates histone modification 
of Il9 locus has not been examined in detail. NFAT1-deficiency results in 
transcriptionally repressive histone modifications at the Il9 promoter. The recruitment of 
acetylation of H3, H4 and methylation of H3K4Me2, associated with transcriptionally 
active chromatin, are attenuated in the absence of NFAT1 (Jash et al., 2012). 
Significantly diminished RNA polymerase II binding is observed in Nfat1-/- Th9 cells, 
correlated with reduced binding of active histone marks (Jash et al., 2012). Potential 
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Smad3 and RBP-Jκ binding motifs have been identified at the Il9 promoter (Elyaman et 
al., 2012). Th9 cells demonstrated enhanced permissive H3K4Me1 and attenuated 
restricted H3K27Me3 modifications in the Smad3 and RBP-Jκ binding sites of the Il9 
promoter (Elyaman et al., 2012). Therefore, the Il9 locus undergoes active histone 
modifications which are required for optimal Il9 expression. 
 
Biology of Interleukin-9 (IL-9) 
IL-9, IL-9 receptor cloning, signaling and expression 
IL-9 is a mast cell and T cell growth factor; however, IL-9 is functionally different from 
other growth factors as IL-9 can provide long term IL-2- and IL-4-independent growth of 
specific helper T cell lines but cannot stimulate the activity of cytolytic T cell lines  
(Hultner et al., 1990; Uyttenhove et al., 1988; Van Snick et al., 1989; Yang et al., 1989). 
The IL-9 gene encodes a 14 kD peptide, which has 144-amino acids including a 18-
amino acid signal peptide (Renauld et al., 1990). The mouse Il9 gene is located on 
chromosome 13 while human IL9 gene is located on chromosome 5 (Mock et al., 1990). 
The murine and human IL-9 genes are 69% identical at the nucleotide level and 55% at 
the protein level. Murine IL-9 can act on human cells; however, human IL-9 is not active 
on murine cells (Renauld et al., 1993). 
 
The IL-9 receptor (IL-9R) is constituted of two subunits: the alpha chain (IL-9Rα) and 
the common gamma chain receptor shared by the cytokines IL-2, IL-4, and IL-7 (Renauld 
et al., 1992; Russell et al., 1994). The mouse receptor contains 468-amino acids while 
human receptor cDNA encodes 522-amino acids with 53% identity with the mouse. Due 
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to alternative splicing, IL-9R mRNA lacks the sequences encoding the cytoplasmic and 
transmembrane domains (Renauld et al., 1992). The IL-9Rα chain is a member of the 
hematopoietin superfamily due to the presence of WSXWS motif in the extracellular 
domain, and the Box1 and Box2 motifs in the intracellular domain. IL-9/IL-9R 
interaction leads to the activation of STAT1, STAT3, and STAT5 (Bauer et al., 1998). 
Amino acids between 338 and 422 including a YLPQ motif in the Box1 intracellular 
domain is critical for IL-9-induced cell growth, activation of STAT3, and induced gene 
expression (Zhu et al., 1997). IL-9-mediated signaling results in formation of STAT5 
homodimers, STAT1 and STAT3 homodimers and heterodimers (Demoulin et al., 1996; 
Hornakova et al., 2009). A single tyrosine residue (Tyr407) in IL-9Rα is phosphorylated 
after ligand binding to the receptor leading to activation of associated Jak1. Mutation of 
this residue demonstrates its importance for IL-9-dependent responses (Demoulin et al., 
1996). IL-9R signaling also activates the MAP kinase and Insulin Receptor Substrate-PI3 
kinase pathways (Demoulin et al., 2003; Demoulin et al., 1996; Yin et al., 1995). IL-9R is 
expressed on T cell lines, and on effector T cells but not on naïve T cells (Cosmi et al., 
2004; Druez et al., 1990). In asthma patients, IL-9R is found on mast cells and PMNs in 
the lung and IL-9R is also expressed in non-hematopoietic cells (Abdelilah et al., 2001; 
Kearley et al., 2011). 
 
IL-9-secreting cells besides Th9 cells 
T cells are one of the sources of IL-9 since it can be produced by long-term T cell lines, 
antigen-specific T cell lines and naïve murine T cells (Schmitt et al., 1989). Among the 
effector T cells, Th2 cells have been shown to produce IL-9 (Gessner et al., 1993). Other 
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Th cells including Th17 cells can also produce IL-9 (Elyaman et al., 2009; Nowak et al., 
2009). Human Th17 cells can secrete IL-9, long-term Th17 cultures have the ability to 
co-express IL-17A and IL-9, and Th17 cells from patients with autoimmune diabetes 
have enhanced IL-9 production (Beriou et al., 2010). In some instances Treg cells may 
also produce IL-9. Both natural Tregs (nTregs) and inducible Tregs (iTregs) can secrete 
IL-9 according to a study where mast cells have been linked to peripheral tolerance (Lu et 
al., 2006). Whether human Treg cells produce IL-9 is not properly understood (Beriou et 
al., 2010). Recently, a specialized subset of T cells has been shown to produce IL-9 
(Dardalhon et al., 2008; Veldhoen et al., 2008b). Naïve CD4+ T cells primed in the 
combination of TGF-β and IL-4 selectively, produce IL-9 abundantly (Dardalhon et al., 
2008; Schmitt et al., 1994; Veldhoen et al., 2008b). Mast cells in the presence of LPS and 
IL-1 can produce IL-9 (Hultner et al., 2000; Stassen et al., 2000). iNKT cells can also 
produce IL-9 (Coquet et al., 2008). 
 
Cell-type specific functions of IL-9 
IL-9 is a cytokine that has biological functions on a number of cell types in addition to T 
cells. IL-9 plays roles on B cell development and function. Transgenic expression of IL-9 
results in enhanced peritoneal CD11b+ B1 B cells, and can recover the B1 cell numbers, 
but not natural IgM production, in xid mice (Knoops et al., 2004; Vink et al., 1999). From 
human B cells IL-9 can augment IL-4-mediated IgE and IgG but not IgM production 
(Dugas et al., 1993; Petit-Frere et al., 1993). IL-9 plays a similar role on germinal center 
B cells which have greater IL-9Rα expression than other B cell types (Fawaz et al., 2007). 
IL-9 promotes mast cell growth and function in response to pathogens (Townsend et al., 
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2000). IL-9, alone or in combination with Stem Cell Factor (SCF) or FcεRI, promotes the 
expression of mast cell proteases and pro-allergic cytokines in cultured mast cells 
(Eklund et al., 1993; Hultner et al., 1990; Lora et al., 2003; Wiener et al., 2004). Together 
with SCF, IL-9 can induce mast cell growth from bone marrow and mast cell progenitors 
(Matsuzawa et al., 2003). Hematopoiesis is also regulated by IL-9. Apart from 
synergizing with IL-3 in promoting the growth of IL-3-dependent cell lines, IL-9 can also 
enhance BFU-E, CFU-E and multi-lineage colony formation in combination with other 
factors including SCF from cord blood and bone marrow precursors (Donahue et al., 
1990; Holbrook et al., 1991; Lemoli et al., 1994; Williams et al., 1990). Human IL-9 is 
also an activator of megakaryocyte progenitor cells (Fujiki et al., 2002). IL-9 transgenic 
expression in the lung alters airway epithelial cell gene expression (Temann et al., 1998). 
The effects of IL-9 in the lung can occur due to indirect effects of IL-13 (Steenwinckel et 
al., 2009; Steenwinckel et al., 2007; Temann et al., 2007; Whittaker et al., 2002). The 
effects of IL-9 on human primary airway epithelial cells and cell lines can result through 
direct induction of mucus genes (Longphre et al., 1999; Louahed et al., 2000; Reader et 
al., 2003; Vermeer et al., 2003). IL-9 also acts on airway smooth muscle cells in the lung. 
Human airway smooth muscle cells express both IL-9 receptors and IL-9 can potentiate 
the ERK-dependent release of CCL11 and IL-8 from these cells (Baraldo et al., 2003; 
Gounni et al., 2004). Thus, IL-9 functions on multiple cell types and is a pleiotropic 
cytokine (Figure 9). 
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Figure 9: IL-9 is a pleiotropic cytokine 
 
IL-9-mediated inflammation 
IL-9 exhibits pro-inflammatory activity in several mouse models of inflammation. 
Genetic studies have provided evidence that IL-9 is a key player in asthma (Nicolaides et 
al., 1997). Transgenic expression of IL-9 in the lung results in allergic inflammation that 
is at least partially dependent on the presence of Th2 cytokines (Temann et al., 1998; 
Temann et al., 2002). IL-25, a cytokine that shares sequence similarity with IL-17 also 
induces allergic inflammation through an IL-9-dependent mechanism (Angkasekwinai et 
al., 2010). Though blocking of IL-9 reduces allergic airway inflammation in standard 
sensitization-challenge model, IL-9-deficient mice still can develop allergic inflammation 
(Cheng et al., 2002; Kung et al., 2001; McMillan et al., 2002). In a chronic model of lung 
inflammation, blocking IL-9 inhibits mastocytosis and airway remodeling. Intratracheal 
administration of IL-9 in naïve C57BL/6 mice leads to lung eosinophilia, Il5Rα 
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expression and elevated serum IgE levels (Levitt et al., 1999). In humans, cells in the 
bronchial mucosa of atopic asthmatics express enhanced Il9 mRNA; correlated with the 
numbers of eosinophils and mast cells at the inflammation site (Shimbara et al., 2000; 
Ying et al., 2002). In the bronchoalveolar lavage fluid of atopic asthmatics segmental 
allergen challenge can enhance IL-9 production from lymphocytes (Erpenbeck et al., 
2003).  
 
In addition to the lung, IL-9 can mediate inflammation in the intestine (Forbes et al., 
2008; Knoops et al., 2005; Osterfeld et al., 2010). Transgenic IL-9 expression or IL-9 
administered by injection can enhance the susceptibility of both active and passive 
anaphylaxis (Knoops et al., 2005). IL-9 may be important for anaphylaxis caused by 
allergen challenge at mucosal surfaces but not parenterally administered allergen as 
systemic anaphylaxis can occur in both Il9-/- and Il9r-/- mice (Forbes et al., 2008; 
Knoops et al., 2005).  
 
The IL-9-mediated pro-inflammatory environment plays protective role in immunity to 
intestinal parasites. Mice bearing transgenic expression of IL-9 can clear worms more 
efficiently after infection with Trichuris muris and Trichinella spiralis (Faulkner et al., 
1997; Faulkner et al., 1998). Adoptive transfer of IL-9 transgenic bone marrow derived 
DC increases immunity to T. spiralis, while anti-IL-9 blocks T. muris immunity (Leech 
and Grencis, 2006; Richard et al., 2000). IL-9-deficient mice are able to control Giardia 
lamblia and Nippostrongylus brasiliensis infection, although neutralization of IL-9 results 
in increased immunity to Leishmania major, owing to blockade of Th2 immunity 
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(Arendse et al., 2005; Li et al., 2004; Townsend et al., 2000). IL-9, though important for 
mastocytosis and goblet cell metaplasia is not required for granuloma formation 
following injection with Schistosoma mansoni eggs (Townsend et al., 2000). IL-9 also 
plays a role in regulating immunity to infectious disease. IL-9 neutralization can be 
therapeutic in the clearance of RSV (Dodd et al., 2009). IL-9 can diminish septic shock 
symptoms by reducing inflammatory cytokines and respiratory burst in the monocytes 
(Grohmann et al., 2000; Pilette et al., 2002).  
 
The exact roles of IL-9 in EAE remain controversial. IL-9 can promote the development 
of peripheral nervous system lesions (Elyaman et al., 2009). IL-9Rα-deficiency or anti-
IL-9 treatment results in delayed EAE development (Li et al., 2011; Nowak et al., 2009). 
However, in a separate report there was increased severity of EAE from Il9r-/- mice 
owing to decreased IL-9 effect on Treg cells (Elyaman et al., 2009). The anti-
inflammatory role of IL-9 is consistent with a described role for IL-9 in promoting mast 
cell dependent tolerance to transplanted allografts and nephritis (Eller et al., 2011; Lu et 
al., 2006). IL-9 certainly has effects in the EAE models on T and non-T cells and the 
effect of blocking IL-9/IL-9R may depend upon the cells present in the 
microenvironment (Nowak et al., 2009). 
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T helper cells: Overall functions 
Each T helper subset is characterized by the expression of individual STAT molecules 
and lineage-specific transcription factors. The effector T cells execute immune functions 
to protect from different kind of invading pathogens. The summary of the transcription 
factors and the functions associated with each T helper subset is depicted below (Figure 
10).  
 
Figure 10: Schematic diagram of various T helper subsets. Each T helper cells is 
characterized by the cytokines they produce and the transcription factor they express. 
These T helper cells play a role in mounting defense against various pathogens. 
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Research goals 
The focus of our research is to understand the transcriptional regulation of IL-9-secreting 
Th9 cells. We have three specific goals for our research. The first goal is to characterize 
the phenotype of IL-9-secreting T cells. Our second goal is to elucidate the transcriptional 
network governing Th9 cells. This aim will specifically look into the role of STAT 
family members and the transcription factors downstream of TGF-β and IL-4 signals 
required for the development of Th9 cells. We have previously shown that the 
transcription factor PU.1 is required for Th9 cell development. Our final goal therefore is 
to define the PU.1-dependent mechanism for the regulation of Il9 gene in Th9 cells. 
 
There has been renewed interest in IL-9 cytokine biology.  Initially IL-9 was 
characterized as a cytokine produced by Th2 cells evident in models of Th2-mediated 
inflammation. That a specific T helper subset exists for secreting IL-9 has been 
highlighted recently in two reports (Dardalhon et al., 2008; Veldhoen et al., 2008b). 
Naïve CD4+ T cells activated and primed in the presence of TGF-β and IL-4 have the 
capacity to secrete IL-9. Therefore we want to characterize the cytokine profile of the 
Th9 subset and determine how the subset differs from other T helper subsets. 
 
We hypothesized that PU.1 might play a positive role in Th9 cell development.  Th2 cells 
ectopically expressed with PU.1-expressing retrovirus produce reduced amount of Th2 
cytokines. Similarly regular Th9 cells secrete diminished amount of Th2 cytokines. We 
observed that PU.1-deficient T cells have an impaired ability to produce IL-9 under Th9 
differentiating conditions.  
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In addition to STAT6, the role of other STAT proteins has not been described in the 
development of Th9 cells. The transcription factors regulated by both TGF-β- and IL-4-
induced signaling have not been examined previously. We therefore establish a 
transcription factor network downstream of TGF-β and IL-4 that regulates IL-9. 
 
PU.1 can bind to the Il9 promoter and there are PU.1-dependent histone modifications in 
Th9 cells. Based on multiple techniques, including retroviral gene transduction and ChIP, 
we define the domains of PU.1 required for Il9 gene induction, demonstrate association 
of histone modifying enzymes with PU.1, chromatin modifications which are PU.1-
dependent and address the mechanisms by which PU.1 induces IL-9 in Th9 cells. 
 
Together, these studies will elucidate how Il9 gene is transcriptionally and epigenetically 
regulated in Th9 cells. 
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MATERIALS AND METHODS 
Mice 
Wild-type (WT) mice on both C57BL/6 and Balb/c background were purchased from 
Harlan Biosciences (Indianapolis, IN). Mice with lymphocyte conditional PU.1 gene 
deletion (Sfpi1
lck-/-
) on C57BL/6 background were previously described and were mated 
to mice expressing the Cre transgene under the control of the Lck promoter (Dakic et al., 
2005). Mice with conditional Stat3 deletion, which were provided by Dr. David Levy 
(New York University, New York, NY) and described previously, were mated to Cd4-cre 
mice (Chiarle et al., 2005; Stritesky et al., 2011). Stat6-deficient mice and Parp14-
deficient mice were described previously and are on a BALB/c and C57BL/6 
background, respectively (Cho et al., 2009; Kaplan et al., 1996a). Runx3
fl/fl
 mice were 
mated to dLck-Cre mice (Yagi et al., 2010). Tbx21-/- mice were described previously and 
were on C57BL/6 background (Szabo et al., 2002). Il4-deficient mice were purchased 
from Jackson Laboratories and were bred in the Indiana University animal facility. All 
mice were maintained in specific pathogen-free conditions and experiments approved by 
the Indiana University Institutional Animal Care and Use Committee. 
 
Murine T helper cell differentiation 
Naive CD4
+
CD62L
+
 T cells were purified from spleens and lymph nodes by magnetic 
selection (Miltenyi Biotec). Naive CD4+ T cells (1×10
6
 cells/ml complete RPMI 1640 
medium) were activated with plate-bound anti-CD3 (2 μg/ml; 145-2C11; BioXcell) and 
soluble anti-CD28 (1 μg/ml; 37.51; BD Biosciences) and cultured under Th9 conditions 
(IL-4 [20 ng/ml; PeproTech], TGF-β [2 ng/ml; R&D Systems], and anti–IFN-γ [10 
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μg/ml; XMG; BioXcell]); Th2 conditions (IL-4 and anti–IFN-γ); Th1 conditions (IL-12 
[5 ng/ml; R&D Systems], IL-2 [50 U/ml; PeproTech], and anti–IL-4 [10 μg/ml; 11B11; 
BioXcell]); Th17 conditions (TGF-β, IL-6 [100 ng/ml; R&D Systems], IL-1β [10 ng/ml; 
eBioscience], IL-23 [10 ng/ml; R&D Systems], anti–IFN-γ, and anti–IL-4); and Treg 
conditions (TGF-β and anti–IL-4). After 3 days, cultures were expanded with fresh 
complete RPMI 1640 medium with IL-4 and TGF-β added to the Th9 cells; half the dose 
of IL-1β, IL-23, and IL-6 added to the Th17 cells; and IL-2 added to Tregs. Following 5 
days of differentiation Th9, Th2, and Th17 cells were re-stimulated with plate-bound 
anti-CD3 (2 μg/ml) for 1 day. Cell-free supernatant was collected and stored at -200C 
until further use. In some experiments Th9 cultures were supplemented with neutralizing 
IL-10 antibody (10 μg/ml; JES5-2A5; Biolegend) and Th2 cultures were treated with 
recombinant IL-9 (10 ng/ml; PeproTech). 
 
Intracellular cytokine staining 
Differentiated cells were stimulated with PMA (phorbol 12-myrisate 13-acetate) (50 
ng/ml; Sigma) and ionomycin (500 ng/ml; Sigma) for a period of 5 hours. Monensin was 
added to the cells for the last 3 hours of stimulation. After fixing the cells with 
paraformaldehyde and permeabilizing with saponin, cells were stained with fluorochrome 
conjugated anti-mouse IL-9 (RM9A4, Biolegend), anti-mouse IL-4 (11B11, Biolegend), 
anti-mouse IL-17A (eBio17B7, eBioscience), anti-mouse IL-10 (JES5-16E3, BD 
Pharmingen) antibodies for 30 minutes at 4
0
C. Intracellular Foxp3 staining was 
performed according to manufacturer’s instructions (eBioscience). Samples were 
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analyzed by flow cytometry using FACSCalibur machine (Beckton Dickinson) and were 
analyzed by WinMDI. 
 
Phospho-STAT protein analysis 
Th2 and Th9 cells were harvested each day during the 5 day differentiation, fixed with 
1.5% paraformaldehyde for 10 min at room temperature, and permeabilized for 10 min 
with 100% methanol at 4
0
C. Cells were then stained for phospho-STAT3 (4/P-STAT3, 
BD Pharmingen) and phospho-STAT6 (J71-773.58.11, BD Pharmingen) after 30 min at 
room temperature. Cells were analyzed by flow cytometry with FACSCalibur. 
 
Cell surface staining 
During five days of Th2 and Th9 cell differentiation, cells were collected each day and 
washed with FACS/ELISA buffer (2% BSA and 0.01% sodium azide in 1X PBS). Cells 
were then surface stained for ST2 (DJ8, MD Biosciences) and IL-4Rα (mIL4R-M1, BD 
Pharmingen) using fluorochrome conjugated antibodies at 4
0
C for 30 minutes. Following 
incubation cells were washed with FACS/ELISA buffer and resuspended in 
FACS/ELISA buffer to analyze by flow cytometry using FACSCalibur. Data were 
analyzed by WinMDI software. 
 
Intracellular c-Maf and GATA3 staining 
Differentiated Th2 and Th9 cells were harvested and were kept unstimulated or 
stimulated with 2 μg/ml anti-CD3 for 6 hours and were fixed with formaldehyde (1.5% 
final concentration) for 10 minutes at room temperature. Cells were then permeabilized 
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with 100% ethanol for 10 minutes at 4
0
C. Following permeabilization cells were stained 
with anti-c-Maf (sc-10019) antibodies for 15 minutes followed by anti-IgG alexa 647 for 
15 minutes at room temperature or with anti-GATA3 (L50-823, BD Pharmingen) for 30 
minutes. 
 
Retroviral transduction 
Bicistronic retroviral vectors encoding mouse GATA3 and human CD4, T-bet, Foxp3, 
JunB, or c-Maf (kindly provided by I.C. Ho, Brigham and Women’s Hospital, Boston, 
MA) and enhanced GFP, or Runx3 and Thy1.1 (kindly provided by Shreevrat Goenka) 
were used to generate virus. Myc-tagged PU.1 cDNA or PU.1 mutant cDNAs were 
cloned into MIEG-eGFP vector (Klemsz and Maki, 1996). The Phoenix-Eco packaging 
cell line were transiently transfected with 15 μg of each purified plasmid by calcium 
phosphate precipitation in chloroquine containing DMEM media to generate retroviral 
supernatants. Cells were cultured at 37
0
C and chloroquine containing DMEM media was 
replaced with fresh DMEM media one day after transfection. After one and two days 
following transfection, the supernatants containing retrovirus were collected, filtered 
through a 0.45 μm filter and stored at -800C. Following 48 hours of differentiation, T 
helper cells were transduced with 2-4 ml of retroviral supernatant containing 8 μg/ml 
polybrene by centrifugation at 2000 RPM at room temperature for 1 hour. After the spin 
infection the retroviral supernatant was replaced with original RPMI 1640-conditioned 
media with 50 U/ml human IL-2. On day 5, transduced cells (eGFP
+
, Thy1.1
+
, or hCD4
+
) 
were analyzed by flow cytometry. In some experiments transduced cells were sorted by 
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flow cytometry before cytokine production, gene expression analyses and chromatin 
immunoprecipitation. 
 
In some experiments developing Th9 cells were transduced with control or PU-Estrogen 
receptor fusion retroviruses with increasing doses (0, 50, 250, and 1000nM) of 4-
Hydroxytamoxifen (4-HT), an active metabolite of tamoxifen which binds estrogen 
receptors each day during 5 day differentiation. The retrovirus supernatants were 
prepared in DMEM media with charcoal treated serum to remove endogenous estrogens. 
Since PU.1 expression at the basal level was already high, 4-HT-inducible gene 
expression was not observed. This may occur due to the presence of phenol red in the 
media thereby reducing the ability of exogenous estrogen to stimulate responses 
(Berthois et al., 1986). 
 
Assessing cytokine production by ELISA 
T cells differentiated for 5 days were harvested, washed and stimulated (1×10
6
 cells/ml) 
with 2 μg/ml plate-bound anti-CD3 for 24 hours to generate cell-free supernatant. In 
some experiments, differentiated Th9 cells were re-stimulated with plate-bound anti-CD3 
and soluble TGF-β (2 ng/ml) for 24 hours. To detect cytokine secretion 2 μg/ml α-IL-4 
(11B11, BD Pharmingen) α-IL-5 (TRFK5, BD Pharmingen), α-IL-10 (JES5-2A5, BD 
Pharmingen), α-IL-13 (eBio13A, eBioscience), α-IL-17A (TC11-18H10, BD 
Pharmingen), α-IL-21 (AF594, R&D Systems) and 1 μg/ml α-IL-9 (D8402E8, BD 
Pharmingen) capture antibodies were dissolved in 0.1M NaHCO3 (pH 9.0) coating buffer. 
50 μl of the capture antibodies were coated in each well of 96-well Nunc-immuno plates 
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and were incubated overnight at 4
0
C. Plates were washed in ELISA wash buffer (0.1% 
Tween-20 in PBS) and blocked for 2 hours in FACS/ELISA buffer at room temperature. 
Supernatants and cytokine standards were added to the plates after FACS/ELISA buffer 
was removed, and plates were incubated overnight at 4
0
C. Biotinylated [α-IL-4 (BVD6-
24G2, BD Pharmingen), α-IL-5 (TRFK4, BD Pharmingen), α-IL-9 (D9302C12, 
Biolegend), α-IL-10 (SXC-1, BD Pharmingen), α-IL-13 (eBio1316H, eBioscience), α-IL-
17A (TC11-8H4.1, BD Pharmingen), and α-IL-21 (BAF594, R&D Systems)] antibodies 
(1 μg/ml) were dissolved in FACS/ELISA buffer and were added to the plates (100 
μl/well) after the plates were washed with ELISA wash buffer. Following 2 hours 
incubation at room temperature plates were washed again with ELISA wash buffer and 
incubated with avidin-alkaline phosphatase  (100 μl/well)(1:2000 dilution; Sigma) in 
FACS/ELISA buffer for 1 hour at room temperature. Cytokine levels were assessed after 
the addition of Sigma 104 phosphatase substrate (5 mg/ml) dissolved in ELISA substrate 
buffer (10% diethanolamine, 0.05 mM MgCl2, 0.02% NaN3, pH 9.8) by measuring 
absorbance at 405 and 450 nm  to subtract the background noise (Bio-Rad microplate 
reader model 680). 
 
Quantitative RT-PCR (qPCR) 
Total RNA was isolated from unstimulated or stimulated (plate-bound anti-CD3; 2 
μg/ml) cells using TRIzol and reverse transcribed, according to the manufacturer’s 
instructions (Invitrogen Life Technologies). For qPCR, cDNA (2 μl), TaqMan Fast 
Universal Master Mix (5 μl) and commercially available primers were used for Bcl6, 
Foxp3, Gata3, Gcn5, Gfi-1, Il9, Il10, Il21, Irf4, Maf, Runx3, Sfpi1, and Tbx21 (Applied 
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Biosystems, 0.5 μl each). DEPC water was added to final reaction volume of 10 μl. RNA 
expression was normalized to the expression of β2-microglobulin. The relative expression 
was calculated by the change-in-threshold (−ΔΔCT) method. 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Catalog numbers of the primers used for real time PCR 
 
Primers Applied Biosystems catalog number 
Bcl6 Mm00477633_m1              
Foxp3 Mm00475156_m1           
Gata3 Mm00484683_m1 
Gcn5 Mm00517402_m1 
Gfi-1 Mm00515853_m1 
Il9 Mm00434305_m1 
Il10 Mm00439614_m1 
Il21 Mm00517640_m1 
Irf4 Mm00516431_m1 
Maf Mm01546091_s1 
Runx3 Mm00450960_m1 
Sfpi1 Mm00488140_m1 
Tbx21 Mm00450960_m1 
 56 
Western blot analysis 
Total cell lysates were prepared from Th9, Th2, or Th1 cells after 5 days of 
differentiation. In some experiments Th9 cell extracts were prepared from WT and 
Sfpi1
lck-/-
 mice. Differentiated Th cells were harvested, washed and lysed in 25 μl of lysis 
buffer (10% glycerol, 1% IGEPAL, 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA and 
protease inhibitor cocktail (1:100; Sigma)). Cells were incubated on ice for 10 minutes 
and spinned down at 14,000 RPM at 4
0
C. The lysates were resuspended in SDS-PAGE 
loading buffer (200 mM Tris-HCl, pH 6.8, 40% glycerol, 8% SDS, 4% β-
mercaptoethanol, 0.04% bromophenol blue). Samples were boiled at 100
0
C for 5 minutes 
to denature proteins and complexes. Protein samples and Precision Blue marker (Bio-
Rad) were loaded and separated on pre-cast 4-12% gradient Bis-tris polyacrylamide gel 
(Invitrogen). After running the gel at 100V for 2-3 hours proteins from the gel were 
transferred onto nitrocellulose membrane (Whatman GmbH) at 40 mA overnight at 4
0
C. 
The blots were blocked in 5% nonfat dry milk at room temperature for 1-2 hours. The 
membrane was immunoblotted using primary antibodies dissolved in PBST with 5% 
nonfat dry milk to detect Gcn5 (sc-20698, Santa Cruz), IRF4 (sc-6059, Santa Cruz), p300 
(sc-584, Santa Cruz), PCAF (sc-8999, Santa Cruz), PU.1 (sc-352, Santa Cruz), and 
Runx3 (sc-130014, Santa Cruz) overnight at 4
0
C. The membrane was washed with 
ELISA wash buffer for 5 minutes 3 times. Secondary antibody diluted in PBST with 5% 
nonfat dry milk was added to the membrane for 1 hour at room temperature. The 
membrane was washed 5 minutes 3 times following incubation. The final reaction was 
developed using Western Lighting Chemiluminescence reagent (Perkin Elmer Life 
Sciences, Wellesley, MA) and classic blue autoradiography film BX (Molecular 
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Technologies, MO) was used to detect the signal. The membrane was stripped in 
stripping buffer (10% SDS, 62.5 mM Tris-HCl, 0.7% β-mercaptoethanol) and reprobed 
with anti-β-actin as loading control.  
 
Chromatin immunoprecipitation (ChIP) 
ChIP assay was performed (with 5-10×10
6
 cells), as previously described with minor 
modifications (Yu et al., 2007). Similar numbers of differentiated cells were kept 
unstimulated, fixed with 1% formaldehyde, resuspended in cell lysis buffer and incubated 
on ice for 10 minutes. Following lysis of the nuclei and shearing the genomic DNA, cell 
lysates were diluted in ChIP dilution buffer, pre-cleared with salmon sperm DNA and 
BSA. Immunocomplex was precipitated with protein A or protein G-agarose beads at 4
0
C 
for 1 hour. The supernatant was incubated in the presence of rabbit polyclonal antibodies 
anti-PU.1 (sc-352 X, anti-Gcn5 (sc-20698, Santa Cruz), anti-Stat6 (sc-1698 X, Santa 
Cruz) anti-Histone H3 (06-755, Upstate), anti-acetyl-H3 lysine 9/18 (07-593, Millipore), 
anti-acetyl-H3 lysine 14 (07-353, Millipore), anti-acetyl-H3 lysine 27 (07-360, 
Millipore), anti-Histone H4 (ab7311, Abcam), anti-acetyl-H4 lysine 5 (07-327, 
Millipore), anti-acetyl-H4 lysine 8 (ab15823, Abcam), anti-acetyl-H4 lysine 16 (07-329, 
Millipore), anti-acetyl-H3 lysine 36 (07-540, Millipore), rabbit IgG (12-370, Millipore), 
mouse monoclonal anti-HDAC1 (sc-8410, Santa Cruz), mouse IgG1 (sc-3877, Santa 
Cruz), goat polyclonal anti-IRF4 (sc-6059 X, Santa Cruz), anti-HDAC2 (sc-6296, Santa 
Cruz), and goat IgG (sc-3887, Santa Cruz)) overnight at 4
0
C. The beads were washed 
consecutively with low salt wash buffer, high salt wash buffer, LiCl wash buffer, and 
twice in TE buffer. The supernatant was collected, supplemented with 2 mM EDTA, 20 
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mM Tris-HCl, 10 mg/ml Proteinase K. DNA cross-links were reversed by incubating 
precipitates overnight at 65
0
C, and DNA was purified by phenol-chloroform extraction 
and ethanol precipitation. DNA quantification was performed with SYBR Green Fast 
PCR Master Mix via an ABI 7500 Fast Real-time PCR system. A standard curve was 
generated from serial dilutions of input DNA to quantify immunoprecipitated DNA. The 
amount of immunoprecipitated DNA from the IgG control was subtracted from the 
amount of immunoprecipitated DNA from the specific antibody ChIP and normalized 
against the amount of input DNA to calculate percentage input.  
 
Primers Sequence 
Gata3 For 
Gata3 Rev 
5’CGTATATGATGAGTCTTCTCTGGGACTTG 3’ 
5’AAATCTCAGAACACACACATTTCCAGGG 3’ 
Il9 CNS1 For 
Il9 CNS1 Rev 
Il9 CNS0 For 
Il9 CNS0 Rev 
5’CAGTCTACCAGCATCTTCCAGTCTAGC 3’ 
5’GTGGGCACTGGGTATCAGTTTGATGTC 3’ 
5’GAGCTGAACGCAGGCCAAGAACGA 3’ 
5’CTTGGAACTAGTTATCTCTCCACTG 3’ 
Irf4 For 
Irf4 Rev 
5’CCGACAGACAGAAGGTGTTCAAAGAAT 3’ 
5’TTCCATTGTCAGAGCCCTGGTAGTAAAC 3’ 
 
Table 2: Primer sequences used for ChIP. 
 
DNA Oligo Pull-down experiment 
Nuclear lysates were prepared from wild-type and Sfpi1
lck-/- 
Th9 cells. Differentiated Th9 
cells were washed in cold PBS and centrifuged at 1500 RPM for 5 min at 4
0
C. Cell 
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pellets were resuspended in ice cold cell lysis buffer (100 mM Tris-HCl, 100 mM NaCl, 
3% MgCl2) for 10 minutes and were incubated for another 10 minutes after adding 20% 
NP-40. Cells were centrifuged 5000 RPM for 5 min at 4
0
C and were lysed in lysis buffer 
for 20 minutes at 4
0
C. Nuclear extracts were collected to fresh tubes after spinning at 
14,000 RPM for 10 minutes at 4
0
C. Streptavidin-agarose beads were incubated with 
consensus or mutated PU.1-binding oligonucleotides in pull-down buffer (25 mM 
HEPES, 15 mM NaCl, 0.5 mM DTT, 0.5% NP-40, 0.1 mM EDTA pH 7.5, 10% 
Glycerol) for 30 minutes at 4
0
C. Following incubation the beads were washed for 3 times 
in pull-down buffer (1 minute each). Extracts were then incubated with the beads and 
salmon sperm DNA for 2 hours at 4
0
C. The consensus PU.1-binding site was previously 
described (Chang et al., 2010). The sequences for the mutated PU.1-binding sites are 
biotin-CTTTTCTGATCGCTGGTATT and its reverse complement. Protein-DNA 
complexes were separated by SDS-PAGE and immunoblots were probed with anti-Gcn5, 
anti-PCAF, and anti-PU.1 antibodies. 
 
Gcn5 small interfering RNA (siRNA) transfection 
Differentiated Th9 cells from wild-type mice were transiently transfected with control or 
Gcn5-specific siRNA (0.2 μM, sc-37947, Santa Cruz) using Amaxa Nucleofector 
(Lonza). Cells were rested overnight in 5% CO2 incubator with hIL-2 (50 U/ml). Cells 
were then either kept unstimulated for ChIP assay or stimulated with 2 μg/ml plate bound 
anti-CD3 for 6 hours for RNA isolation or for 24 hours to collect cell-free supernatant for 
ELISA. 
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RESULTS 
PART I: Phenotype of IL-9-secreting T cells 
Naïve T cells differentiated with TGF-β and IL-4 produce IL-9 
There has been a recent surge of interest towards the understudied cytokine IL-9, a factor 
which has been previously demonstrated to be involved in multiple inflammatory 
responses. More than 15 years ago, one study demonstrated that when T cells are treated 
with TGF-β and IL-4 they secrete IL-9 (Schmitt et al., 1994); this finding has been 
reiterated by two recent reports (Dardalhon et al., 2008; Veldhoen et al., 2008b). These 
primed cells are presently known as Th9 cells. Our initial goal was to further define 
cytokine production by Th9 cells, and to determine the specificity of IL-9 expression 
among Th subsets. To determine if other T helper subsets are capable of secreting IL-9, 
we isolated naïve CD4+ T cells from WT mice and differentiated them under Th1, Th2, 
Th17, Treg, and Th9 (TGF-β+IL-4) cell conditions for 5 days. Il9 expression was 
measured by real time PCR from differentiated cells after anti-CD3 reactivation. 
Expression of Il9 was observed only in Th9 cell conditions (Figure 11A). As the cytokine 
IL-4 is required for the development of both Th2 and Th9 cells, and IL-9 has been shown 
to be secreted in various Th2-mediated inflammation models, we wanted to define the 
production of IL-9 by Th2 cells in detail. To test this, WT naïve CD4+ T cells were 
cultured under Th2 and Th9 cell conditions for 5 days. The percentages of IL-9-secreting 
cells assessed by intracellular staining and the total IL-9 production assessed using 
ELISA and Il9 expression measured by real time PCR, was significantly lower in Th2 
cells (Figure 11B-D). There were very few IL-4-secreting cells (about 3 fold less than 
Th2 cells) produced by Th9 cells (Figure 11B). Th2 and Th9 cells had about 20 % of IL-
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4+IL-9+ double-positive cells (Figure 11B). Published reports had shown that Th17 cells 
can produce IL-9 and conversely, Th9 cells can produce IL-17 (Elyaman et al., 2009; 
Nowak et al., 2009). We observed minimal IL-9 produced by Th17 cells compared to 
Th9 cells by intracellular cytokine staining and ELISA (Figure 11E, F). This observation 
can be attributed to variability in the length of the differentiation and the concentration of 
cytokines used for polarization. In contrast, Th9 cells produced detectable IL-17 but 
significantly less than Th17 cells (Figure 11F). TGF-β-induced Treg cells have also been 
suggested to produce IL-9 (Lu et al., 2006). Thus we compared the levels of Foxp3 and 
IL-9 between Th9 and Treg cells. Th9 cells expressed Foxp3 at a level lower than Tregs 
(Figure 11G). When compared with Th9 cells, Treg cells secreted very low or 
undetectable levels of IL-9 assessed by both intracellular staining and ELISA (Figure 
11G, H). Therefore among various T helper cells, Th9 cells are the predominant 
producers of IL-9. 
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Figure 11: Naïve T cells cultured with IL-4 and TGF-β predominantly produce IL-9. 
(A) Naïve CD4+ T cells from WT mice were differentiated under Th1 (IL-12+ anti-IL-4), 
Th2 (IL-4+ anti-IFN-γ), Th9 (IL-4+ TGF-β+ anti-IFN-γ), Th17 (TGF-β+ IL-6+ IL-21+ 
IL-1β+ anti-IFN-γ+ anti-IL-4), and Treg (TGF-β+ anti-IL-4) cell conditions for 5 days. 
On day 5, cells were re-stimulated with anti-CD3 for 6 hours to isolate RNA from cell 
pellet. Il9 gene expression was assessed by real time PCR. (B-D) WT naïve CD4+ T cells 
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were differentiated under Th2 and Th9 cell conditions (as in A) for 5 days. On day 5, 
cells were stimulated with PMA and ionomycin for 5 hours before intracellular staining 
for IL-9 and IL-4 (B), differentiated cells were also stimulated with anti-CD3 for 24 
hours to collect cell-free supernatant to assess IL-9 production by ELISA (C) and for 6 
hours to measure Il9 by real time PCR (D). (E, F) WT naïve CD4+ T cells were 
differentiated under Th9 and Th17 cell conditions (as in A) for 5 days. On day 5, cells 
were stimulated with PMA and ionomycin for 5 hours before staining intracellularly with 
IL-9 and IL-17A (E), the cells were also stimulated with anti-CD3 for 24 hours to 
measure IL-9 and IL-17A by ELISA (F). (G, H) Naïve CD4+ T cells from WT mice were 
differentiated under Th9 and Treg cell conditions (as in A). On day 5, cells were 
harvested and stained with Foxp3 and IL-9 (G), the differentiated cells were also 
stimulated with anti-CD3 for 24 hours to assess IL-9 by ELISA (H). Data are average ± 
S.D of 6-8 animals from 3-4 experiments (A-D, F-H) or replicates representative of 3 
independent experiments (E). * p<0.05, ** p<0.01, *** p<0.001. 
 
Th9 cells produce lower levels of Th2 cytokines than Th2 cells 
As Th2 and Th9 cells are linked together by the IL-4 requirement for differentiation, we 
wanted to determine the levels of Th2 cytokines produced by Th9 cells. To test this, 
naïve CD4+ T cells were differentiated under Th2 and Th9 cell conditions for 5 days. On 
day 5, polarized cells reactivated with anti-CD3 for 24 hours and IL-4, IL-5, and IL-13 
production was assessed using ELISA. Th9 cells secreted significantly lower levels of IL-
4, IL5, and IL-13 compared to Th2 cells (Figure 12). Studies have suggested that Th9 
cells retain their ‘Th2-ness’ by producing IL-10 abundantly (Dardalhon et al., 2008; 
Veldhoen et al., 2008b). Therefore, IL-10 production was compared between Th2 and 
Th9 cultures in detail. Th2 cells produced significantly higher amount of IL-10 assessed 
by intracellular cytokine staining and ELISA (Figure 13A, B). Il10 was also measured at 
the transcript level when 5 day differentiated Th2 and Th9 cells were reactivated by anti-
CD3 at different time points. The peak of Il10 expression was observed after 6 hours of 
stimulation. Th2 cells had higher Il10 expression than Th9 cells for all the time points 
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measured (Figure 13C). Overall these data show that Th9 cells secrete low levels of IL-4, 
IL-5, IL-10, and IL-13 while they produce IL-9 abundantly.  
 
Figure 12: Th9 cells produce lower levels of Th2 cytokines. Naïve CD4+ T cells from 
WT mice were cultured with Th2 and Th9 cell conditions for 5 days. Differentiated cells 
were stimulated with anti-CD3 for 24 hours. Cell-free supernatant was used to measure 
IL-4, IL-5, and IL-13 using ELISA. Data are average ± S.D of 6-8 animals from 3-4 
experiments. *** p<0.001. 
 
Figure 13: Th9 cells secrete less IL-10 than Th2 cells. (A) WT naïve CD4+ T cells 
were cultured under Th2 and Th9 cell conditions for 5 days. On day 5, cells were 
stimulated with PMA and ionomycin for 5 hours before IL-9 and IL-10 intracellular 
cytokine staining was performed. (B) Differentiated Th2 and Th9 cells were re-stimulated 
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with anti-CD3 for 24 hours and cell-free supernatant was used to assess IL-10 using 
ELISA. (C) Differentiated Th2 and Th9 cells were also activated with anti-CD3 for 0, 6, 
and 24 hours to measure Il10 expression by real time PCR. Data are replicate 
representative of 3 independent experiments (A, C) or average ± S.D of 4 animals from 2 
independent experiments (B). * p<0.05. 
 
IL-9 and IL-10 are not coordinately regulated  
We had earlier demonstrated reciprocal regulation of IL-9 and IL-10 in Th2 cells (Ahyi et 
al., 2009). In a model where Th9 cells were activated by peptide and APCs, the IL-9 and 
IL-10 expression kinetics differed greatly (Tan et al., 2010).  One report has suggested 
that IL-10 can promote IL-9 production in mouse T cells (Monteyne et al., 1997) while 
another study has observed that neutralizing IL-10 receptor in primary Th9 cells or Th2 
cells ‘reprogrammed’ to Th9 cells does not negatively regulate Il9 gene expression 
(Veldhoen et al., 2008b) . To further determine the regulation of IL-9 and IL-10 in Th9 
cells, Th9 cells were treated with neutralizing IL-10 antibody which has been shown to 
decrease IL-10 production (Riemann et al., 2005). IL-9 production was increased when 
Th9 cells were treated with anti-IL-10 with a concomitant reduction in IL-10 production 
(Figure 14A). Neutralizing IL-10 in IL-10
hi
 Th2 cells results in modest increase in Il9 
mRNA (Ahyi et al., 2009). When TGF-β was added to differentiated Th9 cultures during 
anti-CD3 restimulation it resulted in more IL-9 production (Figure 14B). In contrast, IL-
10 production was reduced (Figure 14B). Since Th2 cells express IL-9 receptor (Nowak 
et al., 2009), we wanted to test if Th2 cells treated with IL-9 altered IL-10 production. 
The addition of IL-9 to Th2 cells did not alter IL-10 production (Figure 14C). Therefore, 
even though Th9 cells produce IL-10, IL-9 and IL-10 are not coordinately regulated.  
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Figure 14: IL-9 and IL-10 are not coordinately regulated in Th9 cells. (A) Naïve 
CD4+ T cells from WT mice were cultured under Th9 cell conditions in the presence or 
absence of blocking IL-10 antibody for 5 days. On day 5, cells were re-stimulated with 
anti-CD3 for 24 hours. Cell-free supernatant was collected to assess IL-9 and IL-10 
production using ELISA. (B) WT naïve CD4+ T cells were cultured under Th9 cell 
conditions for 5 days. On day 5, cells were stimulated with either plate-bound anti-CD3 
or plate-bound anti-CD3 and soluble TGF-β (2 ng/ml) for 24 hours. Cell-free supernatant 
was used to assess IL-9 and IL-10 using ELISA. (C) Naïve CD4+ T cells from WT mice 
were cultured under Th2 cell conditions in the presence or absence of recombinant IL-9 
(10 ng/ml). On day 5, anti-CD3 stimulated cell-free supernatant was used to measure IL-
10 using ELISA. Data are replicates representative of 2-3 independent experiments with 
2 mice in each experiment. 
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Foxp3 expression is limited by IL-4 in Th9 cells 
IL-4 is required for the differentiation of Th9 cells as Treg cells cultured in the presence 
of TGF-β and neutralized IL-4, secrete very low amounts of IL-9. To determine the role 
IL-4 plays in Th9 cells, naïve CD4+ T cells from WT mice were cultured with increasing 
doses of TGF-β in the presence (Th9) or absence (Tregs) of IL-4. Increasing doses of 
TGF-β resulted in augmented production of Foxp3+ cells (Figure 15A). However, 
addition of IL-4 attenuated the production of Foxp3+ cells with a concomitant increase in 
the production of IL-9 (Figure 15A). A small percentage of dim IL-9+ cells were 
observed in Treg cells, however no IL-9 was detectable by ELISA from Treg cells 
(Figure 15A, B). Thus one of the roles of IL-4 in Th9 cultures is to suppress Foxp3 
expression. 
 
Figure 15: IL-4 limits Foxp3 expression from Th9 cells. (A) WT naïve CD4+ T cells 
were cultured with increasing doses of TGF-β in the presence (Th9) or absence (Treg) of 
IL-4 for 5 days. On day 5, cells were then intracellularly stained for Foxp3 (left panel) 
and IL-9 (right panel). (B) Differentiated cells from (A) were stimulated with anti-CD3 
for 24 hours. IL-9 production was measured using ELISA. IL-9 was not detected in 
supernatants of Treg cultures. Data are replicates representative of 2-3 independent 
experiments with 2 mice in each experiment. 
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IL-13 cannot substitute for IL-4 in the induction of IL-9-producing T cells 
IL-4 shares some overlapping functions with IL-13 (Wynn, 2003). IL-4 signals via either 
type I IL-4R (IL-4Rα and the common γ chain) or the type II IL-4R (IL-4Rα and IL-
13Rα1). IL-13 receptor is composed of IL-13Rα1 and IL-4Rα, with IL-13Rα2 being a 
negative regulatory receptor.  Most T cells do not express Il13Rα1, although reports have 
shown receptor expression is increased in Th17 cells (Newcomb et al., 2009). Since IL-4 
and IL-13 share similar signaling cascades, we wanted to determine if IL-13 could 
replace IL-4 and secrete IL-9 in the presence of TGF-β. Naïve CD4+ T cells were treated 
with TGF-β and either a fixed amount of IL-4 or increasing doses of IL-13 in the absence 
of IL-4. T cells cultured in the presence of IL-4 and TGF-β produced IL-9 (Figure 16A). 
In contrast, T cells differentiated with TGF-β and IL-13 did not produce IL-9 (Figure 
16A). We wanted to determine if the lack of IL-9 production was due to the lack of 
Il13Rα1 expression. To this end naïve CD4+ T cells were cultured with TGF-β and IL-13 
and Il13Rα1 expression was assessed by real time PCR. T cells treated with TGF-β and 
IL-13 did not express Il13Rα1, consistent with the result that IL-13 failed to induce IL-9 
in the presence of TGF-β (Figure 16B). Since IL-4 attenuated TGF-β-mediated Foxp3 
induction we wanted to determine if IL-13 has a similar effect on Foxp3. In contrast to 
IL-4, IL-13 failed to diminish the TGF-β-mediated Foxp3-producing T cells (Figure 
16C). Thus, although IL-4 and IL-13 have some redundant functions and share signaling 
pathways, IL-4 but not IL-13 promotes the differentiation of Th9 cells. 
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Figure 16: IL-13 cannot substitute for IL-4 to induce IL-9-secreting cells. (A) Naïve 
CD4+ T cells from WT mice were cultured with TGF-β and IL-4 or with TGF-β and 
increasing doses of IL-13 (5, 10, 20 ng/ml) for 5 days. Cell-free supernatant was used to 
assess IL-9 using ELISA. (B) Naïve CD4+ T cells were differentiated as in (A), and 
under Th2 and Th17 culture conditions for 5 days. Il13Rα1 expression was measured by 
real time PCR. (C) Naïve CD4+ T cells were cultured under Th2, Treg, Th9 culture 
conditions, and with TGF-β in the presence or absence of IL-13 for 5 days. Differentiated 
cells were then intracellularly stained for Foxp3. Data are average ± S.D of 4 mice. 
Experiments were done in collaboration with Jared Travers. 
 
IL-23 negatively regulates IL-9 production from Th9 cells 
IL-9 had been shown to synergize with TGF-β to polarize naïve T cells into IL-17-
secreting cells (Elyaman et al., 2009). IL-23 which is required for the maintenance of 
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Th17 cells had been reported to inhibit IL-9 production from Th17 cells; conversely IL-9 
production from IL-23R-deficient Th17 cells was elevated (Elyaman et al., 2009). We 
therefore wanted to define the role of IL-23 in Th9 cells in regulating IL-9 production. 
Th9 cells cultured in the presence of IL-23 resulted in diminished the percentages of IL-
9-producing cells (Figure 17A). This was confirmed using ELISA as well (Figure 17B). 
However, IL-23 did not have a potent effect on the production of IL-17-secreting cells 
(Figure 17A). Whether Th9 cells treated with IL-23 results in increased IL-10 production 
is not known although Th17 cells incubated with IL-23 do not express IL-10 (McGeachy 
et al., 2007). Thus, the data suggests that IL-23 attenuates IL-9 production from Th9 
cells.  
 
Figure 17: IL-23 attenuates IL-9 production from Th9 cells. (A) WT naïve CD4+ T 
cells were differentiated under Th9 cell conditions for 5 days in the presence or absence 
of recombinant IL-23 (10 ng/ml). On day 5 cells, were stimulated with PMA and 
ionomycin before intracellular staining for IL-9 and IL-17A. (B) IL-9 production was 
assessed from anti-CD3 stimulated cells using ELISA. Data are average of two mice. 
 
Type I and type II interferons inhibit IL-9 production from Th9 cells  
In murine studies, IFN-γ reduces IL-4 and TGF-β-mediated IL-9 production (Schmitt et 
al., 1994). However, in human Th9 cells, type I interferons, IFN-α and IFN-β augment 
IL-9 production (Wong et al., 2010). Therefore we wanted to define the role of type I and 
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type II interferons in murine Th9 cell differentiation. Therefore to define the role of type I 
and type II interferons in Th9 cell development, WT Th9 cells were cultured in the 
presence of IFN-α, IFN-β, IFN-γ, and also IL-12 which promotes Th1 differentiation. 
Th9 cells cultured with IFN-γ reduced IL-9 production consistent with the published 
report (Figure 18A, B). Even though there was modest reduction in the percentages of IL-
9-secreting cells when Th9 cells were treated with IFN-α and IFN-β, the decrease in IL-9 
production by type I interferons was more profound when assessed by ELISA (Figure 
18A, B). Though IL-12 reduced IL-9 production from Th9 cells, the effect was not as 
profound as from IFN-β or IFN-γ (Figure 18A, B). As IFN-γ activates STAT1, we 
wanted to determine the role of STAT1 in interferon-mediated IL-9 regulation. STAT1-
deficiency did not affect IL-9 production when Th9 cells were treated with type I 
interferons or IL-12 (Figure 18A, B). However, STAT1 is required for IFN-γ-mediated 
IL-9 suppression in Th9 cells (Figure 18A, B).  
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Figure 18: Type I and type II interferons inhibit IL-9 production. (A) Naïve CD4+ T 
cells from WT and Stat1-/- mice were cultured under Th9 cell conditions in the presence 
of IFN-α (10,000 U/ml), or IFN-β (10,000 U/ml), or IFN-γ (100 ng/ml), or IL-12 (5 
ng/ml) for 5 days. On day 5, cells were harvested and re-stimulated with PMA and 
ionomycin before intracellular staining with IL-9 and IL-4. (B) Cell-free supernatant was 
used from anti-CD3 stimulated cultures (as in A) to measure IL-9 using ELISA. Data are 
average ± S.D of 4 mice. ** p<0.01 
 
As IL-12 activates STAT4, we wanted to define the role of STAT4 in interferon-
mediated regulation of IL-9 in Th9 cells. To test this, Th9 cells from WT and STAT4-
deficient mice were treated with IFN-α, IFN-β, IFN-γ, and IL-12. As demonstrated earlier 
Th9 cells treated with either type I or type II interferons reduced IL-9 production, with 
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IFN-γ having the most profound effect (Figure 19A, B). However, STAT4 was not 
required for regulation of IL-9 production by interferons (Figure 19A, B). STAT4 
deficiency did not significantly affect IL-9 production under standard Th9 conditions or 
when Th9 cells were treated with IL-12 (Figure 19A, B). Overall, these data suggest that 
both type I and type II interferons but not IL-12 negatively regulate IL-9 production. 
 
Figure 19: STAT4 signal is not required for IL-9 inhibition by interferons. (A) Naïve 
CD4+ T cells from WT and Stat4-/- mice were cultured under Th9 cell conditions in the 
presence of IFN-α, or IFN-β, or IFN-γ, or IL-12 for 5 days as in Figure 18. On day 5, 
cells were re-stimulated with PMA and ionomycin before intracellular staining with IL-9 
and IL-4. (B) IL-9 production was assessed using ELISA from stimulated cells. Data are 
average ± S.D of 4 mice.  
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Cytokines regulating IL-9 production from Th9 cells: Summary 
Our findings on the effects of cytokines on IL-9 production are summarized below.  
Cytokine IL-9 Regulation 
IL-12 No effect 
IL-23 Negative 
IFN-α Negative 
IFN-β Negative 
IFN-γ Negative 
IL-10 Negative 
IL-9 No effect? 
TGF-β Positive 
  
Table 3: Summary of IL-9 production from Th9 cells by different cytokines
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PART II: A STAT6-dependent transcriptional network in Th9 cells 
STAT6 and STAT3 are activated in Th9 cells 
STAT6 is required for the development of Th2 cells (Kaplan et al., 1996a; Shimoda et al., 
1996; Takeda et al., 1996). However, recently STAT3 has been demonstrated to 
cooperate with STAT6 in promoting Th2 cell development (Stritesky et al., 2011). Both 
STAT6 and STAT3 molecules were activated during Th2 differentiation (Stritesky et al., 
2011). We therefore wanted to determine if both STAT6 and STAT3 were activated 
during Th9 cell differentiation. To define STAT6 and STAT3 activation during Th9 
differentiation, naïve CD4+ T cells from WT mice were polarized under Th2 and Th9 
cell conditions for 5 days and were assessed for intracellular phospho-STAT6 and 
phospho-STAT3 each day during differentiation. Phospho-STAT6 was identically 
activated between Th2 and Th9 cells (Figure 20A, B). The mean fluorescence intensity of 
phospho-STAT6 positive cells was similar between Th2 and Th9 cells (Figure 20A, B). 
The peak of STAT6 activation was observed on day 2 of differentiation with a second 
peak on day 4 after cell expansion (Figure 20A, B). STAT3 was also phosphorylated in 
Th9 cells albeit with lower percentages and mean fluorescence intensity of phospho-
STAT3-positive cells than Th2 cells (Figure 20A, B). However, both Th2 and Th9 cells 
have similar kinetics of phosphorylated STAT3 (Figure 20 A, B).Together, these data 
suggest that similar to Th2 cells both STAT6 and STAT3 are activated in Th9 cells. 
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Figure 20: STAT6 and STAT3 are activated in Th9 cells. (A) Naïve CD4+ T cells 
from WT mice were cultured under Th2 and Th9 cell conditions for 5 days. Each day 
during differentiation cells were stained for intracellular phospho-STAT6 and phospho-
STAT3. (B) Graphical representation of the percentages (top panel) and mean 
fluorescence intensity (MFI) (bottom panel) of the cells. Data are average ± S.D of 6 
mice. 
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Differential requirement of STAT6 and STAT3 in Th2 and Th9 cells 
As both STAT6 and STAT3 were activated during Th9 cell differentiation we then 
wanted to define the requirement of each of these molecules in the development of Th9 
cells. To determine the role of STAT6, naïve CD4+ T cells were isolated from WT and 
STAT6-deficient mice and were cultured under Th9 cell conditions. IL-9 production was 
completely abolished in the absence of STAT6 assessed by intracellular cytokine staining 
and ELISA, which was consistent with previous reports (Dardalhon et al., 2008; 
Veldhoen et al., 2008b)(Figure 21A, B). This data demonstrates that the STAT6 signaling 
pathway is required for Th9 cell development. To define the role of STAT3 in Th9 
development, naïve CD4+ T cells from WT and Stat3
CD4-/- 
mice were cultured under Th9 
cell conditions and IL-9 production was assessed by intracellular cytokine staining and 
ELISA. Even though STAT3 was activated throughout Th9 differentiation, STAT3 was 
dispensable for the development of IL-9-secreting T cells (Figure 21C, D).  
 
Figure 21: STAT6 but not STAT3 is required for Th9 cell development. (A, B) Naïve 
CD4+ T cells from WT and Stat6-/- mice were cultured under Th9 cell conditions for 5 
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days. On day 5, cells were harvested and stimulated with PMA and ionomycin before 
intracellular staining with IL-9 and IL-4 (A) or were stimulated with anti-CD3 for 24 
hours to assess IL-9 production using ELISA (B). (C, D) Naïve CD4+ T cells from WT 
and Stat3
CD4-/-
 mice were cultured under Th9 conditions for 5 days. Intracellular staining 
for IL-9 and IL-4 (C) and IL-9 production using ELISA (D) was measured as in (A) and 
(B). Data are average ± S.D of 6 mice from 3 independent experiments. * p<0.05. 
 
Since STAT6 is critical for the development of Th9 cells we then wanted to determine 
the role of STAT6 co-factors in Th9 cell development. STAT6 recruits various co-
activators at the IgE promoter in B cells. The STAT6 co-activator PARP14, a poly-ADP 
ribosyltransferase augments and acts as a switch in STAT6-dependent transcription by 
facilitating the clearance of repressive molecules from gene promoters and increasing 
binding of STAT6 (Goenka and Boothby, 2006; Mehrotra et al., 2011). To define the role 
of PARP14 in the development of Th9 cells we compared IL-9 production from WT and 
Parp14-/- Th9 cells. Consistent with the role of PARP14 as a co-activator, diminished 
production of IL-9 was observed in the absence of PARP14 (Figure 22). However, the 
production of IL-10 was not altered in the absence of PARP14 (Figure 22). Together 
these data suggest that STAT6 and its co-factor PARP14 are required for the optimal 
development of Th9 cells.  
 
Figure 22: Absence of STAT6 co-activator PARP14 results in diminished IL-9 
production. (A, B) Naïve CD4+ T cells from WT and Parp14-/- mice were cultured 
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under Th9 cell conditions for 5 days. Differentiated cells were stimulated with PMA and 
ionomycin before intracellular staining with IL-9 and IL-4 (A) or were stimulated with 
anti-CD3 for 24 hours to assess IL-9 and IL-10 production using ELISA (B). Data are 
average ± S.D of 4-5 mice from 2-3 independent experiments.  * p<0.05. 
 
The Il9 promoter is not directly targeted by STAT6 
Since STAT6 is indispensable for the development of Th9 cells, we wanted to examine if 
STAT6 was directly regulating the Il9 gene. The Il9 locus was compared among different 
species. The evolutionary conserved region (ECR) browser was used to scan the Il9 gene 
which showed that the mouse Il9 gene consisted of 5 exons (Figure 23A). rVISTA and 
JASPAR software was used to predict transcription factor binding sites. Two conserved 
non-coding sequences, CNS1 and CNS0 were predicted to be multiple transcription 
factor binding sites of the Il9 gene (Perumal and Kaplan, 2011). CNS1 is located at the 
Il9 promoter while CNS0 is about 7 kb upstream of the transcription start site (Figure 
23A). STAT binding sites were predicted at the CNS1 and CNS0 regions of the Il9 gene. 
To determine if STAT6 was regulating IL-9 production by directly binding to the Il9 
gene, chromatin immunoprecipitation was performed testing the association of STAT6 to 
CNS1 and CNS0 of the Il9 gene in Th2 and Th9 cells. STAT6 binding was detectable at 
the CNS1, more than the CNS0 (Figure 23B). However, the percent input values were 
about 2% of the binding of STAT6 to the Maf and Irf4 promoters in Th2 and Th9 cells 
(Figure 23B). This was consistent with a previous study demonstrating that STAT6 
binding was undetectable in the Il9 locus in Th2 cells by analyzing published ChIP-Seq 
datasets (Wei et al., 2010). Overall, these data suggest that STAT6 is not directly 
targeting the Il9 promoter; however, it may be affecting the binding of other factors to the 
Il9 gene, or binding to regulatory elements that are not yet identified. 
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Figure 23: Il9 promoter is not a direct target of STAT6. (A) Schematic diagram of Il9 
gene with conserved non-coding sequences (CNS). (B) WT naïve CD4+ T cells were 
cultured under Th2 and Th9 cell conditions for 5 days. Chromatin immunoprecipitation 
(ChIP) was performed for STAT6 before qPCR for two Il9 CNS sites, or for the Irf4 or 
Maf promoters, to determine the amount of Stat6 binding. We performed control Ig 
ChIPs for all ChIP assays and subtracted the control Ig values from the specific Ab 
values. All ChIP data in the thesis indicate specific % input. Data are average ± S.D of 
four mice from two experiments. 
 
IRF4 is a relevant transcription factor downstream of the IL-4/STAT6 pathway 
The transcription factor IRF4 has been shown to bind and transactivate Il9 gene (Staudt et 
al., 2010). The absence of IRF4 leads to diminished IL-9 production from Th9 cells 
(Staudt et al., 2010). IRF4 is downstream of IL-4/STAT6 pathway in Th2 cells. Therefore 
we wanted to determine if IRF4 was dependent on the IL-4/STAT6 pathway in Th9 cells. 
To test this, Th9 cells from WT and Stat6-/- mice were assessed for Irf4 expression. In 
the absence of the STAT6 signal there was decreased Irf4 expression in Th9 cells (Figure 
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24A). We then wanted to examine if STAT6 deficiency affects IRF4 binding to the Il9 
gene. Association of IRF4 to the Il9 CNS1 and CNS0 regions was attenuated in Stat6-/- 
Th9 cultures (Figure 24B). These data suggest that IRF4 is a potentially important 
transcription factor downstream of IL-4/STAT6 signal in Th9 cells. 
 
Figure 24: IRF4 is a relevant transcription factor downstream of IL-4/STAT6 
pathway. (A, B) Naïve CD4+ T cells isolated from WT and Stat6-/- mice were cultured 
under Th9 cell conditions for 5 days. From differentiated cells Irf4 expression by real 
time PCR (A) and IRF4 binding to the Il9 gene (B) by ChIP assay was performed. Data 
are average ± S.D of 4 mice from two experiments. 
 
IRF4 alone cannot restore IL-9 production in the absence of STAT6 
Since Irf4 expression was diminished in STAT6-deficient Th9 cells, we wanted to 
determine if ectopic expression of IRF4 was sufficient to rescue IL-9 production. To test 
this, naïve CD4+ T cells from WT and Stat6-/- mice were activated under Th9 cell 
conditions and were ectopically expressed with control (hCD4) or IRF4-expressing 
(IRF4-hCD4) retroviruses. After 5 days of differentiation, cells were magnetically sorted 
based on hCD4-expression and IL-9 production was assessed using ELISA and real time 
PCR after anti-CD3 restimulation. WT Th9 cells transduced with IRF4-expressing 
retrovirus showed an increase in IL-9 production both at the protein and at the transcript 
level (Figure 25A, B). However, ectopic IRF4 expression was not able to induce IL-9 in 
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Stat6-/- Th9 cells (Figure 25A, B). To define the mechanism of the inability of IRF4 to 
rescue IL-9 in the absence of STAT6 signal we wanted to determine if ectopic IRF4 
expression altered the expression of Foxp3 which is suppressed by IL-4 signal. Ectopic 
IRF4 expression in Stat6-/- Th9 cells did not alter Foxp3 production (Figure 25C). In the 
absence of STAT6, T-bet-deficient CD4+ T cells have the ability to produce IFN-γ (Yang 
et al., 2008c). Therefore we determined the level of T-bet after ectopic IRF4 expression 
in Stat6-/- Th9 cells. Ectopic IRF4 expression modestly affected T-bet production (Figure 
25C). These data suggest that IRF4 alone is not sufficient to recover IL-9 production in 
the absence of STAT6 signal and additional factors are required for the development of 
IL-9-secreting T cells. 
 
Figure 25: IRF4 is not sufficient to recover IL-9 production in the absence of 
STAT6. (A, B) Naïve CD4+ T cells from WT and Stat6-/- mice were cultured under Th9 
cell conditions. On day 2, cells were transduced with control (hCD4) or IRF4-expressing 
(IRF4-hCD4) retroviruses. On day 5, cells were collected and magnetically sorted for 
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hCD4+ population. Sorted cells were re-stimulated with anti-CD3 for 24 hours (A) or 6 
hours (B) to assess IL-9 production using ELISA and real time PCR, respectively. (C) 
Naïve cells were cultured and transduced as in (A). Cells were harvested on day 5 and 
stained intracellularly for Foxp3 and T-bet, based on hCD4+ population. Data are average 
± S.D of 4 mice from two experiments. N.D.: Not detected. 
 
IL-4R and ST2 are expressed similarly in Th2 and Th9 cells 
IL-4R is expressed on Th2 cells and the transmembrane form of T1/ST2 is a specific 
marker of murine Th2 cells that is part of the IL-33 receptor (Lohning et al., 1998; 
Schmitz et al., 2005; Xu et al., 1998a). To determine if these factors are also expressed in 
Th9 cells, WT naïve CD4+ T cells were differentiated into Th2 and Th9 cell conditions. 
IL-4R and ST2 expression was compared between Th2 and Th9 cells on each day during 
5 day differentiation. The percentages and the mean fluorescence intensity of IL-4R-
expressing cells were similar between Th2 and Th9 cells (Figure 26A, B). IL-4R 
expression reached the peak on day 4 after the cells were expanded (Figure 26A, B).  The 
percentages and the mean fluorescence intensity of ST2-expressing cells were also 
similar between Th2 and Th9 cells (Figure 26A, B). However, unlike IL-4R expression 
the peak of ST2 expression was on days 2 and 3 after which the levels drop (Figure 26A, 
B). Together, these data indicate no subset-specific difference in IL-4R and ST2 
expression between Th2 and Th9 cells. 
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Figure 26: IL-4R and ST2 are expressed similarly in Th2 and Th9 cells. (A) Naïve 
CD4+ T cells from WT mice were cultured under Th2 and Th9 cell conditions for 5 days. 
Each day during differentiation cells were stained for IL-4R and ST2. (B) Graphical 
representation of the percentages (top panel) and mean fluorescence intensity (bottom 
panel) of the cells. Data are average ± S.D of 4 mice. 
 
The transcription factors Gfi-1 and Bcl6 are expressed at lower levels in Th9 cells 
We next wanted to determine if additional transcription factors that regulate Th2 cells are 
also expressed in Th9 cells. The transcription factor Gfi-1 is important for IL-2 mediated 
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Th2 cell expansion (Zhu et al., 2006a). Bcl6, a transcriptional repressor, limits Th2 
development and inflammation (Dent et al., 1998). To test expression in Th9 cells, naïve 
CD4+ T cells were cultured under T helper cell polarizing conditions.  Gfi-1 expression 
was lower in Th9 cells compared to Th2 cells (Figure 27). Among Th1, Th2, Th9 and 
Th17 cells, Th17 cells had the highest expression of Bcl6, consistent with a previously 
published report (Mondal et al., 2010)(Figure 27). Bcl6 expression was not different 
between Th2 and Th9 cells, and was expressed at a lower level than in Th17 cells (Figure 
27).  
 
Figure 27: The transcription factors Gfi-1 and Bcl6 are expressed at lower levels in 
Th9 cells compared to other T helper subsets. WT naïve CD4+ T cells were cultured 
under Th2 and Th9 (left) or Th1, Th2, Th9, and Th17 (right) culture conditions for 5 
days. RNA was isolated from cell pellet and was used to measure Gfi-1 and Bcl6 
expression by real time PCR. Data are replicates representative of 2-3 independent 
experiments with 2 mice in each experiment.  
 
Th2-specific transcription factors are expressed in Th9 cells 
Since STAT6 was required for the development of both Th2 and Th9 cells, we wanted to 
determine if the expression of transcription factors downstream of STAT6 signaling 
promote Th9 cell development. GATA3 was demonstrated to be critical for the 
development of Th9 cells; however GATA3 was expressed at a lower level in Th9 cells 
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than Th2 cells (Dardalhon et al., 2008). Expression and the role of other Th2-specific 
transcription factors have not been examined carefully in Th9 cells. Therefore we 
examined the expression of Gata3 and Maf in Th9 cells and compared it with other T 
helper cells by real time PCR. Gata3 expression was highest in Th2 cells; however Th9 
cells also expressed Gata3 at a decreased level (Figure 28A). We confirmed this 
observation by analyzing GATA3 protein expression via intracellular staining. GATA3 
protein levels were identical between Th2 and Th9 cells before stimulation (Figure 28B). 
When Th2 and Th9 cells were activated by anti-CD3, the amount of GATA3 protein was 
doubled in Th2 cells (Figure 28B). In contrast, GATA3 protein expression was 
unchanged in stimulated Th9 cells (Figure 28B). Maf, which is critical for IL-4 
production in Th2 cells and IL-10 and IL-21 production in Th17 cells (Hiramatsu et al., 
2010; Ho et al., 1996; Ho et al., 1998; Xu et al., 2009), was expressed abundantly in Th9 
cells (Figure 28C). We also confirmed the results by examining Maf protein expression 
by intracellular staining in Th2 and Th9 cells. Th9 cells had higher Maf protein compared 
to Th2 cells (Figure 28D).  
 
We wanted to further determine if there were differences in kinetics of the Th2 
transcription factors between Th2 and Th9 cells. Gata3 and Maf expression patterns were 
similar between Th2 and Th9 cells with greater induction of Gata3 and Maf in Th2 and 
Th9 cells, respectively, towards the end of the differentiation (Figure 28E). We also 
tested the induction of Irf4 in Th2 and Th9 cells and observed it was expressed 
consistently higher in Th9 cells throughout differentiation (Figure 28E). Overall these 
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data suggest that expression of Gata3, Irf4 and Maf is distinct between Th2 and Th9 
cells.  
 
Figure 28: Th2-specific transcription factors are expressed in Th9 cells. (A, C) Naïve 
CD4+ T cells from WT mice were cultured under Th1, Th2, Th9, Th17, Treg conditions 
or directly ex vivo (naïve) for 5 days. RNA was isolated from cell pellet and real time 
PCR was performed to measure Gata3 (A) and Maf (C) expression. (B, D) WT naïve 
CD4+ T cells were differentiated under Th2 and Th9 cell conditions for 5 days. Cells 
were harvested on day 5 and were kept unstimulated or stimulated with anti-CD3 for 6 
hours before intracellular staining for GATA3 (B) and c-Maf (D) was performed. (E) WT 
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naïve CD4+ T cells were cultured under Th2 and Th9 conditions for 5 days. RNA was 
isolated from cells on each day during differentiation and examined for the expression of 
the indicated genes by real time PCR. Data are replicates representative of 2-3 
independent experiments with 2 mice in each experiment. Panel A-C was performed in 
collaboration with Dr. Rukhsana Jabeen. 
 
Gata3 and Maf expression are STAT6-dependent in Th9 cells 
IRF4 was earlier shown to be dependent on IL-4/STAT6 pathway but not sufficient to 
induce IL-9 in Th9 cells. We therefore wanted to determine if either Gata3 or Maf might 
account for the IL-4/STAT6-dependent induction of IL-9. To test this, differentiated Th9 
cultures from WT and Stat6-/- mice were measured for Gata3 and Maf expression by real 
time PCR. Expression of both Gata3 and Maf was decreased in the absence of STAT6 
signal (Figure 29). These data suggest similar to Th2 cells, GATA3 and c-Maf are 
downstream of IL-4/STAT6 signaling cascade in Th9 cells. 
 
Figure 29: Gata3 and Maf expression in Th9 cells are IL-4/STAT6-dependent. Naïve 
CD4+ T cells isolated from WT and Stat6-/- mice were cultured under Th2 and Th9 cell 
conditions for 5 days. Cell pellet was harvested on day 5 and Gata3 and Maf expression 
was assessed by real time PCR. Data are replicates representative of 3 independent 
experiments with 2 mice in each experiment. 
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IL-4-induced transcription factors repress IL-9 production in Th9 cells 
Since both Gata3 and c-Maf were expressed in Th9 cells we wanted to determine if either 
of the factors directly promoted IL-9 production. To test this, developing Th9 cells were 
transduced with bicistronic retroviruses containing either GATA3 or c-Maf. Following 5 
days of differentiation, IL-9 production was assessed by flow cytometry. Compared to 
Th9 cultures transduced with control retrovirus, transduction of Th9 cells by GATA3 
resulted in a reduction of IL-9-producing cells (Figure 30A). Similarly, a decrease in IL-
9-secreting cells was observed when Th9 cells were transduced with c-Maf-expressing 
retrovirus (Figure 30B). We hypothesized that since both GATA3 and c-Maf can induce 
the production of IL-4, these factors might be augmenting IL-4-secreting cells at the 
expense of IL-9-producing cells. However, neither of these transcription factors enhanced 
the percentages of IL-4-secreting cells (Figure 30A, B). We speculated that increases in 
endogenous IL-4 during the culture were possibly affecting the differentiation of IL-9-
secreting cells. To test this, Th9 cells from Il4-/- mice were analyzed for IL-9 production. 
Exogenous IL-4 was sufficient to induce IL-9 from Il4-/- Th9 cells (Figure 30A, B). We 
then wanted to determine if either GATA3 or c-Maf ectopic expression was affecting IL-
9 production from Il4-/- Th9 cells. Transduction of GATA3 or c-Maf into Il4-/- Th9 
cultures was as effective at reducing IL-9 production as transduction into wild-type cells 
(Figure 30A, B). Therefore, even though GATA3 and c-Maf are expressed in Th9 cells, 
ectopic expression attenuates IL-9 production through effects that are independent from 
the induction of IL-4.  
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Figure 30: Th2 transcription factors repress IL-9 production in Th9 cells. (A, B) 
Naïve CD4+ T cells from WT or Il4-/- mice were cultured under Th9 cell conditions. On 
day 2, cells were transduced with control and GATA3 (A) or control and c-Maf-
expressing retroviruses (B). On day 5, cells were stimulated with PMA and ionomycin 
for intracellular staining of IL-9 and IL-4. Data are average ± S.D of 4-6 mice from 2-3 
independent experiments. Experiments were performed in collaboration with Dr. 
Rukhsana Jabeen. * p<0.05. 
 
Th1-associated transcription factors repress IL-9 production 
Apart from promoting Th2 differentiation, IL-4 and STAT6 interfere with the expression 
and function of transcription factors T-bet and Runx3 which promote IFN-γ expression 
and Th1 differentiation (Afkarian et al., 2002; Djuretic et al., 2007). Therefore we wanted 
to determine if Th1-specific transcription factors negatively regulate IL-9 production 
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from Th9 cells. To test this, Tbx21 and Runx3 expression was assessed among different T 
helper cells. As expected Tbx21 expression was highest in Th1 cells; however, Th9 cells 
expressed similar levels of Tbx21 compared to other T helper cells (Figure 31A). Runx3 
was expressed in most T helper cells with highest expression in Th1 cells (Figure 31A). 
A detectable level of Runx3 was observed in Th9 cells at the protein level (Figure 31B).  
 
Figure 31: Th1 transcription factors, T-bet and Runx3 are expressed in Th9 cells. 
(A) Naïve CD4+ T cells from WT mice were cultured under Th1, Th2, Th9, Th17, Treg 
conditions or directly ex vivo (naïve) for 5 days. RNA was isolated from cell pellet and 
real time PCR was performed to measure the indicated genes. (B) Total cell lysates were 
prepared from Th1, Th2, and Th9 cells, and immunoblot was performed for Runx3. Data 
are replicates representative of 3 independent experiments with 2 mice in each 
experiment. Panel A was performed in collaboration with Dr. Rukhsana Jabeen. 
 
To determine if T-bet and Runx3 were limiting Th9 development, developing Th9 cells 
were transduced with either T-bet or Runx3-expressing retroviruses. Transduction of Th9 
cells with either of the factors resulted in attenuated percentages of IL-9-secreting cells 
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(Figure 32A). To further define the inhibitory roles of T-bet and Runx3, naïve CD4+ T 
cells were differentiated under Th9 cell conditions from WT and T-bet-deficient or WT 
and Runx3-deficient mice. The percentages of IL-9-producing cells were increased from 
both T-bet and Runx3-deficient mice (Figure 32B). However, there was no difference in 
the percentages of IL-4-secreting cells between the wild-type and the gene-deficient Th9 
cells (Figure 32B). These data are complementary to the findings observed in the 
retroviral expression studies. Overall these data suggest that Th1-associated transcription 
factors are inhibitors of IL-9 production from Th9 cells. 
 
Figure 32: T-bet and Runx3 limit IL-9 production. (A) WT naïve CD4+ T cells were 
cultured under Th9 cell conditions for 48 hours before being transduced with control and 
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T-bet-expressing (top panel), or control and Runx3-expressing retroviruses (bottom 
panel). On day 5, cells were harvested and stimulated with PMA and ionomycin before 
intracellular IL-9and IL-4 staining. (B) Naïve CD4+ T cells from WT and Tbx21-/- mice 
(top panel) or WT and Runx3
fl/fl–dLck–Cre mice (bottom panel) were cultured under Th9 
cell conditions for 5 days. On day 5, cells were harvested and stimulated with PMA and 
ionomycin before intracellular IL-9 and IL-4 staining. Data are average ± S.D of 4 mice 
from 2 independent experiments. Panel B (bottom panel) was performed in collaboration 
with Drs. Jinfang Zhu and Ryogi Yagi. * p<0.05. 
 
T-bet but not Runx3 expression is repressed by STAT6 signal in Th9 cells 
Since the STAT6 signal is indispensable for Th9 cell development, we wanted to 
determine if either of T-bet or Runx3 contributed to the lack of IL-9 production in Stat6-
/- Th9 cultures. To test this, Tbx21 and Runx3 expression was measured in differentiated 
Th9 cells from WT and Stat6-/- mice by real time PCR. Tbx21 expression was enhanced 
in the absence of STAT6 (Figure 33). In contrast, Runx3 expression was diminished in 
Stat6-/- Th9 cultures (Figure 33). Together, these data suggest that both T-bet and Runx3 
can limit IL-9 production; however, Runx3 is probably not a contributing factor for the 
lack of IL-9 production in Stat6-/- Th9 cells. Therefore, one of the roles of IL-4/STAT6 
signaling is to limit T-bet-mediated inhibition of IL-9 in Th9 cells.  
 
Figure 33: STAT6 signal represses T-bet but not Runx3 expression in Th9 cells. 
Naïve CD4+ T cells from WT and Stat6-/- mice were cultured under Th9 cell conditions 
for 5 days. RNA was isolated from cell pellet and was used to measure the indicated 
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genes by real time PCR. Data are average ± S.D of 4 mice from 2 independent 
experiments. 
 
STAT6 signal inhibits Foxp3 expression in Th9 cells 
As one of the functions of IL-4 in the Th9 cell development is to inhibit Foxp3, we 
wanted to test if Foxp3 negatively regulates IL-9 production. To test this, we first 
examined the expression of Foxp3 among different T helper cell subsets by real time 
PCR. As expected Treg cells had the highest Foxp3 expression (Figure 34A). Th9 cells 
also expressed Foxp3; however, at a lower level than Treg cells (Figure 34A). To test if 
Foxp3 was a negative regulator of IL-9 in Th9 cells, developing Th9 cells were 
transduced with control or Foxp3-expressing retroviruses and IL-9 production was 
measured by intracellular staining. Ectopic expression of Foxp3 attenuated the 
percentages of IL-9-producing cells without affecting IL-17A induction (Figure 34B). To 
test if STAT6 regulated the expression of Foxp3 in Th9 cells, mRNA from WT and 
Stat6-/- Th9 cultures were examined. In the absence of STAT6 there was enhanced 
expression of Foxp3 (Figure 34C). This suggests that an indirect role of STAT6 during 
Th9 cell development is to suppress Foxp3 expression which would otherwise diminish 
IL-9 production.  
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Figure 34: STAT6 limits Foxp3 inhibition of IL-9. (A) Naïve CD4+ T cells from WT 
mice were cultured under Th1, Th2, Th9, Th17, Treg conditions or directly ex vivo 
(naïve) for 5 days. Foxp3 expression was assessed by real time PCR. (B) Developing Th9 
cells from WT mice were transduced with control or Foxp3-expressing retroviruses. After 
5 days cells were harvested and stimulated with PMA and ionomycin before intracellular 
IL-9and IL-17A staining. (C) Naïve CD4+ T cells from WT and Stat6-/- mice were 
differentiated under Th9 cell conditions for 5 days. RNA was isolated from cell pellet and 
real time PCR was performed to measure Foxp3 expression. Data are average ± S.D of 4-
6 mice from 2-3 independent experiments. Panel B was performed in collaboration with 
Dr. Rukhsana Jabeen. * p<0.05. 
 
Overall these data indicate that the IL-4 signal regulates the expression of both positive 
and negative regulators of IL-9 production (Figure 35). 
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Figure 35: Model of Th9 transcriptional network. Schematic diagram showing the 
summary of STAT6-dependent transcription factor network in Th9 cells. 
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PART III: PU.1 promotes IL-9 expression through a Gcn5-dependent mechanism 
PU.1 is abundantly expressed in Th9 cells 
In the previous section we have described the transcription factor network downstream of 
IL-4 signal required for the development of Th9 cells. We therefore wanted to define the 
transcription factor network downstream of TGF-β signal. Based on the similar ability of 
TGF-β and PU.1 to decrease Th2 cytokine expression (Chang et al., 2005; O'Malley et 
al., 2009), we examined the expression of PU.1 in Th9 cells and compared it among 
different T helper subsets. Naïve CD4+ T cells were polarized under Th1, Th2, Th9, and 
Th17 cell conditions for 5 days and Sfpi1 (the gene which encodes PU.1) expression was 
assessed by real time PCR. Expression of Sfpi1 mRNA was lowest among Th1 and Th17 
cells, while Th2 cells had 3-5 fold more abundant Sfpi1 expression (Figure 36). Th9 cells 
had expressed 2-3 fold higher Sfpi1 than Th2 cells (Figure 36).  
 
Figure 36: PU.1 is abundantly expressed in Th9 cells. WT naïve CD4+ T cells were 
cultured under Th1, Th2, Th9, and Th17 cell conditions for 5 days. On day 5, cells were 
harvested and real time PCR was performed to measure Sfpi1 expression. Data are 
replicates representative of 3 independent experiments. 
 
We then wanted to determine if Il9 and Sfpi1 expression were induced similarly during 
Th9 cell differentiation. To test this, naïve CD4+ T cells from WT mice were cultured 
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under Th2 and Th9 cell conditions and RNA was isolated during each day of 
differentiation. A peak of Sfpi1 expression preceded Il9 induction during differentiation, 
with Th9 cells expressing higher amounts of Il9 and Sfpi1 than Th2 cells (Figure 37A). 
At the end of the differentiation Th9 cells expressed higher levels of Il9 concomitant with 
increased Sfpi1 expression, compared to Th2 cells (Figure 37B). Therefore Sfpi1 is 
expressed consistently higher in Th9 cells than Th2 cells. 
 
Figure 37: IL-9 and PU.1 expression follow similar kinetics with a transient early 
peak during Th9 differentiation. (A) WT naïve CD4+ T cells were cultured under Th2 
and Th9 cell conditions. Cells were collected on each day during differentiation. Il9 and 
Sfpi1 expression was assessed by real time PCR. (B) On day 5, Il9 and Sfpi1 expression 
was measured. Data are replicates representative of 3 independent experiments. 
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PU.1-deficient Th9 cells have impaired IL-9 production 
As PU.1 was predominantly expressed in Th9 cells compared to other Th subsets we 
wanted to determine if PU.1 was required for the development of Th9 cells. To test this, 
naïve CD4+ T cells from WT and PU.1 conditional gene-deficient mice (Sfpi1
lck-/-
) were 
polarized under Th9 culture conditions for 5 days. On day 5, differentiated cells were 
analyzed for IL-9 production. In the absence of PU.1, Th9 cultures had significantly 
reduced percentages of IL-9-secreting cells compared to WT Th9 cultures (Figure 38A). 
There was a corresponding increase in IL-4-producing cells (Figure 38A). Similar to the 
cytokine staining data, IL-9 production was impaired in Sfpi1
lck-/-
 Th9 cultures measured 
using ELISA and real time PCR (Figure 38B, C). To determine if PU.1 also regulated IL-
10 production from Th9 cells, cell-free supernatant from re-stimulated WT and Sfpi1
lck-/- 
Th9 cultures was assessed for IL-10 production. Even though PU.1-deficiency resulted in 
defective IL-9 production, IL-10 production remained unchanged in Th9 cells (Figure 
38D). Since Th9 cells also produce IL-21 we wanted to determine if PU.1 regulated IL-
21 production from Th9 cells. We observed unchanged IL-21 production from PU.1-
deficient Th9 cells compared to wild-type Th9 cells (Figure 38D). Overall these data 
suggest that the transcription factor PU.1 is required for IL-9 production in Th9 cells. 
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Figure 38: PU.1-deficient Th9 cells have impaired IL-9 production. (A) Naïve CD4+ 
T cells from WT and Sfpi1
lck-/-
 mice were differentiated under Th9 cell conditions for 5 
days. Cells were re-stimulated with PMA and ionomycin on day 5 before intracellular IL-
9 and IL-4 staining was performed. (B, C) Cells cultured as in (A) were re-stimulated 
with anti-CD3 for 24 hours (B) and 6 hours (C) to assess IL-9 production using ELISA 
and real time PCR, respectively. (D) Stimulated cells as in (B) were used to measure IL-
10 and IL-21 production using ELISA. Data are average ± S.D of 4-6 mice from 2-3 
independent experiments. * p<0.05, ** p<0.01. 
 
PU.1 ectopic expression enhances IL-9 production 
As a complementary approach to the gene knock-out model of PU.1 we wanted to 
determine if ectopically expressed PU.1 can induce IL-9 production in Th9 cells. To test 
this, developing Th9 cells were transduced with control or PU.1-expressing retroviruses 
and IL-9 production was measured by flow cytometry. Ectopic expression of PU.1 
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increased both the percentages and the mean fluorescence intensity of IL-9-secreting cells 
(Figure 39A, B). In contrast, IL-4 production was reduced when Th9 cells were 
transduced with PU.1 (Figure 39A). When PU.1 was ectopically expressed in Th0 cells 
there was a modest increase in the percentages of IL-9-secreting cells (Figure 39C). 
Overall these data suggest that while Sfpi1
lck-/- 
Th9 cultures have impaired IL-9 
production, ectopic PU.1 expression enhances IL-9 production.  
 
Figure 39: Ectopic PU.1 expression induces IL-9 production. (A) WT naïve CD4+ T 
cells were cultured under Th9 cell conditions for 48 hours before being transduced with 
control or PU.1-expressing retroviruses. Cells were harvested on day 5 and stimulated 
with PMA and ionomycin before staining intracellularly for IL-9 and IL-4 based on 
eGFP+ population. (B) IL-9 MFI from the cells cultured as in (A). (C) WT naïve CD4+ T 
cells were activated with anti-CD3 and anti-CD28 for 48 hours before being transduced 
with control or PU.1-expressing retroviruses. Cells were harvested on day 5 and 
stimulated with PMA and ionomycin before staining intracellularly for IL-9 and IL-4 
based on eGFP+ population. Data are replicates representative of 3 independent 
experiments (A, B) or average of 2 mice (C).  
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Ectopic IRF4 expression does not rescue IL-9 production in PU.1-deficient Th9 cells 
Since IRF4 was shown to be important for the development of Th9 cells, we wanted to 
determine the role of IRF4 in PU.1-mediated IL-9 production. To test this, first we 
determined the expression of Irf4 in WT and PU.1-deficient Th9 cells. Irf4 expression 
was decreased in PU.1-deficient Th9 cells compared to WT Th9 cells (Figure 40A). We 
then wanted to determine if ectopic IRF4 expression was able to recover IL-9 production 
in PU.1-deficient Th9 cells.  We therefore transduced developing Th9 cells from WT and 
Sfpi1
lck-/-
 mice with control or IRF4-expressing retroviruses. Even though IRF4 was able 
to increase the percentages of IL-9-secreting cells from WT cultures, it did not enhance 
the percentages of IL-9-secreting cells from PU.1-deficient Th9 cultures to a level similar 
to WT Th9 cultures transduced with control retroviruses suggesting that IRF4 was not 
sufficient to recover IL-9 production in PU.1-deficient Th9 cells (Figure 40B). 
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Figure 40: Ectopic IRF4 expression does not recover IL-9 production from PU.1-
deficient Th9 cells. (A) Naïve CD4+ T cells from WT and Sfpi1
lck-/-
 mice were cultured 
for 5 days under Th9 cell conditions. RNA was isolated from differentiated cells and Irf4 
expression was assessed by real time PCR. (B, C) Naïve CD4+ T cells from WT and 
Sfpi1
lck-/-
 mice were cultured under Th9 cell conditions for 48 hours before being 
transduced with control or IRF4-expressing retroviruses. Cells were re-stimulated on day 
5 with PMA and ionomycin before intracellular staining for IL-9 and IL-4 was performed 
(B) or IL-9 MFI was assessed (C) based on hCD4+ population.  
 
TGF-β but not IL-4 regulates PU.1 expression 
As we established that PU.1 is one of the transcription factors required for Th9 cell 
development we wanted to determine if PU.1 is downstream of either IL-4 or TGF-β 
signal. When we compared Sfpi1 expression between Th9 and Treg cultures we observed 
that Tregs expressed Sfpi1 4-5 fold higher than Th9 cells (Figure 41A). Since TGF-β is 
the cytokine required for the development of both Th9 and Treg cells, we speculated that 
TGF-β might be regulating PU.1. To test this, we cultured naïve CD4+ T cells with 
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increasing doses of TGF-β in the presence (Th9) or absence (Treg) of a constant dose of 
IL-4 (20 ng/ml). TGF-β dose-dependent induction of Sfpi1 was observed in both Treg 
and Th9 cultures assessed by real time PCR; however, Tregs had higher Sfpi1 expression 
(Figure 41B). In contrast, when Th9 cells were cultured with fixed TGF-β dose (2 ng/ml) 
and in the presence of decreasing IL-4 doses, Sfpi1 expression was not affected by the IL-
4 dose (Figure 41B). However, IL-9 production measured using ELISA from Th9 cells 
was reduced in IL-4 dose-dependent manner when TGF-β was held constant (Figure 
41C). To directly determine if Sfpi1 expression was regulated by IL-4/STAT6 signal we 
assessed Sfpi1 expression in WT and Stat6-/- Th9 cells by real time PCR. There was no 
difference in Sfpi1 expression in the absence of STAT6 (Figure 41D). To test whether 
PU.1 association to the Il9 gene was altered in the absence of STAT6, we performed a 
ChIP assay of PU.1 association at the Il9 locus in WT and Stat6-/- Th9 cultures. In the 
absence of STAT6, PU.1 binding to CNS1 and CNS0 regions of Il9 gene was not altered 
(Figure 41E). These data suggest that TGF-β but not IL-4 controls Sfpi1 expression and 
the fine balance of TGF-β and IL-4 is required for optimal IL-9 production. 
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Figure 41: TGF-β but not IL-4 regulates PU.1 expression. (A) WT naïve CD4+ T 
cells were cultured under Th9 and Treg cell conditions for 5 days. Sfpi1 expression was 
measured on day 5 by real time PCR. (B, C) WT naïve CD4+ T cells were cultured with 
increasing doses of TGF-β in the presence (Th9) or absence (Treg) of IL-4 (20 ng/ml, left 
panel). On day 5, Sfpi1 expression was measured. Naïve CD4+ T cells were also cultured 
Th9 cell conditions with fixed dose of TGF-β (2 ng/ml) and decreasing doses of IL-4 for 
5 days. Cells were harvested on day 5 and were kept unstimulated or re-stimulated with 
anti-CD3 to assess Sfpi1 expression by real time PCR (B) or IL-9 production using 
ELISA (C), respectively. (D, E) Naïve CD4+ T cells from WT and Stat6-/- mice were 
cultured under Th9 cell conditions for 5 days. Following differentiation cells were used to 
measure Sfpi1 expression by real time PCR (D). PU.1 binding to the Il9 locus was 
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assessed by chromatin immunoprecipitation (E).  Data are replicates representative of 3 
independent experiments. 
 
Blocking endogenous TGF-β production in Th2 cells reduces Il9 expression 
PU.1 is expressed in the IL-4
lo
 population of Th2 cells (Chang et al., 2010). Therefore we 
wanted to determine whether the IL-4
lo
, PU.1-expressing Th2 cells are really Th9 cells. 
To test this, Th2 cultures from WT mice were treated with neutralizing TGF-β antibody 
and Sfpi1 expression was assessed by real time PCR. Th2 cells treated with anti-TGF-β 
resulted in two-fold decreased Sfpi1 expression with a concomitant reduction in Il9 
expression (Figure 42). Therefore endogenous TGF-β production in a Th2 culture can 
promote the development of Th9 cells which is consistent with the report demonstrating 
that developed Th2 cells treated with TGF-β can switch to a Th9 phenotype (Veldhoen et 
al., 2008b).  
 
Figure 42: Blocking endogenous TGF-β production in Th2 cells leads to reduced Il9 
expression. Naïve CD4+ T cells were cultured under Th2 cell conditions in the presence 
of control or TGF-β neutralizing antibody and under Th9 cell conditions for 5 days. Cells 
were harvested on day 5 and were either re-stimulated with anti-CD3 for 6 hours (left 
panel) or kept unstimulated (right panel) to measure Il9 and Sfpi1, respectively, by real 
time PCR. Data are replicates representative of 2 independent experiments. 
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Increased histone deacetylase binding to the Il9 locus in the absence of PU.1 
PU.1 has been shown to bind directly to the Il9 promoter in Th9 cells (Chang et al., 
2010)(Figure 41E). However, mechanisms for PU.1-dependent Il9 expression in Th9 
cells have not been defined. Global gene expression results from a balance between 
histone acetylation and deacetylation controlled by a group of enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. Global 
hyperacetylated states can be generated through the use of HDAC inhibitors which 
induce expression of a subset of genes (Luo and Dean, 1999; Van Lint et al., 1996). 
Therefore we wanted to determine if HDAC association to the Il9 locus was PU.1-
dependent. We examined the binding of the class I HDACs, HDAC1 and HDAC2, in WT 
and PU.1-deficient Th9 cultures at the two previously described CNS regions of the Il9 
locus by ChIP assay. Increased association of both the HDAC molecules was observed at 
the CNS1 in the absence of PU.1 (Figure 43). In contrast, HDAC binding at CNS0 was 
lower than CNS1 and was unaffected in the absence of PU.1 (Figure 43). This suggests 
that enhanced HDAC binding to the Il9 promoter in the absence of PU.1 could possibly 
contribute to reduced Il9 transcription. 
 
Figure 43: Increased histone deacetylase binding at Il9 locus in the absence of PU.1. 
Naïve CD4+ T cells from wild-type and Sfpi1
lck-/-
 mice were cultured under Th9 cell 
conditions for 5 days. ChIP assay was performed for HDAC1 and HDAC2 before 
quantitative PCR for two Il9 CNS sites. Data are average ± S.D of 4 mice from 2 
independent experiments.* p<0.05. 
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HDAC inhibitor enhances IL-9 production 
As HDAC association was increased to the Il9 promoter in the absence of PU.1, we 
wanted to determine if HDAC inhibition reverses repressive chromatin modification and 
leads to augmented IL-9 production. To test this, naïve CD4+ T cells from WT mice were 
cultured under Th9 polarizing conditions in the presence of trichostatin A (TSA), an 
antifungal antibiotic that selectively inhibits class I and class II HDACs. Th9 cells treated 
with TSA had enhanced percentages of IL-9-secreting cells and increased Il9 gene 
expression (Figure 44A, B). To determine if TSA treatment enhanced the induction of 
other cytokines produced by Th9 cells we examined the expression of Il10 and Il21. In 
contrast to Il9 expression, TSA treatment did not affect the expression of Il10 or Il21 
(Figure 44B). Overall these data indicate that HDAC inhibition specifically enhanced Il9 
induction in Th9 cells. 
 
Figure 44: HDAC inhibitor only enhances IL-9 production. (A) WT naive CD4+ T 
cells were cultured under Th9 conditions for 5 days in the presence or absence of 
trichostatin A (TSA). On day 5, cells were re-stimulated with PMA and ionomycin before 
intracellular staining for IL-9 and IL-4 was performed. (B)  Differentiated Th9 cells were 
stimulated with anti-CD3 for 6h before RNA isolation. Il9, Il10, and Il21 gene expression 
 109 
was assessed by real time PCR. Data are average ± S.D of 4-6 mice from 2-3 independent 
experiments. * p<0.05. 
 
HDAC-mediated IL-9 induction is PU.1-dependent 
Since TSA specifically enhanced IL-9 production in Th9 cells we wanted to determine if 
TSA treatment altered the expression of Th9-specific transcription factors, PU.1 and 
IRF4.  Differentiated Th9 cells treated with TSA were examined for Sfpi1 and Irf4 
expression by real time PCR. We observed an increase in Sfpi1, but not Irf4 expression 
after TSA treatment (Figure 45A). This was confirmed by immunoblots of total cell 
lysates prepared from Th9 cells treated with TSA (Figure 45B). As the expression of 
Sfpi1 was enhanced after TSA treatment we wanted to determine if TSA-mediated 
enhanced IL-9 production was PU.1-dependent. To test this, WT and PU.1-deficient Th9 
cultures were treated with TSA and IL-9 production was measured using ELISA. Even 
though TSA was able to enhance IL-9 production significantly from WT Th9 cells, 
addition of TSA in PU.1-deficient Th9 cultures did not augment IL-9 production (Figure 
45C). Together, these data suggest HDAC inhibition-induced IL-9 production in Th9 
cells is PU.1-dependent. 
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Figure 45: HDAC-mediated IL-9 induction is PU.1-dependent. (A) Naïve CD4+ T 
cells from WT mice were cultured under Th9 cell conditions for 5 days in the presence or 
absence of TSA. Cells were harvested on day 5 to assess Sfpi1 and Irf4 expression by real 
time PCR. (B) Total cell extracts were immunoblotted for PU.1, IRF4, and β-actin as a 
control (left panel), blots were scanned and presented in densitometry units (right panel). 
(C) Naïve CD4+ T cells from wild-type and Sfpi1
lck-/-
 mice were cultured under Th9 cell 
conditions in the presence or absence of TSA for 5 days. On day 5, cells were re-
stimulated with anti-CD3 for 24 hours and cell-free supernatant was used to measure IL-9 
production using ELISA. Data are average ± S.D of 4 mice from 2 independent 
experiments. ** p<0.01 (A, paired t-test; C, One way ANOVA post hoc Bonferroni 
correction). 
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TSA treatment enhances histone acetylation and Th9-associated transcription factors 
binding to the Il9 promoter 
Since HDAC inhibition increases histone acetylation we wanted to determine if TSA-
induced Il9 expression correlated with altered histone acetylation at the Il9 gene. To test 
this, ChIP assay was performed to assess histone acetylation of H3K14 and H4K5 
residues at the Il9 promoter when WT Th9 cells were treated with TSA. We observed 
enhanced acetylation of both histone lysine residues after TSA treatment (Figure 46). We 
further tested if TSA treatment altered PU.1 and IRF4 binding to the Il9 gene. An 
increase in PU.1 and IRF4 association was observed at the Il9 promoter, despite TSA not 
affecting Irf4 expression (Figure 46). Together, these data suggest that increased IL-9 
production after HDAC inhibition correlated with enhanced histone acetylation and 
increased PU.1 and IRF4 binding to the Il9 promoter. 
 
Figure 46: TSA treatment enhances histone acetylation and PU.1, IRF4 binding at 
the Il9 promoter. WT naïve CD4+ T cells were harvested under Th9 cell conditions for 
5 days in the presence or absence of TSA. On day 5, ChIP assay was performed for 
AcH3K14, AcH4K5, PU.1 and IRF4 before quantitative PCR for Il9 promoter. Data are 
replicates representative of 3 independent experiments.  
 112 
The activation domains of PU.1 induce IL-9 in Th9 cells 
Transcription factors are composed of different functional domains. PU.1 also has 
multiple functional modules including N-terminal activation domain and C-terminal 
DNA binding domain (Figure 47A). Activation and DNA-binding domains are broadly 
required for transactivation. As PU.1 is required for the development of Th9 cells we 
wanted to define the structural requirements for PU.1-mediated IL-9 induction. To test 
this, we transduced developing WT Th9 cells with control retrovirus, full-length PU.1-
expressing retrovirus (PU.1) and PU.1 mutant-expressing retroviruses that lacked the 
transactivation domain (Δ33-100), the PEST domain (Δ118-160) or had a point mutation 
in the DNA-binding domain (R232G) that results in diminished DNA binding. Intact 
PU.1 enhances both the percentages and the mean fluorescence intensity of IL-9-
secreting T cells (Figure 47B, C). In contrast, cells transduced with either the PU.1 
transactivation mutant or with the DNA-binding mutant retroviruses failed to induce IL-9 
(Figure 47B, C). The PEST mutant was able to modestly increase IL-9-producing cells; 
however, it was not as efficient as the intact PU.1 in transduced cells (Figure 47B, C) 
Overall, these data suggest that the activation domain and DNA-binding domain of PU.1 
are required for the induction of IL-9.  
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Figure 47: Activation and DNA-binding domains of PU.1 are important for IL-9 
induction. (A) Schematic diagram of PU.1 domain structure along with the mutants used 
in the PU.1 structure function analysis. (B, C) WT naïve CD4+ T cells were cultured 
under Th9 cell conditions for 48 hours before being transduced with control or full-length 
PU.1 (PU.1) or PU.1 mutant-expressing retroviruses. On day 5, cells were re-stimulated 
with PMA and ionomycin. Percentages of IL-9-secreting cells (B) and IL-9 mean 
fluorescence intensity (C) were analyzed based on eGFP+ cells. Data are average ± S.D 
of 4 mice from 2 independent experiments. ** p<0.01. 
 
To further demonstrate the requirement of the activation domain in IL-9 expression, we 
transduced developing PU.1-deficient Th9 cultures with retroviruses expressing full-
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length PU.1 or activation domain mutant PU.1 and control retrovirus. WT Th9 cells were 
transduced with control retrovirus only. As expected PU.1-deficient Th9 cells transduced 
with control retrovirus had significantly attenuated IL-9-secreting cells by flow cytometry 
(Figure 48A) or IL-9 production using ELISA compared to WT Th9 cells (Figure 48B). 
However, full-length PU.1was able to restore IL-9 production in PU.1-deficient Th9 cells 
to a level similar to WT Th9 cells transduced with control retrovirus (Figure 48A, B). In 
contrast, the activation domain mutant had significantly impaired ability to recover IL-9 
in PU.1-deficient Th9 cells (Figure 48A, B). Overall, these data suggest that the 
activation domain of PU.1 is important for the induction of IL-9. 
 
Figure 48: Activation domain mutant of PU.1 fails to rescue IL-9 in PU.1-deficient 
Th9 cells.  (A-C) Naïve CD4+ T cells from wild-type and Sfpi1
lck-/-
 mice were cultured 
under Th9 cell conditions and transduced with control, full-length or PU.1 activation 
domain mutant-expressing retroviruses. After 5 days, cells were stimulated with PMA 
and ionomycin for 5 hours and flow cytometry was performed based on eGFP+ cells (A, 
B) or eGFP+ cells were sorted and re-stimulated with anti-CD3 for 24 hours. Cell-free 
supernatant was collected to measure IL-9 using ELISA (C). Data are average ± S.D of 3 
mice. * p<0.05, ** p<0.01 (One way ANOVA post hoc Bonferroni correction). 
 115 
Altered histone acetyltransferase binding at the Il9 locus 
As PU.1 can bind to the Il9 promoter in Th9 cells (Chang et al., 2010), we hypothesized 
that PU.1 was also recruiting other factors such as histone modifying enzymes including 
histone acetyltransferases to the Il9 locus for transactivation. HATs-mediated acetylation 
of lysine residues reduces electrostatic interactions between histone and the 
phosphodiester backbone of DNA thereby facilitating the accessibility of trans-acting 
factors to the gene (Strahl and Allis, 2000). To test this, we examined the recruitment of 
three commonly described HATs; Gcn5, PCAF, and p300 in WT and PU.1-deficient Th9 
cells to Il9 locus by chromatin immunoprecipitation. Significantly diminished association 
of both Gcn5 and PCAF at the CNS1 and CNS0 region of the Il9 locus was observed in 
the absence of PU.1 (Figure 49A). In contrast to a previous report demonstrating that 
PU.1 recruited p300 to the IgK locus in B cells (Bai et al., 2005), an enhanced binding of 
p300 at the Il9 promoter was observed in the absence of PU.1 (Figure 49A). Therefore, 
PU.1 is required for the association of specific HATs to the Il9 promoter. 
 
It is possible that PU.1-deficient Th9 cells express a reduced amount of the HAT 
molecules which would contribute to decreased specific HATs association to the Il9 
promoter. To test this, total cell extracts from WT and PU.1-deficient Th9 cells were 
prepared for immunoblots for Gcn5, PCAF, and p300. There was no difference in the 
expression of these HAT molecules between WT and PU.1-deficient Th9 cells (Figure 
49B). Overall, these data imply that differential recruitment of the HAT molecules to the 
Il9 locus was not because of their altered expression in the absence of PU.1. 
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Figure 49: Altered histone acetyltransferase binding at the Il9 gene. (A) Naïve CD4+ 
T cells from wild-type and Sfpi1
lck-/-
 mice were cultured under Th9 cell conditions for 5 
days. Cells were then fixed and ChIP assay was performed for Gcn5, PCAF, and p300 
before quantitative PCR for two Il9 CNS sites. (B) Total cell lysates were prepared from 
WT and PU.1-deficient Th9 cells and were immunoblotted for Gcn5, PCAF, and p300. β-
actin was used as loading control (left panel). Blots were scanned and presented as 
densitometry units (right panel). Data are average ± S.D of 6-8 mice from 3-4 
experiments (A) or representative of two independent experiments (B). * p<0.05, ** 
p<0.01. 
 
Altered histone acetylation at the Il9 locus 
Since there was differential recruitment of HATs to the Il9 locus in the absence of PU.1, 
we wanted to define the functional consequences of altered HAT binding. Previously we 
demonstrated decreased total H3 acetylation at the Il9 promoter in PU.1-deficient Th9 
cultures (Chang et al., 2010). We therefore examined the acetylation of specific histone 
residues in WT and PU.1-deficient Th9 cells. Significantly diminished histone acetylation 
of histone H3K14 was observed at the Il9 promoter in PU.1-deficient Th9 cells (Figure 
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50A). Acetylation of H3K9/18, H4K5, H4K8, and H4K16 was diminished significantly 
at both CNS1 and CNS0 of the Il9 gene (Figure 50A). In contrast, there was no difference 
in acetylation of H3K27 and H3K36 between WT and PU.1-deficient Th9 cells (Figure 
50A). As a control we compared total H3 and H4 at the Il9 promoter between WT and 
PU.1-deficient Th9 cells and observed no difference in total histone content at the locus 
(Figure 50B). Collectively, these data indicate that PU.1 regulates specific histone 
acetylation at the Il9 locus. 
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Figure 50: Altered histone acetylation at the Il9 gene. (A-B), Naïve CD4+ T cells 
from wild-type and Sfpi1
lck-/-
 mice were cultured under Th9 cell conditions for 5 days.  
On day 5, cells were harvested and subjected to ChIP assay for AcH3K9/18, AcH3K14, 
AcH4K5, AcH4K8, AcH4K16, AcH3K27, and AcH3K36 before quantitative PCR for Il9 
CNS1 and Il9 CNS0 (A) or for total H3 and H4 before quantitative PCR for Il9 CNS1 
(B). Data are average ± S.D of 6-8 mice from 3-4 experiments. * p<0.05, ** p<0.01. 
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PU.1 associates directly with Gcn5 
Since we observed reduced Gcn5 and PCAF recruitment to the Il9 locus in the absence of 
PU.1, we wanted to determine if PU.1 was able to directly associate with either of these 
HAT molecules. To test this, we first examined association of PU.1 with each HAT by 
co-immunoprecipitation. However, we were unable to observe any significant 
association. We therefore hypothesized that PU.1 interacts with HATs more efficiently 
when bound to DNA. To test this, DNA-affinity precipitation assay (DAPA) was 
performed with nuclear lysates prepared from WT and PU.1-deficient Th9 cells incubated 
with a biotinylated WT oligonucleotide (oligonucleotide containing a consensus PU.1 
binding site) or mutant oligonucleotide (oligonucleotide containing a mutated PU.1 
binding site) in the presence of streptavidin-agarose. Following incubation, immunoblot 
was performed to assess Gcn5 and PCAF precipitation. WT DNA-bound PU.1 was able 
to precipitate Gcn5 from wild-type lysates (Figure 51A). In contrast, Gcn5 was not 
precipitated when WT oligonucleotide was used with PU.1-deficient Th9 extracts or the 
mutated oligonucleotide was used either WT or PU.1-deficient Th9 extracts (Figure 
51A). PCAF was not precipitated from wild-type or PU.1-deficient Th9 lysates using 
either oligonucleotide (Figure 51A). Together, these data suggest that DNA-bound PU.1 
is able to directly associate with Gcn5, but not PCAF. 
 
We then wanted to determine if the requirement for the activation domain in the 
induction of IL-9 correlated with a requirement for the activation domain to interact with 
Gcn5. To test this, phoenix-GP packaging cells were transfected with control, full-length 
or Δ33-100 mutant PU.1 plasmids and DAPA was performed. We observed Gcn5 
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precipitate when cells were transfected with full-length plasmid (Figure 51B). In contrast, 
the precipitate was not observed when the cells were transfected with the PU.1 activation 
mutant plasmid (Figure 51B). This suggests that DNA-bound PU.1 requires the activation 
domain to precipitate Gcn5 which correlates with the requirement of activation domain 
for inducing IL-9. 
 
Figure 51: PU.1 associates with Gcn5. (A) Naïve CD4+ T cells from WT and Sfpi1
lck-/-
 
mice were cultured under Th9 cell conditions for 5 days.  On day 5, nuclear lysates were 
prepared from differentiated cells and were incubated with WT oligonucleotide 
(oligonucleotide with consensus PU.1-binding site) or mutant oligonucleotide 
(oligonucleotide with mutated PU.1-binding site) and streptavidin-agarose. Lysates were 
then subjected to immunoblot for Gcn5, PCAF and PU.1. Input samples were prepared 
from untreated nuclear lysates. (B) Phoenix-GP packaging cell lines were transfected 
with control (MIEG), full-length PU.1 (PU.1) or activation domain mutant PU.1 (Δ33-
100)-expressing plasmids. Nuclear extracts were then prepared and subjected to DAPA 
using WT oligonucleotide before immunoblot for Gcn5 (left panel). Densitometry of the 
immunoblots was performed where the background signal (MIEG) was subtracted from 
the full-length or activation domain mutant PU.1 immunoblot signal and data are 
presented as arbitrary densitometry units from 3 experiments (right panel). * p<0.05. 
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Ectopic expression of functional PU.1 restores Gcn5 binding to the Il9 promoter 
We next wanted to determine if transduced PU.1 recruited Gcn5 to the Il9 promoter in the 
absence of endogenous PU.1. To test this, we examined whether ectopic expression of 
PU.1 recovered Gcn5 binding to the Il9 promoter in PU.1-deficient Th9 cells. Developing 
WT Th9 cells were transduced with control retrovirus while PU.1-deficient Th9 cells 
were transduced with control, full-length and PU.1 activation mutant-expressing 
retroviruses. We observed significant decrease in Gcn5 binding to the Il9 promoter when 
PU.1-deficient Th9 cells were transduced with control retrovirus compared to WT Th9 
cells (Figure 52). However, full-length PU.1 was able to rescue Gcn5 binding in PU.1-
deficient Th9 cells (Figure 52). In contrast, cells transduced with the activation domain 
mutant failed to rescue Gcn5 binding (Figure 52). This data further underlines the 
importance of the activation domain, which is critical for Gcn5 binding to the Il9 
promoter. 
 
Figure 52: Ectopic expression of PU.1 rescues Gcn5 binding to the Il9 promoter. 
Naïve CD4+ T cells from wild-type and Sfpi1
lck-/-
 mice were cultured under Th9 
conditions and after 48 hours transduced with control, full-length or PU.1 activation 
domain mutant-expressing retroviruses. After 5 days, eGFP+ cells were sorted and were 
subjected to ChIP for Gcn5 before quantitative PCR for Il9 promoter. Data are average ± 
S.D of 3 mice.  ** p<0.01 (One way ANOVA post hoc Bonferroni correction). 
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Gcn5 inhibition leads to diminished Il9 expression 
Since PU.1 associates with and recruits Gcn5 binding to Il9, we wanted to determine if 
reduced Gcn5 expression affects Il9 gene expression. Gcn5-null embryos die during 
embryogenesis. Therefore we transfected differentiated Th9 cells with control or Gcn5-
specific siRNA.  Th9 cells transfected with Gcn5-specific siRNA resulted in significantly 
decreased Gcn5 mRNA and decreased Gcn5 binding to the Il9 promoter (Figure 53A, B). 
Concomitantly, IL-9 production was significantly reduced when Gcn5 expression was 
inhibited (Figure 53C). To determine if altered Gcn5 expression affected the production 
of other cytokines we measured the amount of IL-10 and IL-21 produced by Th9 cells 
with diminished Gcn5 expression. Reduced Gcn5 expression did not alter the production 
of IL-10 and IL-21, suggesting that the Il9 locus was a specific target of Gcn5 (Figure 
53C). This was also consistent with our previous data that Th9 production of IL-10 and 
IL-21 was PU.1-independent (Figure 38D)(Chang et al., 2010). These data suggest that 
Gcn5 is recruited by PU.1, and is required specifically for the production of IL-9 but not 
other cytokines produced by Th9 cells. 
 
To define a mechanism for how Gcn5 functionally contributed to Il9 expression, we 
examined the binding to PU.1 and IRF4 to the Il9 promoter following transfection of 
differentiated Th9 cells with control or Gcn5-specific siRNA. Decreased Gcn5 
expression did not affect PU.1 or IRF4 binding to the Il9 promoter (Figure 53D). To 
examine if reduced Gcn5 expression in Th9 cells decreased histone acetylation we 
assessed histone acetylation of specific lysine residues mediated by Gcn5. Gcn5 
acetylates H3K9/18, H4K8, and under some circumstances H4K5 (Kouzarides, 2007; 
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Kuo et al., 1996; Zhang et al., 1998b). Acetylation of histone H3K9/18, H4K5 and H4K8 
at the Il9 promoter was significantly attenuated when Gcn5 was inhibited (Figure 53E).  
 
Figure 53: Gcn5 inhibition reduces IL-9 production. (A-C), WT naive CD4+ T cells 
were cultured under Th9 conditions for 5 days. Differentiated cells were then transfected 
with control or Gcn5-specific siRNA. After transfection cells were rested overnight with 
IL-2 and were then stimulated with anti-CD3 for 6h for isolating RNA or for 24h to 
harvest cell free supernatant for ELISA (A, C) or kept unstimulated for ChIP (B). (D-E), 
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ChIP assay was performed from Th9 cells transfected with Gcn5 siRNA as in (A) for 
Gcn5, PU.1, IRF4, AcH3K9/18, AcH4K5 and AcH4K8 followed by quantitative PCR 
with primer for Il9 CNS1. Data are average ± S.D of 4-6 mice from 2-3 experiments. * 
p<0.05, ** p<0.01. 
 
Together, these data suggest that Gcn5 inhibition leads to reduced IL-9 production 
concomitant with decreased specific histone acetylation of Il9 although it is not required 
for PU.1 and IRF4 association to the Il9 gene. The schematic of PU.1-dependent IL-9 
induction in Th9 cells is shown below (Figure 54). 
 
Figure 54: Mechanism of PU.1-dependent IL-9 induction in Th9 cells 
 
 125 
PART IV: Alternative pathways of IL-9 regulation 
Th2 cells treated with pro-inflammatory cytokines can induce IL-9 
The pro-inflammatory cytokines IL-1β, IL-6, and IL-21 have been shown to enhance IL-9 
production in human T cell cultures (Putheti et al., 2010; Wong et al., 2010). We 
therefore wanted to determine if these cytokines can augment IL-9 production in murine 
T cells. To test this, we cultured Th2 and Th9 cells in the presence or absence of IL-1β, 
IL-6, and IL-21 individually or in combinations. As demonstrated previously, IL-9 
production was higher in Th9 cells than Th2 cells (Figure 55A). However, when Th2 
cells were cultured with the combination of three cytokines IL-9 production was 
enhanced dramatically which was not observed when Th2 cells were cultured with 
individual cytokines (Figure 55A). There was a modest increase in IL-9 production when 
Th9 cells were treated with IL-1β, IL-6, and IL-21 compared to standard Th9 conditions 
(Figure 55A). As PU.1 has been shown to be required for the induction of IL-9 in Th9 
cells we wanted to determine if PU.1 was required for IL-9 induction when Th2 cells 
were treated with the pro-inflammatory cytokines. We observed PU.1-dependent IL-9 
production when Th9 cells were cultured under standard IL-9 culture conditions (Figure 
55B). However, PU.1 was dispensable for Th2 cell mediated IL-9 production by the pro-
inflammatory cytokines (Figure 55B). In the absence of PU.1 there was enhanced IL-9 
production when Th9 cells were cultured with IL-1β, IL-6, and IL-21 (Figure 55B). 
 
STAT3 is activated by IL-6, and IL-21. To define if the pro-inflammatory cytokine 
mediated IL-9 induction was dependent on STAT3 we cultured Th2 and Th9 cells in the 
presence or absence of IL-1β, IL-6, and IL-21 from WT and Stat3CD4-/- mice. As 
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demonstrated previously STAT3-deficient Th9 cells did not have defective IL-9 
production (Figure 55C). STAT3 was also dispensable for IL-9 production when Th9 
cells were treated with IL-1β, IL-6, and IL-21 (Figure 55C). In contrast, IL-9 production 
was severely impaired in the absence of STAT3 when Th2 cells were cultured with IL-
1β, IL-6, and IL-21 (Figure 55C). Together these data demonstrate that IL-9 can be 
alternatively induced when Th2 cells are exposed to an inflammatory cytokine 
environment, and this process is STAT3-dependent.  
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Figure 55: Th2 cells treated with pro-inflammatory cytokines can induce IL-9. (A) 
WT naïve CD4+ T cells were cultured under Th2 and Th9 cell conditions in the presence 
or absence of pro-inflammatory cytokines IL-1β, IL-6, and IL-21 individually or in 
combination for 5 days. On day 5, cells were re-stimulated with anti-CD3 to assess IL-9 
production using ELISA. (B) Naïve CD4+ T cells from WT and PU.1-deficient (top 
panel) or WT and Stat3
CD4-/-
 mice (bottom panel) were cultured as in (A). On day 5, cells 
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were re-stimulated with anti-CD3 for 24 hours to measure IL-9 production using ELISA. 
Data are replicates representative of 2 independent experiments. 
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DISCUSSION 
One of the focuses of this thesis is characterization of Th9 cells, which predominantly 
produce IL-9. While defining the phenotype of Th9 cells we observed that other Th cell 
lineages produce very modest amount of IL-9. Even though Th9 cells are related to Th2, 
Th17, and Treg cells because of shared cytokines that promote their development, Th9 
cells secrete low level of Th2, and Th17-associated cytokines. IL-13, related to IL-4 in 
both function and signaling pathway cannot replace IL-4 to synergize with TGF-β to 
produce IL-9. IL-23, the cytokine required for the maintenance of Th17 cells negatively 
regulates IL-9 production. Type I and type II interferons also inhibit IL-9 production 
from Th9 cells. 
 
Next we defined the transcription factor network downstream of IL-4 and TGF-β signals 
in Th9 cells. PU.1, the transcription factor critical for the development of Th9 cells is 
downstream of the TGF-β signal. Even though both STAT6 and STAT3 are activated 
during Th9 cell differentiation only STAT6 is required for Th9 cell development.  IRF4, 
another transcription factor required for Th9 cells is downstream of IL-4/STAT6 
pathway. We also show that Th2-associated transcription factors, including GATA3, c-
Maf, are IL-4/STAT6-dependent in Th9 cells; however, they inhibit IL-9 production. We 
further observed that Th1-specific transcription factors T-bet and Runx3 inhibit IL-9 
production from Th9 cells. 
 
As PU.1 is required for the development of Th9 cells we defined the PU.1-dependent 
mechanism for induction of IL-9. We observed that PU.1 is required for differential 
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recruitment of specific histone acetyltransferases to the Il9 locus in Th9 cells. 
Functionally this leads to PU.1-dependent specific histone modifications of the Il9 gene. 
Furthermore, we observed that PU.1 is able to form a complex with Gcn5, one of the 
HATs. Reduced Gcn5 expression resulted in attenuated IL-9 production. 
 
Finally, we provide evidence of an alternative pathway for IL-9 induction. Th2 cells 
cultured in the presence of IL-1β, IL-6, and IL-21 can promote PU.1-independent but 
STAT3-dependent induction of IL-9. 
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PART I: Defining the phenotype of IL-9-secreting T cells 
Naïve T cells primed with TGF-β and IL-4 produce IL-9 
Renewed interest had been generated in the biology of the understudied cytokine IL-9. 
The work on IL-9 had been mostly focused on its role as a pro-inflammatory cytokine 
and as T cell and mast cell growth factor. IL-9 is produced in different Th2-mediated 
inflammatory models. Recent studies have demonstrated that T cells cultured in the 
presence of TGF-β and IL-4 can secrete IL-9 and are known as Th9 cells (Dardalhon et 
al., 2008; Veldhoen et al., 2008b). IL-4 was able to block the generation of TGF-β-
induced Tregs and promote IL-9 and IL-10 production (Dardalhon et al., 2008). TGF-β 
was able to reprogram polarized Th2 cells into IL-9-secreting T cells (Veldhoen et al., 
2008b). As these published reports suggested the presence of an additional member in Th 
subset, we wanted to optimize and characterize the phenotype of Th9 cells in detail. We 
observed that naïve CD4+ T cells cultured with TGF-β and IL-4 can produce high 
amounts of IL-9 (Figure 11A). IL-4 is required for Th2 and Th9 cell differentiation, while 
TGF-β is associated with Th9, Th17 and Treg cell differentiation. Previous studies have 
documented the ability of Th17 and Treg cells to produce IL-9 (Elyaman et al., 2009; Lu 
et al., 2006). One study has shown that TGF-β and IL-9 can prime T cells into IL-17-
secreting cells (Elyaman et al., 2009). We observed that Th2, Th17, and Tregs produce 
very low to undetectable levels of IL-9 (Figure 11B-H). In contrast, Th9 cells secrete 
significantly reduced amount of IL-4, IL-5, IL-13 and IL-17; cytokines produced by Th2 
and Th17 cells (Figures 11E-F, 12). Even though TGF-β was required for the 
differentiation of Th9 cells, Foxp3 was expressed at a reduced level in Th9 cells 
compared to Tregs (Figure 11G). We also observed that the amount of IL-10 produced by 
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Th9 cells is lower than Th2 cells, contrary to published reports (Dardalhon et al., 2008; 
Veldhoen et al., 2008b)(Figure 13). This observation can be attributed to the variability in 
differentiation conditions and the length of differentiation used in different studies. Our 
studies also demonstrate that IL-9 and IL-10 are not coordinately regulated in Th9 cells 
(Figure 14). This observation is consistent with our previous published report indicating 
that in Th2 cells IL-9 and IL-10 are reciprocally regulated (Ahyi et al., 2009). Together, 
these data suggest that TGF-β and IL-4 prime T cells to produce predominantly IL-9; 
however, Th9 cells have the ability to secrete reduced amounts of other cytokines.  
 
IL-4 is indispensible for Th9 cell differentiation 
IL-4 shares functions and signaling pathways with another Th2 cytokine, IL-13. We 
therefore wanted to determine if IL-4 could be substituted by IL-13 to synergize with 
TGF-β to induce IL-9. We observed that IL-13 could not synergize with TGF-β to 
produce IL-9 (Figure 16). As Th17 cells are the only Th subset to express functional 
Il13Rα1 (Newcomb et al., 2009) we wanted to determine if Il13Rα1 was expressed when 
naïve CD4+ T cells were cultured with TGF-β and IL-13. We could not detect Il13Rα1 
when T cells were primed with IL-13 and TGF-β (Figure 16B) suggesting that lack of 
functional Il13Rα1 expression was one of the reasons of naïve CD4+ T cells not being 
able to produce IL-9 when cultured with TGF-β and IL-13. 
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PART II: Defining the STAT6-dependent Th9 transcriptional network 
Multiple STAT proteins are required for T effector subset development 
There has been a shift from the concept that one STAT molecule is required for one T 
effector subset, to one where multiple STAT molecules control the expression of one T 
effector subset. Initially STAT4 was shown to be critical for Th1 cell development; while 
STAT6 was required for the development of Th2 subset (Kaplan et al., 1996a; Kaplan et 
al., 1996b; Shimoda et al., 1996; Thierfelder et al., 1996). However, this paradigm was 
modified when STAT1 was shown to be important for Th1 cell development (Afkarian et 
al., 2002). STAT5 was documented to be important for Treg cell development (Burchill 
et al., 2007; Yao et al., 2007), after STAT5 was demonstrated to function with STAT6 for 
Th2 cell development (Cote-Sierra et al., 2004; Zhu et al., 2003). The requirement of 
STAT3 in addition to STAT6 in the development of Th2 cells further shifted from the 
paradigm of one STAT-one phenotype to multiple STAT-one phenotype (Stritesky et al., 
2011). STAT3 was shown to be critical for the development of Th17 cells and STAT4 
was reported to be important for the memory Th17 responses (Mathur et al., 2007). 
Therefore, in this thesis we wanted to define the requirement of STAT proteins in Th9 
cell development. 
 
Differential requirement of STAT proteins in the development of Th9 cells 
STAT6 is required for the development of Th2 cells. However, STAT3 also cooperates 
with STAT6 to promote Th2 cell development (Stritesky et al., 2011). We therefore 
wanted to define the role of both STAT6 and STAT3 in Th9 cell development. Both 
STAT6 and STAT3 were activated during Th9 cell differentiation although the 
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percentages and the mean fluorescence intensity of STAT3-positive Th9 cells were 
slightly lower than Th2 cells (Figure 20). Consistent with published reports we observed 
complete impairment of IL-9 production in the absence of STAT6 (Figure 21A, B). This 
suggests that the IL-4/STAT6 pathway is critical for Th9 cell development. Furthermore, 
we observed the requirement for the STAT6 co-factor PARP14 in promoting Th9 cell 
development, consistent with the importance of STAT6 (Figure 22).  In contrast, 
although STAT3 was activated throughout Th9 cells differentiation it was dispensable for 
the development of Th9 cells (Figure 21C, D). STAT3 could be activated by IL-4 in 
some conditions (Orchansky et al., 1999), yet, STAT3 remained activated in STAT6-
deficient Th2 cells (Stritesky et al., 2011). Similar to Th17 cells, Th9 cells also have the 
ability to produce IL-21 (Kaplan et al., 2011). IL-21 produced by Th17 cells is STAT3-
dependent (Wei et al., 2007). In Th17 cells STAT3 can bind to the Il21 promoter (Wei et 
al., 2007). Therefore, STAT3 might be regulating the production of IL-21 but not IL-9 in 
Th9 cells. We also show that IL-9 can be generated when Th2 cells are primed with IL-6, 
IL-21 and IL-1β (Figure 55). IL-6 and IL-21 both activate STAT3, and the absence of 
STAT3 almost abolished IL-9 production when T cells are cultured with IL-4, IL-6, IL-
21, and IL-1β (Figure 55). Therefore, STAT3 could play an important role in an 
alternative mode of IL-9 induction. This might be relevant in vivo, where immune cells 
are exposed to a plethora of cytokines and STAT3 could drive Th2 cells to produce IL-9. 
The role of STAT5 has not been examined in Th9 cell development. As IL-2-activated 
STAT5 plays a key role in Th2 cell differentiation and IL-2 is essential for IL-9 
production by CD4+ T cells we speculate STAT5 might play an important role to 
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promote Th9 cell development (Cote-Sierra et al., 2004; Fung et al., 2005; Schmitt et al., 
1994; Zhu et al., 2003). 
 
STAT6 targets in Th9 cells 
Since IL-4/STAT6 signaling was required for the development of Th9 cells, we wanted to 
define if STAT6 regulates IL-9 by directly binding to the Il9 gene. When the Il9 gene 
was scanned, potential STAT binding sites were observed at CNS1 and CNS0 regions 
(Figure 23A). STAT6 binding was observed at the Il9 promoter (Figure 23B); however, 
the binding was very low when compared to STAT6 binding to the Maf or Irf4 
promoters. STAT6 binding to CNS0 was even lower than binding to the Il9 promoter 
(Figure 23B). This observation was consistent with the finding that STAT6 binding was 
undetectable in the Il9 locus in Th2 cells (Wei et al., 2010). Importantly, STAT6 could be 
binding to regions of DNA outside of CNS1 and CNS0. Thus, although STAT6 is 
required for Th9 cell development, it does not bind proximal regions of the Il9 gene. 
 
STAT6 is required for the expression of Gata3, Irf4, and Maf in Th2 cells (Veldhoen, 
2010; Zhu et al., 2010). Therefore we speculated that GATA3, IRF4, and c-Maf are 
targets of STAT6 in Th9 cells. In the absence of STAT6 signal in Th9 cells Gata3, Irf4, 
and Maf expression was attenuated (Figures 24A, 29). STAT6 is not only required for 
Irf4 expression in Th9 cells but also important for IRF4 binding to the Il9 gene. The 
absence of STAT6 results in diminished IRF4 recruitment at the Il9 locus which could be 
due to decreased Irf4 expression (Figure 24B). Therefore, IRF4 a transcription factor 
required for Th9 cells development is downstream of STAT6 signal. However, IRF4 
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alone was not sufficient to recover IL-9 production from STAT6-deficient Th9 cells 
suggesting that additional factors downstream of IL-4/STAT6 pathway are required to 
induce IL-9 (Figure 25).  
 
The role of IL-4 could be to suppress inhibitory molecules in Th9 cells. IL-4 had been 
previously shown to repress Foxp3 expression (Chapoval et al., 2010; Mantel et al., 2007; 
O'Malley et al., 2009). To further define the function of IL-4 we cultured Th9 cells in the 
presence of increasing TGF-β doses with a constant dose of IL-4. We observed IL-4 
reduced Foxp3-positive cells in Th9 cells compared to Treg cells (Figure 15). Foxp3-
expressing Treg cells had barely detectable levels of IL-9-secreting cells while Th9 cells 
had higher IL-9-producing cells (Figure 15), implying Foxp3 plays an inhibitory role in 
the development of Th9 cells. We observed ectopically expressed Foxp3 repressed IL-9 
production from Th9 cells (Figure 34). That IRF4 over expression failed to reduce Foxp3 
expression was probably one of the reasons for its inability to recover IL-9 production 
from STAT6-deficient Th9 cells (Figure 25C).  Therefore, the IL-4 signal regulates the 
expression of both positive and negative regulators of IL-9 production and both IL-4 and 
TGF-β are required for the development of IL-9-producing cells. IL-4-induced Th2 cells 
where endogenous TGF-β is blocked produce very low amounts of IL-9. Similarly, in 
TGF-β-induced Treg cells, where IL-4 is not added, there are undetectable amounts of 
IL-9 produced. 
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Th2-associated transcription factors negatively regulate IL-9 production 
Since Th2-specific transcription factors were dependent on the STAT6 signal in Th9 cells 
we wanted to determine the role of each of these factors. Gata3, Maf, and Irf4 was 
expressed throughout Th9 differentiation, with Gata3 expressed higher in Th2 cells, 
while Maf and Irf4 were expressed more in Th9 cells (Figure 28E). When either GATA3 
or Maf was transduced in Th9 cells, the percentages of IL-9-producing cells were 
diminished (Figure 30). However, neither of the factors enhanced IL-4 production from 
Th9 cells (Figure 30). Even in the absence of endogenous IL-4 in Th9 cells, GATA3 or 
Maf can reduce IL-9-producing cells similar to the decrease in WT Th9 cells (Figure 30). 
Therefore neither GATA3 nor c-Maf directly regulates the Il9 gene. It would be 
interesting to know how siRNA-mediated reduced expression of GATA3 and c-Maf in 
Th9 cells affect IL-9 production. GATA3 was shown to be required for the development 
of Th9 cells using conditional mutant cells (Dardalhon et al., 2008). It can be speculated 
that GATA3 might act as an intermediate in the IL-4/STAT6-dependent reduction of 
Foxp3 as is demonstrated for GATA3 in Treg cells (Mantel et al., 2007); however, recent 
studies have indicated that GATA3 is required for the function of Treg cells (Wang et al., 
2011; Wohlfert et al., 2011). Whether GATA3 is temporally required early in Th9 
differentiation has not been examined in detail. GATA3 might help prevent Th9 cells 
from switching to a Th17 phenotype, even though one study has demonstrated that cells 
from GATA3-transgenic mice can induce IL-17 production (van Hamburg et al., 2008). 
However, cells with transgenic GATA3 expression are protected from EAE. It is possible 
that ectopic GATA3 expression in Th9 cells enhances IL-17-secreting cells. c-Maf might 
be involved in the regulation of other genes in Th9 cells. Th9 cells secrete IL-21 and as 
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IL-21 is a c-Maf target in other Th lineages, there might be a role for c-Maf in promoting 
IL-21 production in Th9 cells. c-Maf has been shown to regulate IL-10 production in 
Th17 cells (Xu et al., 2009) and might be important for IL-10 production by Th9 cells as 
well. Whether GATA3 or c-Maf over expression leads to reduction in PU.1 or IRF4, the 
transcription factors required for Th9 cell development, has not been examined carefully. 
There could also be kinetic effects of the expression of each factor during T helper cell 
differentiation that might be obscured by ectopic expression during in vitro culture. 
Although we did not observe significant differences in expression of these factors until 
the final days of Th2 and Th9 differentiation, it is still possible that a balance of these 
factors, at particular times during the differentiation process, is critical for appropriate IL-
9 production.  
 
Th1-associated transcription factors repress IL-9 production 
IL-4 is a negative regulator of T-bet and Runx3, transcription factors required for Th1 
cell differentiation. Therefore we hypothesized that T-bet and Runx3 are negative 
regulators of IL-9 production. We observed ectopic Runx3 and T-bet expression 
diminished the production of IL-9-secreting cells (Figure 32A). In contrast, T-bet-
deficient and Runx3-deficient Th9 cells have enhanced IL-9 production (Figure 32B).  T-
bet and Runx3 probably contribute to attenuation of Il9 expression in Th1 cells, similar to 
their effect at the Il4 locus. This could be through both direct and indirect mechanisms. In 
previously generated ChIP-seq datasets of Runx3/CBF-β and T-bet binding in Th1 cells 
(Yagi et al., 2010), both factors bind directly to the Il9 gene; T-bet at a major peak around 
-22.5 kb and smaller peaks between +7 to +9 kb, and Runx3 at a major peak around +5 
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kb and minor peaks at -25, -17, -7 and +11 kb. Therefore they likely bind to the Il9 locus 
in Th9 cells. They might also have indirect effects by regulating other transcription 
factors required for IL-9 production. Runx3, however might not be responsible for the 
lack of IL-9 production in Stat6-/- Th9 cultures, since expression of Runx3 was decreased 
in the absence of STAT6 (Figure 33). Another contributing factor to the failure of IRF4 
to rescue IL-9 in STAT6-deficient Th9 cells was probably of its ability to modestly affect 
Tbx21 expression (Figure 25C). Increased expression of Tbx21 in the absence of STAT6 
suggests that the IL-4/STAT6 signal is required to limit T-bet-mediated inhibition in Th9 
cells. Overall, IL-4/STAT6 signal regulates the expression of several transcription factors 
required for the induction of IL-9. 
 
STAT6-dependent transcriptional network in Th9 cells: Summary 
We propose the following model of the STAT6-dependent transcriptional network in Th9 
cells (Figure 35). Downstream of IL-4/STAT6 pathway is IRF4 which promotes Th9 cell 
development. However, other factors downstream of STAT6 signal are required as IRF4 
alone is not sufficient to recover IL-9 in the absence of STAT6. The IL-4/STAT6 
pathway is also critical to inhibit TGF-β-induced Foxp3 expression, and Tbx21 
expression to promote IL-9 production.
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PART III: Gcn5 is required for PU.1-dependent IL-9 production in Th9 cells 
The transcription factor PU.1 promotes the development of Th9 cells 
PU.1, an ETS family transcription factor, regulates Th2 heterogeneity. PU.1 is 
specifically expressed in the IL-4
lo
 subpopulation of Th2 cells and ectopic PU.1 
expression in Th2 cells attenuates the production of Th2-specific cytokines partly by 
interacting and interfering with the function of GATA3 and IRF4 (Ahyi et al., 2009; 
Chang et al., 2005). In contrast, reduced PU.1 expression enhances Th2 cytokine 
production (Chang et al., 2009; Chang et al., 2005). We observed PU.1 was abundantly 
expressed in Th9 cells (Figure 36), and speculated that the specific deletion of PU.1 in T 
cells would have defect in IL-9 production. Impaired IL-9 production was observed in the 
absence of PU.1 (Figure 38). There was a modest increase in IL-4 production (Figure 
38A). Consistent with this finding, ectopic expression of PU.1 in Th9 cells enhanced the 
percentages of IL-9-secreting cells (Figure 39A, B). In this thesis we wanted to define the 
mechanism of PU.1-dependent IL-9 induction in Th9 cells. 
 
TGF-β regulates Sfpi1 expression 
In the previous sections, we defined the downstream factors of IL-4 signal required for 
Th9 cell development. We then wanted to determine the factors downstream of TGF-β 
signal important for promoting Th9 cells. As we established PU.1 as one of the key 
transcription factors critical for Th9 cell development we wanted to determine the 
cytokines regulating the expression of PU.1. We observed that Sfpi1 was expressed 
higher in Treg cells compared to Th9 cells (Figure 41A). As TGF-β is required for the 
differentiation of both Th9 and Tregs, we speculated that TGF-β might be regulating 
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PU.1. When activated T cells were cultured with increasing doses of TGF-β in the 
presence or absence of constant IL-4, an increase in Sfpi1 expression was observed 
(Figure 41B). However, when TGF-β was kept constant and IL-4 doses were varied there 
was no IL-4-dose-dependent alteration in Sfpi1 expression (Figure 41B). Consistent with 
this finding we observed Sfpi1 expression and PU.1 binding to the Il9 gene was 
unaffected in the absence of STAT6 (Figure 41D, E). Moreover, ectopic PU.1 expression 
in Th2 cells can augment IL-9-secreting cells while decreasing IL-4-secreting cells 
(Chang et al., 2010). These results suggest that IL-9-secreting cells arise when there is a 
balance between the TGF-β signal that induces Sfpi1 expression, and the IL-4 signal that 
limits Foxp3 expression (Figures 15, 41). When endogenous TGF-β production is 
blocked in Th2 cells it reduces Sfpi1 expression concomitant with a reduction in Il9 gene 
expression (Figure 42). This suggests endogenous TGF-β in Th2 cultures can promote 
IL-9 production and TGF-β regulates PU.1 expression. 
 
HDAC inhibitor-mediated IL-9 induction is PU.1-dependent 
Global gene expression results from a balance between histone acetylation and 
deacetylation regulated by the group of enzymes HATs and HDACs, respectively. 
Chromatin structure is dependent on strong interactions between positively charged 
lysine residues of histone and negatively charged phosphate groups of DNA. Acetylation 
of histone lysine residues by HATs diminishes the electrostatic interaction between 
histone and DNA thereby allowing accessibility of transcription factors to a gene (Strahl 
and Allis, 2000). HDACs reverse this process thereby restricting transcription factors 
access to a gene. However, HDAC inhibition reverses repressive chromatin and induces 
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the expression of a subset of genes (Luo and Dean, 1999; Van Lint et al., 1996). HDAC 
activity has been demonstrated to regulate T cell development and function (Shakespear 
et al., 2011). T cell-specific deletion of HDAC1 results in increased IL-4 production from 
in vitro cultured Th2 cells and enhanced allergic airway inflammation (Grausenburger et 
al., 2010). HDAC2 has been shown to be required for B cell proliferation (Yamaguchi et 
al., 2010). We observed that HDAC association at the Il9 promoter was enhanced in the 
absence of PU.1 which could contribute to reduced IL-9 production in the absence of 
PU.1 (Figure 43). In contrast, when Th9 cells were treated with the HDAC inhibitor TSA, 
IL-9 production was enhanced (Figure 44). However, TSA treatment did not alter the 
expression of other cytokines produced by Th9 cells including IL-10 and IL-21, 
suggesting that in Th9 cells the Il9 locus was a specific target of HDAC inhibition 
(Figure 44B). TSA treatment enhanced the expression of Sfpi1 but not Irf4 indicating that 
PU.1 might be important TSA-mediated IL-9 induction (Figure 45A, B). We observed 
that in the absence of PU.1, TSA did not induce IL-9 production (Figure 45C). TSA-
induced Il9 expression was correlated with enhanced histone acetylation at the Il9 gene 
and increased PU.1 and IRF4 binding at the Il9 promoter (Figure 46). A recent study has 
demonstrated that functional cooperation of NFAT1 and NF-κB augments IL-9 
transcription (Jash et al., 2012). In another report it was documented that the binding sites 
of NFAT and GATA3 at human IL5 promoter were critical for TSA-mediated enhanced 
IL5 expression (Han et al., 2007). Therefore the presence of NFAT binding sites in the Il9 
gene (Perumal and Kaplan, 2011) could be crucial for TSA-mediated enhanced Il9 gene 
transcription. It is also possible that TSA could enhance Il9 promoter activity as one 
report has demonstrated that TSA treatment enhanced CD154 promoter activity (Pham et 
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al., 2005). It had been shown that TSA increased RNA polymerase II recruitment to the 
hLHR gene promoter (Zhang and Dufau, 2002). TSA can potentially enhance the specific 
recruitment of RNA polymerase II to the Il9 promoter thereby enhancing Il9 gene 
transcription. Though PU.1 is regulated by HDAC inhibition, the effects might be cell-
type specific. HDAC inhibition in macrophage and pro-T cell lines resulted in loss of 
PU.1 expression (Laribee and Klemsz, 2001). Consistent with our observations, the HAT 
inhibitor, curcumin, reduced PU.1 expression in Th9 cultures (Ramming et al., 2012). 
Therefore HDAC inhibition may enhance Il9 transcription by several mechanisms. 
 
Structural requirements of PU.1 to induce IL-9  
PU.1, like most transcription factors, consists of multiple functional domains (Figure 
47A). It regulates the expression of myeloid and lymphoid genes required for lineage 
development and function. Multiple functional domains have been identified at the N-
terminus of PU.1 (Hagemeier et al., 1993; Klemsz and Maki, 1996; Kominato et al., 
1995; Shin and Koshland, 1993). The ETS DNA-binding domain is located at the C-
terminus and mediates DNA binding and interactions with multiple proteins (Karim et al., 
1990; Klemsz et al., 1990; Nagulapalli et al., 1995). The PEST domain, enriched in 
proline, glutamic acid, serine and threonine has been shown to control protein stability. 
The PEST domain has not been generally associated with gene transactivation (Erman 
and Sen, 1996; Klemsz and Maki, 1996; Kominato et al., 1995). Th2 cells over expressed 
with PU.1 activation domain or the PEST domain mutant did not alter cytokine 
production significantly compared to Th2 cells transduced with full-length PU.1; 
however, PU.1 DNA-binding mutant has reduced ability to regulate Th2 cytokine 
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production (Chang et al., 2005). PU.1 had been reported to interact and interfere with 
GATA3 at the Il4 locus to regulate Th2 heterogeneity (Chang et al., 2005). We had 
demonstrated the ability of PU.1 to bind to the Il9 promoter directly while the DNA-
binding mutant of PU.1 results in impaired ability to bind to the Il9 gene (Figure 
41E)(Chang et al., 2010) When Th9 cells were ectopically expressed with full-length 
PU.1 there were enhanced percentages and mean fluorescence intensity of IL-9-secreting 
cells (Figure 47B, C). In contrast, Th9 cells transduced with either activation domain 
mutant or DNA-binding domain mutant failed to augment IL-9 production (Figure 47B, 
C). We observed a modest increase in the percentages of IL-9-secreting cells when Th9 
cells were transduced with the PEST domain mutant (Figure 47B, C) which is consistent 
with a published report showing that the PEST domain plays a negative role in monocyte-
specific gene expression (Nishiyama et al., 2004). That the activation domain was 
required for IL-9 expression was further demonstrated when the PU.1 activation domain 
mutant had a significantly attenuated ability to recover IL-9 in PU.1-deficient Th9 cells, 
while the full length PU.1 was able to rescue IL-9 production to a level similar to WT 
Th9 cells transduced with control retrovirus (Figure 48). Therefore, PU.1 requires 
multiple domains to regulate the Th9 phenotype. 
 
Altered HAT binding and histone acetylation at the Il9 locus 
Since PU.1 binds to the Il9 promoter in Th9 cells, we speculated one functional role of 
PU.1 is possibly recruiting other factors such as histone modifying enzymes including 
HATs to the Il9 locus. Even though PU.1 is a critical factor in cellular differentiation, 
little work has extensively focused on the interaction of PU.1 and HAT molecules. A 
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limited number of studies suggested that PU.1 interacts with HATs including p300, 
Tip60, and MOZ (Bai et al., 2005; Hlubek et al., 2001; Katsumoto et al., 2006). Contrary 
to the published report that PU.1 recruited p300 to the Igκ locus in B cells, we observed 
enhanced p300 association at the Il9 promoter in the absence of PU.1, suggesting that 
other transcription factors may mediate p300 recruitment in Th9 cells (Bai et al., 
2005)(Figure 49A). However, the association of Gcn5 and PCAF to the Il9 gene was 
attenuated in the absence of PU.1 (Figure 49A). Therefore in the absence of PU.1 there 
was differential recruitment of HAT molecules; despite the expression of these HATs 
being unaffected by the absence of PU.1 (Figure 49B). There could be potentially 
differential recruitment of other HATs including CBP, MOZ and Tip60 at the Il9 locus 
mediated by PU.1.  
  
The functional consequences of altered HAT binding to Il9 gene could be altered histone 
acetylation at the Il9 locus. The Il9 locus in Th9 cells is characterized by increased 
acetylation of total histone H3, histone H4 and specific histone H3K9/18 (Chang et al., 
2010). PU.1-deficient Th9 cells had reduced H3 but unchanged H4 acetylation than WT 
Th9 cells (Chang et al., 2010). The specificity of PU.1 effects on histone acetylation was 
evident in significantly attenuated acetylation of H3K9/18, H3K14, H4K5, H4K8 and 
H4K16 in PU.1-deficient Th9 cells, while acetylation of histone H3K27 and H3K36 
remained unchanged (Figure 50). In addition to acetylation, histone lysine residues 
undergo methylation as well. It is possible that PU.1 can also mediate histone lysine 
methylation. PU.1 has been shown to repress GATA1 to block erythroid differentiation 
program by recruiting histone methyltransferase Suv39h, thereby causing methylation of 
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histone H3K9 (Stopka et al., 2005). Therefore PU.1 can potentially recruit different 
histone methyltransferases at the Il9 locus. However, histone methylation of H3K27 was 
PU.1-independent (Chang et al., 2010). Thus, PU.1 regulates specific histone modifying 
enzyme association and histone modifications at the Il9 locus. 
 
Gcn5 is required for the induction of IL-9 in Th9 cells 
Since the recruitment of Gcn5 and PCAF to the Il9 gene was attenuated we wanted to 
define if either of these factors were required for IL-9 expression. We observed DNA-
bound PU.1 was able to associate with Gcn5 but not PCAF suggesting that PU.1 
specifically associates with Gcn5 (Figure 51A). The requirement for the activation 
domain for IL-9 induction was also correlated with a requirement for the activation 
domain to interact with Gcn5 as DNA-bound PU.1 activation mutant failed to precipitate 
Gcn5 (Figure 51B). The activation domain of PU.1 was also required to recruit Gcn5 
binding to the Il9 promoter as PU.1-deficient Th9 cells transduced with activation 
domain mutant failed to recover Gcn5 binding (Figure 52).  
 
Gcn5 functionally contributed to Il9 expression as IL-9 production was diminished when 
Gcn5 expression was reduced (Figure 53A-C). However, attenuated Gcn5 expression did 
not affect IL-10 and IL-21 production implying that the Il9 locus in Th9 cells is a specific 
target of Gcn5 (Figure 53C). Inhibition of Gcn5 expression did not affect PU.1 or IRF4 
binding to the Il9 gene; however, there was significantly reduced acetylation of H3K9/18, 
H4K5, and H4K8 the target lysine residues of Gcn5 (Figure 53D, E). It is also possible 
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that Gcn5 inhibition can also lead to reduced acetylation of H3K14 and H4K16, the other 
known lysine residues acetylated by Gcn5 (Struhl, 1998). 
 
Gcn5 is required for PU.1-dependent IL-9 production in Th9 cells: Summary 
We propose the following mechanism for the requirement of Gcn5 in PU.1-dependent IL-
9 induction (Figure 54). In developing Th9 cells PU.1 binds to the Il9 promoter leading to 
complex formation and recruitment of Gcn5-containing chromatin remodeling 
complexes. Gcn5 is a subunit of multiprotein complexes including SAGA (Spt-Ada-
Gcn5-Acetyltransferase), ATAC (Ada Two-A Containing Complex), and STAGA (Spt3-
TAF9-Gcn5-Acetyltransferase) (Lee and Workman, 2007). The domain structure of Gcn5 
includes an N-terminal PCAF homology domain, the acetyltransferase domain, and a C-
terminal bromodomain (Nagy and Tora, 2007). The bromodomain, an approximately 
110-amino acid module is required for recognizing acetylated histone tails to regulate 
acetylation-dependent chromatin modification. It is hypothesized that Gcn5-containing 
chromatin acetylates a site on histone tail without binding to it. That specific site is 
subsequently bound by another Gcn5-containing complex leading to acetylation of an 
adjacent site, thus propagating the modification (Nagy and Tora, 2007). The metazoan 
Gcn5-containing complex exists in two distinct forms: a 2 MD Gcn5-containing STAGA 
complex and a 700 kD ATAC complex (Baker and Grant, 2007; Kusch et al., 2003). Spt 
(Suppressor of Ty) molecules are involved in facilitating TATA-binding protein (TBP) 
function and can act as eukaryotic transcription elongation factors (Winston, 2001). Ada 
or adaptor proteins are critical in forming a catalytic core to confer lysine specificity for 
nucleosomal acetylation (Balasubramanian et al., 2002; Bhaumik and Green, 2002). TBP-
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associated factors (TAFs), which act as co-activators are important for promoter selection 
during transcription. They are critical for transcription from TATA-less promoters (Lee 
and Young, 2000). Transformation/transcription domain-associated protein (TRRAP) is a 
subunit of many HAT complexes. TRRAP is a key player in DNA repair and 
transcription by recruiting HAT complexes to chromatin (Robert et al., 2006). The mouse 
Gcn5 sequence is 98% identical with human GCN5 sequence; however, the mouse gene 
encodes an extended N-terminal domain with high similarity to PCAF-containing domain 
(Xu et al., 1998b). Full-length mouse Gcn5 protein can acetylate both free and 
nucleosomal histones H3 and H4, in contrast to yeast and human Gcn5 proteins that 
selectively acetylate free core histones (Xu et al., 1998b). There is an indirect recruitment 
of PCAF to the Il9 locus as well. Overall, the recruitment of specific HATs leads to 
histone acetylation. In the absence of PU.1, there is enhanced HDAC recruitment at the 
Il9 locus. While Gcn5 is not required for PU.1 or IRF4 binding to the Il9 gene, it is 
important for controlling histone acetylation at the Il9 gene promoter. Gcn5-dependent 
histone acetylation probably enhances binding of TCR-induced factors including NF-κB 
or NFAT which are important for Il9 gene expression (Jash et al., 2012). It may also 
facilitate the progression of general transcription factors like RNA polymerase II (Sanso 
et al., 2011). PU.1 could also recruit other specific histone modifying enzymes and 
interact with other transcription factors at the Il9 locus to contribute to IL-9 production. 
As histone acetyltransferases emerge as key targets for drugs (Dekker and Haisma, 2009), 
development of small molecule inhibitors of Gcn5 could become relevant in reducing the 
level of IL-9 in allergic patients. 
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FUTURE DIRECTIONS 
PART I: Role of STAT6-dependent transcription factors in Th9 cells 
STAT6-dependent Th9 regulation 
STAT6 is critical for the development of Th9 cells (Figure 21). IRF4 which is 
downstream of STAT6 in Th9 cells is not sufficient to recover IL-9 production in the 
absence of STAT6 (Figure 25). The transcription factors GATA3 and c-Maf are also 
downstream of STAT6 in Th9 cells. However, when over expressed in Th9 cells they 
attenuate IL-9 production (Figure 30). This suggest that there are other factors 
downstream of STAT6 which act together to induce IL-9 production in Th9 cells. To 
examine potential factors downstream of the STAT6 pathway relevant for IL-9 induction 
we will perform a microarray with Th9 cells from WT and Stat6-/- mice. The Il9 locus 
has potential binding sites of multiple transcription factors including AP-1, NFAT and 
NF-κB (Perumal and Kaplan, 2011). We expect expression of some transcription factors 
associated with AP-1, NFAT, and NF-κB family will be greatly diminished in the 
absence of STAT6 in Th9 cells. Therefore transducing WT and STAT6-deficient Th9 
cells with retroviruses expressing specific transcription factors that are greatly attenuated 
in the absence of STAT6 signal will be important to define the ‘missing’ factors 
downstream of STAT6 signal. If no recovery of IL-9 is observed from the STAT6-
deficient Th9 cells ectopically expressed with a single factor, developing Th9 cells will 
be transduced with a combination of factors and assess IL-9 production. Furthermore it 
will be relevant to assess whether the expression of T-bet and Foxp3, the negative 
regulators of IL-9, is altered after developing Th9 cells are transduced with a single or 
combination of transcription factors.  
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To define the mechanism how additional transcription factors regulate IL-9 production in 
Th9 cells it will be important to examine the binding of potential transcription factors to 
the Il9 gene by performing chromatin immunoprecipitation using Th9 cells from wild-
type mice and determine if the absence of STAT6 affects the association of the factors to 
the Il9 locus. Furthermore, it will be critical to determine if any one of those transcription 
factors can transactivate Il9 gene using luciferase reporter assay. Together these 
experiments will provide the insight into the additional factors required for STAT6-
dependent Il9 transcription.  
 
PART II: PU.1-mediated Il9 gene regulation in Th9 cells 
Defining the role of additional HATs in Th9 cells 
Numerous HAT molecules regulate histone acetylation of lysine residues. We have 
investigated the role of some of the well-defined HATs in PU.1-dependent IL-9 induction 
and observed PU.1-mediated differential recruitment of the HAT molecules to the Il9 
gene (Figure 54). PU.1 has been shown to mediate the recruitment of the HATs MOZ, 
Tip60, and p300. PU.1 inhibits acetylation mediated by CBP, another HAT molecule 
(Hong et al., 2002). However, our preliminary data suggests that in the absence of PU.1 
there is decreased association of CBP to the Il9 gene. We will therefore like to expand the 
relevance of these findings by examining the PU.1 mediated recruitment of other HAT 
molecules to the Il9 gene including CBP and define their functional consequences. It will 
also be important to determine if any one of these additional HAT molecules associate 
directly with PU.1. If PU.1 can associate with any other HATs in addition to Gcn5 we 
could alter the expression of the specific HAT molecule and determine its effect in 
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inducing the Il9 gene. We will further determine if the altered expression of the HAT 
molecules associated with PU.1 also affects the expression of other HAT molecules. 
 
Determining PU.1-mediated histone methylation in Th9 cells 
We have demonstrated PU.1 mediates specific histone acetylation at the Il9 locus (Figure 
50). However, PU.1 can also regulate histone methylation as is evident from a previous 
study (Stopka et al., 2005). H3K27 trimethylation was not PU.1-dependent (Chang et al., 
2010). Our preliminary data suggests that H3K4 methylation is PU.1-dependent. Histone 
methylation adds complexity to chromatin modifications as the lysine residues can 
undergo mono-, di-, or tri-methylation. Methylation of H3K4, H3K36, and H3K79 has 
been associated with transcription activation (Kouzarides, 2007). H3K4, and H3K36 
methylation play roles in transcriptional elongation (Kouzarides, 2007). In contrast, 
H3K9, H3K27, and H4K20 methylation has been implicated in transcriptional repression 
(Kouzarides, 2007). Therefore, we could also examine specific histone methylation status 
at the Il9 locus in WT and PU.1-deficient Th9 cells. If PU.1 regulates histone methylation 
at the Il9 locus then it can speculated that it could possibly regulate the recruitment of 
histone methyltransferases, the enzymes which catalyze histone methylation. Therefore it 
will be important to determine if PU.1 regulates recruitment of histone methyltransferases 
at the Il9 locus in Th9 cells.  These data will define the extensive histone modifications at 
the Il9 locus.  
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Defining the maintenance and commitment of Th9 cells 
Th1, Th2 and Th17 cells have been shown to maintain their ability to secrete their 
characteristic cytokines after multiple rounds of cultures in vitro. Whether long term Th9 
cells retain their ability to secrete IL-9 has not been examined in detail. Therefore it will 
be important to define the ability of long term Th9 cultures to secrete IL-9. The amount 
of IL-17 secreted by Th17 cells decreases over each round during long term cultures. 
However, in vitro cultured long term Th17 cells display restricted plasticity. Furthermore, 
we will determine if long term Th9 cultures can also produce cytokines signature of other 
T helper subsets or if they show limited plasticity. It will be informative to determine if 
long term Th9 cells begin to produce IL-17 and IL-4 as TGF-β and IL-4 are required for 
the differentiation of Th17 and Th2 cells, respectively. Since PU.1 is one of the 
transcription factors required for Th9 cell development, the expression of PU.1 during 
each round of the long term Th9 cultures will be assessed. To test the requirement of 
PU.1 in maintenance of long term Th9 cells we could take advantage of Sfpi1
fl/fl
 mice 
which are Cre negative. We will transduce either first, second or last round of long term 
Th9 cultures with Cre-expressing retrovirus. From the sorted cells we will determine if 
the deletion of PU.1 earlier or later results in any altered phenotype. These studies will 
provide insight in to the maintenance of Th9 cells.  
Though long term Th17 cells have the ability to secrete IL-17, these cells are not 
committed. Therefore it will be relevant to define if Th9 cells are committed. Long term 
polarized Th9 cells will be cultured under Th1, Th2, and Th17-skewing conditions for 
one more round of culture. One aliquot of cells will be cultured under Th9 cell conditions 
as control. We will determine the ability of Th9 cells to produce IFN-γ, IL-4, and IL-17 
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along with IL-9. If long term Th9 cells lose the ability to produce IL-9 and switch to 
other T helper subsets then it would also be informative to assess the expression of 
transcription factors associated with other T helper subsets including T-bet, GATA3, and 
RORγt. Furthermore when Th9 cells are switched to Th2 or Th17 phenotype it would be 
important to determine if Th9 cells switched to Th2 or Th17 can be reconverted to Th9 
cells when they are activated under Th9-skewing conditions. 
 
Epigenetic status of long term Th9 cultures 
The epigenetic status of the Il9 locus in Th9 cells which is a combination of enhanced 
positive histone marks and reduced repressive marks have been described previously 
(Chang et al., 2010). However, the chromatin modifications of the Il17 gene which is 
expressed at a low level by Th9 cells has not been examined carefully. Repressive marks 
are abundant in Th17-associated genes in Th1 and Th2 cells (Wei et al., 2009). The 
Tbx21 locus in Th2 and Th17 cells has both positive H3K4Me3 and negative H3K27Me3 
marks. The instability of Th17 cells is correlated with remodeling of the Ifng locus when 
Th17 cells are treated with IL-12 (Mukasa et al., 2010). As recent studies demonstrate the 
presence of bivalent chromatin marks associated with a particular T helper subset, it will 
be informative to determine the epigenetic status of Il9 gene in long term Th9 cultures. If 
the long term cultures do not maintain their phenotype it will also be important to define 
if the Il9 gene is associated with more repressive chromatin marks and fewer positive 
chromatin marks. We will examine the common histone modifications including total and 
specific H3 and H4 acetylation marks and histone methylation marks. Furthermore, we 
could expand our studies by examining the epigenetic modification at the Th2 and Th17-
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specific gene loci. It would be interesting to look at repressive marks at the Il9 locus as 
well as the Th2 and Th17 associated genes when Th9 cells would be switched to Th2 and 
Th17 cells and then converted back to Th9 cells. Overall, these studies will elucidate 
epigenetic regulation associated with long term Th9 cells. 
 
PART III: Defining the role of PU.1 in inflammatory disease models 
Experimental autoimmune encephalomyelitis (EAE) 
Th9 cells have been implicated in autoimmune diseases including EAE with distinct 
pathological phenotype (Jager et al., 2009). As PU.1-deficient Th9 cells have defective 
Th9 differentiation in vitro and reduced inflammation in an OVA-induced allergic airway 
disease model (Chang et al., 2010), it will be important to determine if PU.1-deficiency 
ameliorates EAE. To test this, we will immunize WT and PU.1-deficient mice with MOG 
peptide and assess the features of EAE. If the absence of PU.1 ameliorates EAE disease 
severity we will determine if PU.1-deficient animals treated with recombinant IL-9 after 
EAE immunization restores EAE to the level of wild-type animals treated with control 
antibody. As PU.1 deficiency in T cells does not affect IL-17 production (Chang et al., 
2010) it will be relevant to assess if there is any change in MOG-specific IL-17 
production in peripheral lymph nodes and in the CNS. Furthermore, PBS or Th9 cells 
from 2D2 mice (TCR transgenic mice specific to MOG peptide) will be transferred to 
Sfpi1
lck-/-
 mice. These studies will determine if in vitro generated Th9 cells can restore 
EAE symptoms and demonstrate the importance of PU.1 for the development of Th9 
cells in vivo and its role in EAE. 
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Define the role of PU.1 in worm infection 
As IL-9 has been shown to be important for immune responses against worm infection 
(Faulkner et al., 1997; Faulkner et al., 1998; Richard et al., 2000), it will be informative 
to assess if PU.1-deficiency affects worm clearance. To test this, WT and Sfpi1
lck-/-
 mice 
will be infected with Trichuris muris. As PU.1 is required for IL-9 production we 
speculate that the absence of PU.1 will adversely affect worm clearance compared to 
wild-type mice. Additionally we will assess cytokine production from colon, and from in 
vitro stimulated lymphocytes. Colon contractility will also be measured. As mucus 
production by goblet cells is a hallmark of helminthic infection we could further 
determine if PU.1-deficiency results in alteration of goblet cell numbers in the infection 
model. Whether Th9 cells regulate mast cells in inflammation has not been examined 
carefully. It will be interesting to determine the mast cell content of the colon during 
worm infection and whether PU.1 deficiency affects the recruitment of mast cells. 
Whether the absence of PU.1 results in defective recruitment or survival of mast cells in 
cecum will also be determined. Together these studies will determine the importance of 
PU.1 during worm immunity. 
 
Define the effects of PU.1 during respiratory syncytial virus infection 
Infants with respiratory syncytial virus (RSV) bronchiolitis have elevated levels of IL-9 
in the bronchial sections. Following RSV challenge, mice vaccinated with vaccinia virus 
expressing respiratory syncytial virus G protein demonstrate exacerbated disease marked 
by increased IL-9 production (Dodd et al., 2009). Depletion of IL-9 during immunization 
alleviates the disease with reduced Th2 cytokines (Dodd et al., 2009). Therefore it will be 
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important to determine if the absence of PU.1 reduces the disease severity after wild-type 
and PU.1-deficient mice are vaccinated and then challenged with RSV. Weight of mice, 
total BAL leukocytes and differential BAL fluid leukocyte count will be determined 
along with the cytokine profile in the BAL fluid. To determine if the absence of PU.1 
during the challenge or immunization phase affects the disease severity, we will mate 
mice having Sfpi1 floxed allele with mice expressing tamoxifen-inducible estrogen 
receptor-Cre fusion. These mice will be treated with tamoxifen at different time points to 
remove PU.1 expression either during challenge or during immunization. To determine if 
PU.1 depletion results in altered RSV-specific serum antibody level, we could measure 
RSV-specific different IgG levels. As IL-9 elimination during immunization or challenge 
phase has different outcomes, it will be informative to transfer CD4+ T cells from 
Sfpi1
fl/fl 
mice where PU.1 was deleted during immunization or during challenge to naïve 
recipient mice before infecting them with RSV 24 hours later. In addition to determining 
the cytokines produced in the BAL fluid it will also be relevant to assess the cytokines 
produced in the lung. 
 
Together, these future studies would determine additional transcription factors 
downstream of STAT6 signal required for the development of Th9 cells. These studies 
will provide further insights into the role of PU.1 in Il9 gene regulation and its role in 
inflammatory disease models. Transcription factors can be targeted for pharmacological 
interference because of their modular structure. Small molecule pharmaceutical targets 
include upstream activating pathways of transcription factors, DNA-binding activity, and 
the ligand-binding domains of transcription factors. As improvements in structure-based 
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techniques enhance the design for novel small molecule inhibitors targeting transcription 
factors have become more relevant as drug targets. Therefore if PU.1 is involved in 
multiple inflammatory diseases targeting the transcription factor will pave the way for 
future therapeutics. 
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